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1 Introduction  
The human UMOD gene encodes uromodulin, also referred to as Tamm Horsfall protein, and 
is specifically expressed in cells of the thick ascending limb of the loop of Henle and the early 
distal convoluted tubule of the nephron. Since its discovery by Igor Tamm and Frank Horsfall 
in 1950, uromodulin and its function in the organism have been subject to more than 1000 
scientific studies. However, its exact physiologic role remains unexplained (Serafini-Cessi et 
al., 2003; Vyletal et al., 2010). In recent years, there has been a renewed interest in 
uromodulin due to the detection of a strong association of the UMOD gene with chronic 
kidney diseases (CKD) in humans in several genome wide association studies (Kottgen et al., 
2012). Besides the association to the common disease CKD, mutations within the UMOD 
gene causes the orphan renal disease uromodulin-associated kidney disease (UAKD). 
Associated with UMOD mutations are three autosomal dominant disorders: Familial juvenile 
hyperuricaemic nephropathy (FJHN1), medullary cystic kidney disease type 2 (MCKD) and 
glomerular cystic kidney disease, all of which have in common hyperuricaemia, 
tubulointerstitial nephritis and progressive renal failure (Hart et al., 2002; Serafini-Cessi et 
al., 2003). In recent years the term uromodulin-associated kidney disease (UAKD) has been 
introduced to summarize these clinical variants based on their underlying genetic cause. 
Therapy is hitherto confined to allopurinol as a symptomatic treatment of gout caused by 
hyperuricaemia in UAKD patients (Schaffer et al., 2010).  
The pathophysiology of UAKD has been studied in vitro and in vivo on both transgenic and 
ENU-mutant mouse models (Bernascone et al., 2010). The autosomal dominant mutant 
mouse lines Umod
A227T
 ( = UREHR4) and Umod
C93F 
( = UREHD1) were established in the 
Munich ENU mouse mutagenesis project (Hrabe de Angelis et al., 2000). Both harbour a 
missense point mutation in the murine Umod gene and exhibit increased plasma urea levels as 
a cardinal symptom (Kemter et al., 2009; Prueckl, 2011). 
The larger aim of this study was to assess the suitability of the Umod
A227T
 and Umod
C93F
 
mouse lines as a model for UAKD. For this purpose, the renal histomorphology of Umod
A227T
 
and Umod
C93F
 mutant mice was compared with regard to their allelic status and type of the 
Umod mutation and a potential correlation between their histological and clinical phenotypes 
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was investigated. In addition, the development of kidney alterations between the ages of 14 
and 20-22 months was to be assessed. For this purpose, qualitative and quantitative-
morphological analysis was performed on kidneys of mice of both lines and age groups.  
Furthermore, a therapeutic approach with the molecular chaperone 4-phenylbutyric acid (4-
PBA) and the superoxide dismutase mimetic tempol was conducted to test a potential 
ameliorating effect of these drugs on the clinical phenotype of Umod mutant mice. To this 
end, both chemicals were administered as a drinking solution to male homozygous mutant 
mice of both lines and to wild-type littermates (controls) over a period of two months. Urine 
and blood plasma parameters as well as renal histology of mice in the two treatment groups 
were compared to those receiving pure drinking water (placebo).  
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2 Literature 
2.1 Structure and function of the mammalian nephron  
Each nephron constitutes a structural and functional unit of the kidney. The nephron is 
essential for blood filtration, followed by solute and water absorption and excretion thereof. 
Thus, the nephron regulates electrolyte homeostasis as well as blood pressure and volume. 
Each nephron comprises a glomerulus and a Bowman’s capsule, a proximal convoluted 
tubule, the loop of Henle and a distal convoluted tubule (Hees & Sinowatz, 2000; McGavin & 
Zachary, 2009).  
The renal corpuscle, consisting of glomerulus and Bowman’s capsule, lies in the renal cortex. 
It is the glomerulus where the initial blood filtering occurs. In humans, within 24 hours, 1000-
2000 l of blood is pumped through the glomerular capillaries where water, ions and molecules 
smaller than 69 kDa penetrate the glomerular filter (Hees & Sinowatz, 2000; König et al., 
2002). The resulting filtrate is isosmotic with the blood plasma and is called primary urine: It 
passes on to the proximal convoluted tubule via the urinary pole of the renal capsule. About 
99% of the primary urine is reabsorbed while passing through the tubular system of the 
nephron (Hees & Sinowatz, 2000).  
The proximal tubule can be divided into a pars convoluta and a pars recta. Its most 
characteristic feature is a luminal brush border formed by microvilli to optimize the resorptive 
function of this nephron compartment. Its cuboidal epithelial cells are rich in mitochondria 
that provide energy for active transport mechanisms (Hees & Sinowatz, 2000). Na
+
/K
+
-
ATPase in the basolateral membrane of the epithelial cells is the most significant antiporter in 
the reabsorption of sodium and water, with the latter flowing out of the lumen along a 
concentration gradient. The resulting sodium gradient in turn drives co-transport channels for 
the reabsorption of inorganic phosphate, glucose and amino acids. Both potassium and urea 
leave the lumen via paracellular solvent drag and simple diffusion. On the other hand, the 
proximal tubule is an important location for secretion of substances like creatinine and 
ammonium (Schmidt et al., 2010; von Engelhardt, 2012).  
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Connecting proximal and distal tubules, the loop of Henle lies mainly in the renal medulla and 
can be divided into three segments: a descending, a thin ascending and a thick ascending limb 
(Hees & Sinowatz, 2000). While the descending limb has a low permeability to ions and urea, 
its high water permeability together with a high solute concentration in the renal medulla 
allows for osmosis and thus for a substantial increase in urine concentration to occur in this 
part of the nephron. In the thin ascending limb which is not permeable to water but permeable 
to ions, the resulting highly osmotic urine then causes ions to pass from the urinary lumen into 
the medullary interstitium along a concentration gradient. Since this segment is impermeable 
to water, a hypoosmotic urine and a hyperosmotic interstitium are the result near the renal 
papilla (McGavin & Zachary, 2009; Schmidt et al., 2010; von Engelhardt, 2012).  
This countercurrent multiplier system is completed by the distal straight tubule, or thick 
ascending limb (TALH) of Henle (Hees & Sinowatz, 2000). Also impermeable to water, 
TALH cells actively reabsorb sodium, potassium and chloride ions by means of the Na
+
-K
+
-
2Cl
-
-cotransporter NKCC2 which is a TALH-specific ion transporter. As potassium ions 
passively flow back into the lumen via K
+
-channels such as ROMK, a positive electron 
potential is created in the tubular lumen. Consequently, paracellular absorption of divalent 
cations such as Ca
2+
 and Mg
2+
 sets in (Kuhlmann et al., 2008; Schmidt et al., 2010). The 
correct function of the TALH is essential for creation and maintenance of a hypertonic 
interstitium of the renal medulla and thus for the urine concentration capability of the kidney. 
Beyond its contribution to a hypotonic urine, the TALH, together with early distal convoluted 
tubule parts, is the location where uromodulin, formerly called Tamm-Horsfall protein, is 
expressed and excreted into the urine (Pollak & Arbel, 1969).  
Finally, the filtrate reaches the distal convoluted tubule (DCT) which connects the loop of 
Henle with the collecting duct system (Hees & Sinowatz, 2000). Like its proximal 
counterpart, the distal convoluted tubule controls urinary pH through bicarbonate and proton 
exchange. Furthermore, the basolateral Na
+
-K
+
-ATPase creates a Na
+
 concentration gradient 
which causes sodium to leave the lumen via a Na
+
-Cl
-
 -symport, simple diffusion as well as a 
luminal Na
+
-H
+
-antiport. This creates a net negative electric potential along the DCT, which 
in turn inhibits a passive Na
+
 resorption and active transport remains the only option for 
sodium absorption. The Na
+
-H
+
-antiport increases H
+
 secretion which creates an intracellular 
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alkalosis and a consequent K
+
-accumulation in the lumen. The hormone aldosterone is the 
major extrarenal regulator in DCT electrolyte resorption (Reilly & Ellison, 2000; Kuhlmann 
et al., 2008; Schmidt et al., 2010).  
2.2 Structure and function of uromodulin 
2.2.1 Discovery and structure  
The protein uromodulin was discovered at the Rockefeller Institute in New York City in 1950 
by Estonia-born Igor Tamm and his American mentor Frank Lappin Horsfall (Hirst, 1979; 
Choppin, 2007). Hence uromodulin derived its original name: Tamm Horsfall Protein (THP). 
Having isolated and purified uromodulin from normal human urine by means of salt 
precipitation, Tamm and Horsfall investigated its biochemical properties and found that the 
protein interacted with influenza, mumps and Newcastle disease viral hemagglutination 
(Tamm & Horsfall, 1950, 1952). 
Further investigations showed that THP is the most abundantly expressed protein in 
mammalian urine, with its urinary excretion in humans ranging from 20 to 200 mg per day, 
the mean lying between 30 and 50 mg / 24 h under physiological conditions (Kumar & 
Muchmore, 1990; Kreft et al., 2002). Due to eight glycosylation sites, uromodulin is rich in 
carbohydrates which can account for up to 30% of its molecular weight of around 90 kDa in 
SDS-PAGE (Gottschalk, 1952; Grant & Neuberger, 1973). THP expression is confined to the 
cells of the thick ascending limb of Henle (TALH) and early distal convoluted tubule cells, 
excluding macula densa (Schenk et al., 1971; Hoyer et al., 1979; Bachmann et al., 1990). 
In 1985 Muchmore and Decker examined the urine of pregnant women for its 
immunosuppressive compounds and, in the process, purified an 85-kDa glycoprotein that was 
able to withhold antigen-specific T-cell proliferation as well as monocyte cytotoxicity. Due to 
these immunomodulating properties and its source, namely urine, Muchmore and Decker 
suggested for the protein to be called “uromodulin”. They also concluded from their 
experiments that uromodulin was a monomeric protein with several intrachain disulphide 
bridges, an approximate carbohydrate content of 30% and that it showed a tendency to form 
aggregates (Muchmore & Decker, 1985). Apart from the above characteristics, uromodulin 
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was found to resemble THP in that it is synthesized in the kidney and in that it is ubiquitous in 
non-pregnant female as well as in male urine. Sequence analysis finally revealed that 
uromodulin and THP are the same glycoprotein and henceforth both terms have been used 
interchangeably (Pennica et al., 1987).  
As for its primary structure, the uromodulin precursor molecule contains 640 amino acids 
(aa). The first 24 aa at the N-terminus serve as a signal peptide for the protein to be 
transported to the endoplasmic reticulum (ER) which is also where this signal-residue is 
removed enzymatically. Although the resulting 616 aa-protein provides 8 sites for N-
glycosylation, only 7 of them bind glycan moieties. Glycosylation of uromodulin starts in the 
ER is continued in the Golgi apparatus (Rindler et al., 1990; van Rooijen et al., 1999; Vyletal 
et al., 2010) (Figure 2.1).  
 
 
Figure 2.1: Primary amino acid structure of uromodulin. From left to right: leader peptide, (cleavage site at 
amino acid 23), epidermal growth factor (EGF)-like domains I-III, domain of 8 conserved cysteines (D8C), zona 
pellucida (ZP) domain and a glycosylphosphatidylinositol (GPI) glycosylation site at amino acid 614. Ψ: N-
glycosylation site. Number of amino acids refers to the human uromodulin aa sequence. (Rampoldi et al., 2011) 
License for the reuse of this figure was obtained in agreement with the Nature Publishing Group.  
 
Further subunits of uromodulin include three epidermal growth-factor-like domains (EGF I-
III) which are formed by aa residues 31-64, 65-107 and 108-149, respectively. EGF II and III 
were found to not only bind calcium but also to be rich in cysteine residues forming stable 
intramolecular disulphide bridges (Fletcher et al., 1970; Hamlin & Fish, 1977). While the 
function of EGF-like domains remain incompletely understood, the relevance of their cysteine 
residues C1-C6 for a correct tertiary protein structure is indisputable (Rampoldi et al., 2003) 
The existence of a fourth EGF-like domain between EGF III and the zona pellucida domain 
has hitherto been subject to debate. The peptide in question (aa 281-336) connects the zona 
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pellucida domain (aa 334-585) to D8C. D8C is the most recently identified subunit of 
uromodulin, stretching from aa residues 199 to 287. D8C stands for “domain with eight 
conserved cysteine residues” and has the potential to form four disulphide bridges (Yang et 
al., 2004; Lens et al., 2005). Zona pellucida and, presumably, EGF-like domains participate in 
the extracellular polymerization of uromodulin into superhelices (Rampoldi et al., 2003). In 
total, uromodulin disposes of 24 putative disulphide bridges to link the 48 cysteine residues. 
ER chaperones facilitate this process (Malagolini et al., 1997) (Figure 2.1).  
At the C-terminus, a hydrophobic 16 aa- peptide signals to ER-transpeptidase to link a 
glycosylphosphatidylinositol (GPI) anchor to the C-terminus that results from the cleavage of 
the aforesaid 16 aa-signal stretch. (Pennica et al., 1987; Ferguson & Williams, 1988; Rindler 
et al., 1990). The GPI-addition, together with the Golgi-perfected glycans, is essential for the 
glycoprotein to reach and integrate into the apical plasma membrane of TALH cells (Brown 
& Rose, 1992; Benting et al., 1999).  
Fixed to the outer layer of the plasma membrane by its GPI fragment, the mature uromodulin 
molecule protrudes into the lumen where proteolytic cleavage at residue phenylalanine 587 
releases a 563-aa glycoprotein into the urine (Rindler et al., 1990; Santambrogio et al., 2008; 
Vyletal et al., 2010). Urinary uromodulin is made up of double-helix filaments that 
polymerize to 1500-4000 nm long supramolecular strands with a tendency to assemble in 
gelatinous matrices (Bayer, 1964; Hoyer et al., 1979; Jovine et al., 2002) (Figure 2.2). 
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Figure 2.2: Uromodulin maturation, excretion and polymerization in the TAHL. GPI anchoring, disulphide 
bond formation and N-glycosylation occur in the endoplasmic reticulum. Glycan chains are modified in the 
Golgi apparatus. Release of an intramolecular hydrophobic interaction by a not yet identified protease (scissors) 
creates a polymerization-competent monomer that polymerizes in filaments. (Rampoldi et al., 2011) License for 
the reuse of this figure was obtained in agreement with the Nature Publishing Group. 
 
2.2.2 Function of uromodulin 
Uromodulin can polymerize to gel-like matrices. Notably, uromodulin polymers take on 
various forms, and reversibly so, depending on cation concentrations: 100 mmol/l NaCl and 1 
mmol/L CaCl2 each trigger uromodulin gelation and both concentrations typically occur in 
normal urine (Stevenson et al., 1971; Wiggins, 1987). These gel-like interconnections are 
hypothesized to form a water-proof layer on top of the luminal surface of TALH cells, thereby 
contributing to the upkeep of the medullary countercurrent gradient (Hoyer & Seiler, 1979; 
Hoyer et al., 1979). Because of interactions with uromodulin molecules that are still cell-
anchored, the gel is likely to move forward at a slow pace and thus to prolong the passage of 
sodium and potassium in the TALH so as to augment their reabsorption there (Vyletal et al., 
2010).  
Type 1 fimbriated E.coli, a major pathogen in urinary tract infections (UTIs), carry another 
lectin-type adhesin with an affinity for high-mannose sequences which are found in both 
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urinary uromodulin and the urothelial membrane glycoproteins uroplakin Ia and Ib (Sharon, 
1987; Wu et al., 1996; Barnett & Stephens, 1997; Martinez et al., 2000). The competitive 
binding of THP to E.coli fimbria shown in vitro validly suggests how uromodulin could 
obviate bacterial colonization of the urinary tract in vivo (Pak et al., 2001). Transurethral 
introduction of Klebsiella pneumoniae and Staphylococcus saprophyticus into the bladder of 
wild-type and uromodulin-knockout mice revealed a deceased clearance of these bacteria 
from the urinary tract in knockout mice. This finding suggests that the protective function of 
uromodulin against bacterial cystitis is not confined to infections with E.coli (Raffi et al., 
2005) 
Mo et al. (2004a) for the first time delivered in vivo results from uromodulin knockout mice 
indicating that uromodulin has a protective potential against calcium oxalate crystal 
formation.  
Numerous investigations have been undertaken concerning the affinity of uromodulin for 
other urinary proteins. Rhodes et al. (1993) demonstrated that urinary uromodulin binds 
immunoglobulin G. Evidence was provided for enhanced uromodulin-IgG interaction in both 
glomerulo- and interstitial nephritis patients. This appeared not to be true for children with 
malignancies of lymphoid cells (Olczak et al., 1999b; Olczak et al., 1999a).  
In vitro experiments regarding the binding of uromodulin glycomoiety to plant lectins, 
cytokines or albumin indicated for the resulting bonds to repress lymphocyte proliferation 
(Serafini-Cessi et al., 1979; Cummings & Kornfeld, 1982; Hammarstrom et al., 1982). 
Beyond that, polymorphonuclear neutrophils, lymphocytes and monocytes can bind to, and be 
activated by, uromodulin (Horton et al., 1990; Thomas et al., 1993; Yu et al., 1993).  
El-Achkar et al. (2008) showed that uromodulin-knockout (Umod
-/-
) mice are more 
susceptible to acute ischemic damage. Thus, after renal ischemia reperfusion injury, proximal 
tubular cells were more damaged and Toll-like receptor 4 (TLR4) was expressed to a greater 
extent in the proximal tubular cells of Umod 
-/-
 than in Umod
+/+
 mice. From their results the 
authors concluded that uromodulin can act as an indirect anti-inflammatory agent on 
neighbouring tubular segments as well. Therefore the authors suggested that the absence of 
uromodulin led to an increased inflammatory response and renal injury in THP
-/-
 mice. 
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The presence of uromodulin in the primary cilia of TALH cells points to a potential ciliary 
function of the protein. Ciliary expression of uromodulin was found to be reduced in MCKD2 
patients harbouring an UMOD mutation (Zaucke et al., 2010). 
Since uromodulin and its regulatory mechanisms have, for the most part, been studied under 
in vitro or standardized in vivo conditions, there is controversy as to whether the above 
observations are applicable to physiological or pathological processes in the body. (Moonen 
& Williamson; Vyletal et al., 2010). Comprehension of uromodulin in its full biological 
context remains therefore insufficient. However, the interest of the scientific community in 
uromodulin has risen in recent years, as a strong association of the uromodulin gene with 
chronic kidney diseases in humans has been identified in several genome wide association 
studies (Boger & Heid, 2011; Kottgen et al., 2012). The results of two studies also suggest a 
connection of single nucleotide polymorphisms close to the UMOD gene to hypertension and 
cardiovascular disease (Iwai et al., 2006; Padmanabhan et al., 2010). Padmanabhan et al. 
(2010) consider an impaired renal function as an influence on their findings .  
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2.3 Uromodulin-associated kidney disease (UAKD) 
2.3.1 Pathophysiology of UAKD  
2.3.2 Genetic causes  
Uromodulin-associated kidney disease (UAKD) is an autosomal dominant orphan 
nephropathy caused by an allelic disorder in the UMOD gene which, in humans, is located on 
chromosome 16. UAKD comprises three clinically diagnosed syndromes: familiar juvenile 
hyperuricaemic nephropathy type 1 (FJHN 1), medullary cystic kidney disease type 2 (MCKD 
2) and glomerular cystic kidney disease (GCKD) (Hart et al., 2002; Bleyer et al., 2011).  
 
Figure 2.3: Genomic and protein structure of uromodulin and positions of published UMOD mutations 
causing UAKD. Top panel: published human UMOD mutations as published in 2011 are shown relative to their 
location in the human UMOD gene and their effect on uromodulin protein sequence. Middle panel: exon and 
intron structure of the human UMOD gene. Bottom panel: Top single-nucleotide polymorphisms identified in 
genome-wide association studies are related to their position in the UMOD gene. (Rampoldi et al., 2011) License 
for the reuse of this figure was obtained in agreement with the Nature Publishing Group. 
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More than 50 UMOD mutations have hitherto been detected in humans (Figure 2.3). The 
majority of them clusters in exons 4, 5 and 8 of the gene which is located on chromosome 
16p12.3 (http://www.genenames.org/data/hgnc_data.php?hgnc_id=12559; Vyletal et al., 
2010; Bollee et al., 2011; Smith et al., 2011). More than 90% of them constitute missense 
mutations and 62% of all UMOD mutations affect a cysteine residue and thus potentially alter 
the tertiary protein structure (Williams et al., 2009). In-frame deletions occur to a small extent 
as well and can reduce the protein by up to 33 aa (Hart et al., 2002; Vyletal et al., 2010). 
Thus, the most frequent consequence of UMOD mutations is an aa exchange, oftentimes in 
the form of one more or less cysteine residue. So far, mutations leading to a complete loss of 
uromodulin expression could not be related to UAKD (Bleyer et al., 2011).  
2.3.3 Abnormalities at the molecular level  
While the known mutations in the UMOD gene lead neither to a complete loss of expression 
nor to the expression of a shortened protein, they may alter the aa sequence of uromodulin, 
with cysteine being the most frequently substituted residue (Dahan et al., 2003). The majority 
of such mutations was found in exon 4 which encodes the EGF-like domains (Hart et al., 
2002). Since all 24 cysteine residues are assumed to be part of intramolecular disulphide 
bridges, mutations affecting cysteine will lead to severe abnormalities in tertiary structure and 
protein stability. Similarly, a mutation-induced decrease in calcium affinity of EGF-like 
domains is likely to result in comparable structural alterations (Werner et al., 2000; Rampoldi 
et al., 2003). 
2.3.4 Effects at the cellular level in vitro 
Transient transfections of various cell lines with both mutant and wild-type UMOD constructs 
showed that plasma membrane expression of mutant uromodulin was significantly decreased 
when compared to wild-type controls. Immunofluorescence revealed that this impairment of 
protein trafficking was due to the conglomeration of immature mutant uromodulin in the 
enlarged endoplasmic reticulum. Wild-type uromodulin was still secreted in transfected cells 
but to a significantly lesser extent (Choi et al., 2005b). Western blot analysis on the other 
hand resulted in equal transcription/translation efficiencies for both wild-type and mutant 
uromodulin. The dominant negative effect of the mutation is evident in the fact that the 
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amount of wild-type uromodulin still generated falls to substantially less than fifty per cent 
(Bleyer et al., 2011). Of the intracellular uromodulin found in wild-type transfected cells, the 
greater fraction was localized in the Golgi apparatus (Bernascone et al., 2006) 
In 2005 Choi et al. observed a stronger early apoptosis signal in cells transfected with mutant 
uromodulin constructs. They also found, however, that colchicine, a mitosis inhibitor used to 
treat gout, and sodium 4-phenylbutyrate, a chemical chaperone, both enhanced uromodulin 
trafficking and excretion and led to a decrease in cell death. On the other hand, allopurinol, 
therapeutically used to control hyperuricaemia, had no effect on cell viability (Choi et al., 
2005b). Since in vitro experiments can only provide for cellular-level research, more coherent 
investigations of UAKD pathophysiology have to be conducted in vivo. 
2.3.5 Phenotypes of UAKD 
For a long time familiar juvenile hyperuricaemic kidney disease (FJHN) and medullary cystic 
kidney disease type 2 (MCKD2) were regarded as two distinct diseases with overlapping 
symptoms. The key phenotypic differentiator was the occurrence of corticomedullary cysts in 
MCKD2 versus a lack thereof in FJHN (Scolari et al., 2004). It turned out that the largely 
common phenotype was no coincidence: both FJHN and MCKD2 were genetically mapped to 
the same chromosomal region (16p11 – 16p13) and were caused by mutations in the UMOD 
gene. (Kamatani et al., 2000; Dahan et al., 2001; Hart et al., 2002; Wolf et al., 2007). An 
artificial separation between these two diseases has since given way to the widely-used term 
MCKD2/FJHN complex (Dahan et al., 2001; Bleyer et al., 2003).  
An Italian family displays yet a third phenotype due to a missense mutation in UMOD 
(C315R): glomerulocystic kidney disease (GCKD) (Gusmano et al., 2002; Rampoldi et al., 
2003).  
2.3.6 Clinical features of UAKD 
Hyperuricaemia is the first clinical sign of UAKD and usually starts during childhood due to 
insufficient renal excretion of uric acid. Most patients, especially males, develop gout and 
gouty arthritis in their teen years (Bleyer et al., 2003; Vylet'al et al., 2006). Over time, urinary 
uromodulin excretion diminishes to the point of complete absence. Urine concentration ability 
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may be impaired, leading to polyuria and paediatric enuresis (Bleyer et al., 2011). Further 
clinical sings of UAKD in humans frequently include a reduced fractional excretion of uric 
acid (men: < 5%; women: < 6%) or a creatinine clearance below 80 ml/min. Serum creatinine 
levels may rise above norm anytime between five and forty years of age. (Hart et al., 2002; 
Bleyer & Hart, 2007). It is not until later in life (between the third and seventh decade) that 
patients develop chronic renal failure and end stage renal disease and require renal 
replacement therapy. As UAKD progresses, ultrasound imaging may reveal macroscopic 
alterations of the kidney such as reduced renal volume or medullary cysts. However, those are 
inconsistent findings and cannot be regarded as pathognomonic for UAKD. (Dahan et al., 
2003; Bleyer et al., 2011).  
2.3.7 Histopathology  
Immunohistochemical staining of kidney biopsies of affected patients illustrates how mutant 
uromodulin forms clusters within the cytoplasm of TALH, thus contrasting the picture of 
control biopsies where anti-THP staining revealed a more even distribution of the protein 
throughout the cell, with a slight emphasis along the apical cell membrane (Dahan et al., 
2003; Rampoldi et al., 2003) (Figure 2.4).  
 
 
 
 
Figure 2.4: Immunohistochemical staining for uromodulin 
in human kidney biopsies. (A) Homogenous intracellular 
distribution and apical reinforcement of the uromodulin signal 
in the TALH cells of a control kidney biopsy. (B) Kidney 
biopsy of human with UMOD mutation showing condensed 
perinuclear clusters of the protein. (Vylet'al et al., 2006) 
License for the reuse of this figure was obtained in agreement 
with the Nature Publishing Group.  
 ___________________________________________________________________ Literature 
15 
 
Another common finding in both MCKD2/FJHN and GCKD is progressive interstitial fibrosis 
and tubular atrophy accompanied by thickened, lamellated basal membranes (Rampoldi et al., 
2003; Nasr et al., 2008; Smith et al., 2011) (Figure 2.5). Interstitial fibrosis and tubular 
atrophy are also referred to as IFTA (Bröcker et al., 2010). Typically, the renal interstitium of 
UAKD patients is focally infiltrated with inflammatory cells (Dahan et al., 2003). 
Occasionally, dilated or cystic tubules are part of the histopathology in MCKD2/FJHN 
patients but to a significantly lesser extent than the features described above (Scolari et al., 
2004). If at all, they are mostly diagnosed comparatively late (Bleyer et al., 2005). GCKD is 
distinguished by cystic dilations of the glomerular tuft while tubular cysts occur rather 
sparsely (Sharp et al., 1997; Scolari et al., 2004). Whether the sporadic occurrence of 
glomerulosclerosis is a consequence of tubular atrophy or not is subject to debate (Bleyer et 
al., 2005; Bleyer et al., 2011).  
 
  
 
 
 
Figure 2.5: Masson Trichrome staining of a 
representative renal biopsy specimen of a human 
patient with a UMOD mutation. Interstitial fibrosis 
appears as blue staining and surrounds tubules and 
glomeruli. Some of the tubules are dilated and show a 
flattened, at times wrinkled, epithelium. Original 
magnification x10. (Adam et al., 2012) License for 
the reuse of this figure was obtained in agreement 
with Elsevier.  
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2.3.8 Ultrastructural alterations 
In UAKD patients, the histopathological findings coincide with abnormalities on the 
ultrastructural level. Electron microscopy of renal biopsy tissue of UAKD patients revealed 
lamellar perinuclear stacks in TALH and distal tubule cells. What appeared to be hyperplastic 
membranes of the endoplasmic reticulum (ER) contained electron-dense accumulations of 
granules. The latter could be proven to be uromodulin by means of immunohistochemistry. 
No such abnormalities were observed in other cell compartments, nor were they found in 
proximal tubular cells. Cortical patches of tubular atrophy and interstitial fibrosis as well as 
interstitial infiltrates of mononuclear leukocytes were further findings which, in their context, 
all hinted to a storage disease that caused chronic tubulointerstitial nephropathy (Scolari et al., 
2004; Nasr et al., 2008). As for the assumption that the impairment of protein processing be 
confined to the ER, immunofluorescence staining revealed a colocalization of ER- and 
UMOD-markers in individuals suffering from UAKD (Vyletal et al., 2010) (Figure 2.6).  
 
 
Figure 2.6: Transmission electron 
microscopy (TEM) of a distal tubular cell. 
The cell contains hyperplastic ER bundles 
(arrow) where few mitochondria alternate 
with areas of dilated ER containing storage 
material (arrowhead). Electron micrograph, 
original magnification x6000. (Nasr et al., 
2008). License for the reuse of this figure 
was obtained in agreement with the Nature 
Publishing Group.  
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2.3.9 UAKD therapy  
To date, UAKD has been treated only symptomatically, meaning that patients receive 
allopurinol or, in case of intolerance, the uricosuric benzbromarone so as to ameliorate 
hyperuricaemia and gout (Fairbanks et al., 2002; Schaffer et al., 2010). Allopurinol inhibits 
xanthine oxidase, an enzyme that is necessary to form uric acid from xanthine and 
hypoxanthine (Pacher et al., 2006). While opinions diverge on the effect of allopurinol on the 
progression of renal disease, in vitro studies revealed that it did not help the intracellular 
trafficking of mutant uromodulin, nor did it improve cell viability (Moro et al., 1991; 
Fairbanks et al., 2002; Bleyer et al., 2003; Choi et al., 2005b) 
2.4 Murine models for functional analysis of uromodulin and of UAKD 
In vivo research of the function of uromodulin and of UAKD has been performed on 
knockout, transgenic and ENU-mutant mouse lines. In 2004, two knockout mouse lines were 
generated: Umod
tm1Kuma
 (Bates et al., 2004) and Umod
tm1Xrw
 (Mo et al., 2004b). To elucidate 
the pathomechanism of UAKD, a transgenic mouse line expressing the human C148W 
UMOD mutation was established by a Japanese group (Takiue et al., 2008b) while the murine 
mutation (C147W) corresponding thereto is represented by the Italian Tg
UmodC147W
 mouse line 
(Bernascone et al., 2010). Umod
A227T
 and Umod
C93F
 are both UAKD mouse lines derived 
from the Munich ENU-mouse mutagenesis project and harbour a point mutation in the Umod 
gene (Kemter et al., 2009; Prueckl, 2011).  
2.4.1 Knockout mouse lines  
The two knockout lines Umod
tm1Kuma
 and Umod
tm1Xrw
 were produced by means of gene 
targeting: A targeting vector disrupting the Umod gene was constructed, linearized, and 
electroporated into murine embryonic stem (ES) cells. ES cells showing the correct gene 
targeting were microinjected into blastocysts of C57BL/6J mice to obtain chimeras that were 
crossed with Black Swiss mice. Their offspring was screened for heterozygous (Umod
+/-
) 
mutant animals which were interbred to create wild-type (Umod
 +/+
) and homozygous   
(Umod
-/-
) mutant knockout mice. In line Umod
tm1Xrw
, exons 1-4 and a proximal promoter 
region of the Umod gene were deleted. In line Umod
tm1Kuma
, exon 2 of Umod was disrupted.  
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Both knockout lines were independently used to examine the role of uromodulin in ascending 
urinary tract infections. For this purpose, bladders of wild-type and knockout mice were 
inoculated with Type 1-fimbriated E.coli. Umod
tm1Kuma
 mice were also infected with Type P-
fimbriated E.coli. Despite the ability of the urothelium to chip bacteria-infested, apoptotic 
cells, bacterial colonization remained significantly higher in experimentally infected bladders 
of knockout mice. Since lectin adhesins of Type 1 fimbriae have been shown to bind to 
mannosylated glycoproteins of urothelial plaques, the results of the Umod knockout 
experiments gave rise to the assumption that uromodulin, being itself rich in mannose 
moieties, competitively binds to Type 1 fimbriae and thus acts as defence mechanism against 
urinary tract infection with this strain of E.coli (Bates et al., 2004; Mo et al., 2004b). In 
addition, Mo et al. (2004a) observed that their uromodulin-deficient mice (Umod
tm1Xrw
/ 
Umod
tm1Xrw
) were more prone to developing renal calcium oxalate crystals than wild-type 
controls. In their experiment drinking water had been supplemented with the oxalate precursor 
ethylene glycol (1%) and 4 IU/ml vitamin D3 to augment calcium absorption. The authors 
listed calcium-binding EGF-like domains of uromodulin as a potential explanation for its 
direct interference with renal stone formation. Umod
tm1Xrw
 knockout mice did not show 
features of UAKD, i.e. they exhibited neither renal cysts nor fibrosis up to 24 months of age 
(Bates et al., 2004). The blood chemistry and kidney function of Umod-knockout mice was 
inconspicuous under steady-state conditions. Umod
-/-
 mice of the Umod
tm1Xrw
 strain showed 
only significantly higher urinary sodium and chloride excretions than wild-type controls. 
Other ions and urinary creatinine excretion remained unchanged. It was therefore suggested 
that renal NaCl reabsorption might be impaired due to a uromodulin deficiency (Mo et al., 
2007).  
Like the Umod
tm1Xrw
 knockout strain, Umod
tm1Kuma
 knockout mice did not exhibit alterations 
in kidney morphology, serum electrolytes, water intake, or urine excretion of potassium and 
uric acid. In contrast to Umod
tm1Xrw
 knockout mice, Umod
tm1Kuma
 knockout mice had no 
alterations in urinary sodium excretion compared to wild-type littermate controls. 
Augmenting fluid consumption of Umod
tm1Kuma
 mice by sucrose administration had no effect 
on blood and urine parameters of knockout mice. However, there were three significant 
differences between Umod
-/-
 (Umod
tm1Kuma
 / Umod
tm1Kuma
) mice and their wild-type littermate 
controls: creatinine clearance in knockout mice was lowered by 63% compared to wild-type 
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controls. Secondly, wild-type mice counterbalanced water deprivation by reducing their 
urinary flow to 47%. Umod
-/-
 mice still excreted 72% of the original urine volume under these 
circumstances. No significant electrolyte losses were observed, though. Thirdly, a mild 
upregulation of various distal nephron transporters (α-subunit of Na+-K+-ATPase, NKCC2, 
NHE3, barttin, ClC-K2, ROMK, NCC, α-subunit of ENaC) was detected in Umod-/- mice 
under steady state conditions while juxtaglomerular mRNA expression of both COX-2 and 
renin were downregulated by 51% and 32%, respectively (Bachmann, Mutig et al. 2005). 
The Umod
tm1Xrw 
knockout strain was used to investigate the role of uromodulin in ischemia 
reperfusion injury (IRI). After reperfusion ischemia uromodulin expression rose in TAL cells 
and the interstitium of the outer medulla in Umod
+/+
 mice. Tubular dilation, necrosis and 
epithelial detachment were detected in both Umod
-/-
 and Umod
+/+
 kidneys after IRI, 
particularly in the outer medulla. In knockout mice necrotic tubules were visible after 15 
minutes clamp time while it took 30 minutes of IRI for wild-type kidneys to develop diffuse 
tubular necrosis. Overall renal injury was more severe in Umod
-/-
 mice at all times of IRI (15, 
and 30 minutes). As for tubular cast formation, it was found to correlate to the degree of renal 
injury rather than to the presence of absence of uromodulin (El-Achkar et al., 2008).  
2.4.2 Mutant human UMODC148W transgenic mouse line  
In 2008 Takiue et al. published a transgenic mouse line harbouring the human UMOD 
mutation C148W which had been found in FJHN/MCKD2 patients (Rampoldi et al., 2003). 
For the construction of the transgene, murine Umod promotor sequences were fused to the 
human UMOD cDNA sequence after incorporation of the T444G mutation. The 5587 bp 
murine Umod promoter-augmented T444G human UMOD chimeric gene construct was 
injected into fertilized oocytes of C57BL/6 inbred mice. 32% of the F0 offspring were found 
to harbour the transgene. Hemizygous mice were compared to non-transgenic littermates 
which served as wild-type controls (Rezende-Lima et al., 2004; Takiue et al., 2008b). RT-
PCR revealed murine Umod gene expression in both transgenic and wild-type kidneys 
whereas human UMOD mRNA detection was confined to transgenic kidneys. Both Western 
blot and immunofluorescence results showed the presence of human and murine uromodulin 
protein in microsomes of TALH cells. Murine uromodulin was expressed in the form of a 103 
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kDa and a 117 kDa protein in both strains. A comparison of the renal uromodulin levels of 
wild-type and transgenic mice revealed a significant increase of the 103 kDa protein in 
transgenic kidneys. Interstrain comparison of urine uromodulin excretion showed no 
difference at any age. However, transgenic mice excreted endogenous uromodulin only. Both 
forms of murine uromodulin (103 kDa and 117 kDa) as well as the 93 kDa human uromodulin 
appeared in the soluble and insoluble fraction of the Triton X-100 extraction, indicating that 
they all reached the plasma membrane (Takiue et al., 2008a). UMOD
C148W
 transgenic mice 
did not exhibit impaired kidney function (Takiue et al., 2008b). The authors suggest mice 
hemizygous for the UMOD
C148W
 mutation could serve as a model for the initial stages of 
UAKD granted that mutant uromodulin causes the accumulation of wild-type uromodulin in 
the plasma membrane and only later leads to decline in urinary excretion, followed by 
intracellular retention, cell death and extensive renal pathology (Takiue et al., 2008a) 
2.4.3 TgUmodC147W transgenic mouse line 
The second transgenic mouse model for UAKD was published by Bernascone et al. in 2010 to 
mirror the human UMOD mutation C148W by integrating the equivalent murine mutation 
C147W into an Umod minigene. The transgene comprised a 2.9 kb promoter, exons 1-11, the 
3’ sequence and, in front of EGF-like domain I, an HA-tag to mark the transgenic 
uromodulin. Two strains were produced: one with the wild-type Umod sequence and the other 
one harbouring the Umod mutation C147W. FVB mouse eggs were fertilized and injected 
with wild-type or C147W Umod transgene copies and produced 8 wild-type and 5 C147W 
transgenic founder mice. Both lines showed stable transmission of a fully inserted transgene 
and were inconspicuous compared to their non-transgenic littermates in terms of viability and 
general condition. Wild-type transgenic Umod mRNA expression was found to be 50% of the 
endogenous gene while C147W Umod transcription approximated the endogenous level to 
80%. Western blot analysis showed that both Tg
Umodwt
 and Tg
UmodC147W
 mice expressed two 
isoforms of transgenic uromodulin: the mature 120 kDa protein and its immature ER 
precursor protein of about 100 kDa. Compared to Tg
Umodwt
 kidneys, those of Tg
UmodC147W
 mice 
showed a markedly increased amount of both proteins, particularly of the precursor protein. 
Regarding the exact localization of uromodulin expression, immunofluorescence co-staining 
with nephron segment-specific markers confined it to the TALH and the distal convoluted 
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tubule. Western blot analysis of the urine revealed a clear reduction of both transgenic and 
endogenous uromodulin in Tg
UmodC147W
 mice. Immunohistochemistry for transgenic 
uromodulin depicted a protein accumulation in a granular pattern within the tubular cells of 
Tg
UmodC147W
 kidneys rather than on the apical cell membrane. Kidney sections of 3-month-old 
Tg
UmodC147W
 mice compared to those at 6 months of age showed that intracellular aggregation 
intensified with age. Tg
Umodwt
 kidney cells contained homogenously spread uromodulin with 
an increased localization along the apical membrane. In some Tg
UmodC147W
 kidney sections, 
the authors detected an increased amount of uromodulin along the basolateral membrane of 
tubular cells as well as interstitial uromodulin deposits and referred to an interstitial protein 
release as a potential explanation. Regarding the difference between wild-type and mutant 
uromodulin distribution within TALH cells, immunofluorescence results were concordant 
with immunohistochemistry. A co-localization of mutant uromodulin and ER chaperone 
markers specified the endoplasmic reticulum as the organelle of protein retention. In addition, 
the presence of intraluminal casts was a frequent observation in Tg
UmodC147W
 mice. In a 
comparison of baseline plasma and urine parameters between Tg
UmodC147W
 and Tg
Umodwt
 mice 
Tg
UmodC147W
 plasma showed significantly increased urea and creatinine concentrations. 
Plasma vasopressin activity was higher in mutant mice as well. Both water intake and urine 
excretion in mutant mice were higher than in Tg
Umodwt
 mice. Furthermore, Tg
UmodC147W
 strain 
had hypercalciurea as well as lowered urinary pH and osmolality. The urine concentrating 
ability of Tg
UmodC147W
 mice remained low after water deprivation. Since the expression of 
vasopressin and its target genes was elevated after water deprivation, the authors suspected 
this hypoosmolality to be based on kidney malfunction. Progressive histopathological lesions 
in Tg
UmodC147W
 kidneys were found by light and electron microscopy: Findings at 12 weeks of 
age included tubular dilation and casts, tubular atrophy, and foci of interstitial fibrosis and 
inflammatory infiltrates. At 24 weeks of age, tubulointerstitial damage had progressed and 
intensified. At this age, some of the dilated tubules had become cystic and were HA-positive, 
indicating a selective damage of TALH cells expressing mutant uromodulin. The renal 
medullary interstitium was infiltrated with a higher number of macrophages than at 12 weeks 
of age. Tubular basement membrane disintegration and epithelial detachment thereof were 
further observations. On ultrastructural analysis of TALH epithelium, intracellular membrane 
stacks appeared hyperplastic but ribosome-less and were filled with droplets of high electron 
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density. Other cellular compartments (organelles, membrane) were frequently defective as 
well. Tg
Umodwt
 mice exhibited no pathological findings between 3 and 6 months of age. An 
downregulation of both mRNA and protein expression of TALH-specific transporters 
(NKCC2, ROMK, ClC-Kb) but not of transporters characteristic for other nephron segments 
was regarded as further evidence for selective TALH damage (Bernascone et al., 2010).  
2.4.4 ENU-induced Umod mutant mice  
Two mutant mouse lines are subject to this study: Umod
A227T
 (UREHR4) and Umod
C93F
 
(UREHD1). Both are derived from the Munich ENU mouse mutagenesis project in which 
intraperitoneal injection of ENU 10-week-old male C3H mice produced random point 
mutations in spermatogonial stem cells. After mating them to C3H females, offspring 
occurred with mutant phenotypes interfering with various organ and metabolism functions 
(Aigner et al., 2007). For the generation of novel mouse models showing kidney disease, 
clinical chemical analysis was carried out at an interval of 3 weeks in 3-month-old animals. 
G1 mice with elevated plasma urea levels (>70 mg/dl) in both tests were selected for further 
breeding with wild-type CH3 females. Inheritance of abnormal phenotypes was tested in G2 
offspring from the mating of the affected G1 mouse and wild-type C3H mice. The screen for 
recessive mutations was carried out on G3 mice produced in a two-step breeding scheme from 
G1 mice which did not harbour dominant mutations. Inheritance of phenotypes in the inbred 
C3H genetic background was tested on G4 intercross or G4 x G3 backcross offspring 
(Rathkolb et al., 2000b; Rathkolb et al., 2000a; Aigner et al., 2007). Thus, the ENU mouse 
mutagenesis project resulted in the development of five mouse lines exhibiting increased 
plasma urea levels: The two mouse lines which are subject to this study are line UREHD1 and 
line UREHR4. Both mutant mouse lines harbour a dominant mutation, with mutant mice of 
line UREHD1 exhibiting a stronger phenotype than line UREHR4 (Aigner et al., 2007; 
Kemter et al., 2009; Prueckl, 2011).  
2.4.4.1 UmodA227T mutant mice  
The mutant mouse line UREHR4 was phenotypically grouped as an autosomal recessive 
mutant mouse line exhibiting increased plasma urea levels. In 2009, Kemter et al. identified 
the causative mutation of this mutant mouse line within the uromodulin cDNA nucleotide 
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position 971 leading to an aa exchange from alanine to threonine at position 227. Henceforth, 
the mouse line has been referred to as Umod
A227T
.
 
The mutation is of interest in that it occurs 
in a region of the gene which is well conserved between species and where numerous human 
UMOD mutations causing UAKD are known (W202, R204, C217, R222, C223, T225, P236, 
and C248) (Figure 2.7) (Bleyer et al., 2003; Dahan et al., 2003; Wolf et al., 2003; Kudo et al., 
2004).  
 
Figure 2.7: Uromodulin protein structure and sequence alignment of murine uromodulin. AA 202–252 
correspond to aa 201–251 of the human sequence. I-III: EGF-like domains; ZP domain: zona pellucida 
domain;*, N-terminal signal peptide; **, sequence contained in propeptide which is cleaved during protein 
processing and linked to a GPI anchor. Bold A: alanine at position 227. The positions of the different mutations 
reported in humans are highlighted (W202, R204, C217, R222, C223, T225, P236, C248) (6, 10, 21, 36). 
(Kemter et al., 2009) 
 
Clinical chemistry data of plasma and urine were collected for wild-type, heterozygous and 
homozygous Umod
A227T
 mutant mice of both genders. Wild-type littermates served as 
controls for all analyses performed. As adult heterozygous mutants mice also exhibited a mild 
phenotype significantly different from wild-type littermate controls, the Umod
A227T
 mutation 
were reclassified as a dominant mutation.  
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At 2 weeks of age, neither urea nor creatinine levels in the plasma of mutant mice were 
increased. While a trend towards higher plasma cholesterol and triglyceride levels was 
observed for two-week-old heterozygous mutant females, this did not apply to homozygous 
mutant females or mutant males. Four-month-old homozygous and heterozygous mutant mice 
of both genders exhibited plasma urea and creatinine levels that were significantly raised 
above those of sex-matched wild-type littermates. At this age, the plasma of both male and 
female mutant mice contained lower amounts of cholesterol, triglycerides and non-esterified 
fatty acids than that of gender-matched wild-type mice. Between ages 3 and 4 months, 
homozygous mutants excreted urine of comparatively low osmolality, its volume being 1.5 
fold higher than that of wild-type controls. Homozygous mutant mice of both genders also 
showed a marked decrease in urine-to-plasma ratios of sodium, potassium, urea and uric acid. 
Regarding fractional excretion values, however, only those for urea and uric acid were 
significantly lower in homozygous mutant mice. Hyperuricaemia did not occur presumably 
due to preserved uricase activity in mice which is absent in humans. Moreover, 
hypercalciuria, hypermagnesiuria and a decreased excretion of uromodulin were observed in 
both male and female homozygous mutant mice. Although mature, fully glycosylated 
uromodulin was detected in the urine of homozygous mutant mice, urinary uromodulin 
excretion was considerably decreased in homozygous mutant mice compared to wild-type 
mice. Only a mild increase of water consumption was detected in homozygous mutants Water 
deprivation revealed impaired urine concentrating abilities of homozygous mice. Body 
weight, fat mass and fat content were reduced in Umod
A227T
 mutants of both genders whereas 
their lean content was higher than that of wild-types. Also, homozygous mutant mice 
exhibited a significant reduction in metabolic rate. Osteopenia due to increased urinary 
calcium excretion was evident in four-month-old homozygous mutant mice where dual-
energy X-ray absorptiometry revealed a decline in bone mineral density and content. Upon 
light microscopy, kidneys sections of 3-6 month-old heterozygous and homozygous mutant 
mice did not differ from those of wild-type controls. Immunohistochemistry analysis on the 
other hand revealed that uromodulin distribution in mutant TALH cells compared to that of 
UAKD patients: protein clusters assembled around the nucleus and differed therefore from the 
homogenous, apically reinforced staining visible in wild-type kidney sections. Electron 
microscopy of mutant TALH cells bore further resemblance with UAKD histopathology: piles 
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of what appeared to be hyperplastic ER membranes with sporadically visible granules 
surrounded the nucleus. Mice heterozygous for the Umod
A227T
 mutation exhibited a milder 
phenotype than homozygous mutant mice of this line. Also, elevated plasma urea levels were 
detected at a higher age in heterozygous than in homozygous Umod
A227T
 mutant mice (Kemter 
et al., 2009). The authors suggest that mutant Umod
A227T
 uromodulin exerts a gain-of-toxic 
function by interfering with the ER homeostasis due to highly impaired uromodulin 
maturation and retention within the hyperplastic ER. The coordinated interaction of the 
numerous ion transporters expressed in TALH cells is important for the TALH function of 
reabsorbing up to 20% of the glomerular filtrate and for the ability of the kidney to 
concentrate and dilute urine (Gamba & Friedman, 2009). Therefore, structural alterations and 
disturbance of ER homeostasis due to maturation retardation of mutant uromodulin might 
cause TALH dysfunction in Umod
A227T
 mutant mice through which the impaired renal 
function like impaired urinary concentration ability, hypercalciuria and hypermagnesiuria can 
be explained (Greger, 1985; Gamba, 2005). Due to the afore-discussed parallels to UAKD 
pathology, the Umod
A227T
 line is regarded as a suitable murine model for this disease (Kemter 
et al., 2009).  
2.4.4.2 UmodC93F mutant mice  
The founder of this mouse line was male No. 20003171 of the Munich ENU mouse 
mutagenesis project. This G1 mouse exhibited high plasma urea levels in the clinical chemical 
screen and was subsequently identified as carrier of a dominant mutation. The mutant line 
UREHD1 was bred by mating phenotypically heterozygous mutant mice to C3H wild-type 
littermates (Aigner et al., 2007). The exact point mutation was later identified as the base pair 
exchange G→T of nucleotide 278 of the Umod gene. Causing a substitution of cysteine (C) 
by phenylalanine (F) at position 93 of uromodulin, this mutation affects disulphide bond C93-
C105 in the EGF-like domain II of uromodulin (http://www.uniprot.org/uniprot/Q91X17; 
Prueckl, 2011). An analogue disulphide bond exists in human uromodulin between C94 and 
C106 and can be disrupted by UMOD mutation C106Y (Figure 2.8) 
((http://www.uniprot.org/uniprot/P07911); Zaucke et al., 2010).  
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Figure 2.8: Uromodulin protein structure and sequence comparison of AA 6–106 (EGF-like domain II) 
between different species. I-III: EGF-like domains; ZP domain: zona pellucida domain;*, N-terminal signal 
peptide; **, sequence contained in propeptide which is cleaved during protein processing and linked to a GPI 
anchor. The red box marks the cysteine residue at position 93. The black boxes mark aa at positions C77, V93; 
and C106where human UMOD mutations have been identified (figure modified after Prueckl, 2011). 
 
Upon further phenotypic analysis of Umod
C93F
 mutant mice, the above described observations 
were confirmed: heterozygous Umod
C93F
 mutant mice showed significant urine concentration 
deficiency, accompanied by polyuria and polydipsia. Urinary uromodulin excretion was 
reduced in heterozygous mutant mice. At the age of 39-42 weeks, heterozygous Umod
C93F
 
mice of both genders were hypercalciuric and hypercalcaemic, had an increased plasma 
activity of alkaline phosphatase and showed signs of osteopenia. Male heterozygous mutant 
mice exhibited significant hypermagnesiuria and increased natri- and kaliuresis while a 
decreased plasma phosphate concentration was seen in heterozygous mutant females. 
Fractional excretion of both urea and uric acid was reduced, with heterozygous mutant mice 
showing uraemia from 7 weeks post-partum and homozygous mutant mice as early as 2 
weeks post-partum. Body weight of 5-week-old heterozygous mutant mice was significantly 
lower than that of wild-type littermates. Although their daily ingestion was increased, adult 
heterozygous mutant mice had a lower body fat mass and content and a higher lean content 
than wild-type controls. Blood plasma analysis performed on 9-month-old heterozygous 
Umod
C93F
 mutant mice revealed microcytic anaemia as well as a reduction in erythrocyte 
number, haemoglobin and haematocrit, mean corpuscular volume, mean corpuscular 
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haemoglobin and red blood cell distribution width. On the whole, a phenotypic analogy could 
be drawn between of heterozygous Umod
C93F
 mutant and homozygous Umod
A227T
 mutant 
mice (Prueckl, 2011).  
2.5 ER stress and the unfolded protein response 
Secretory proteins such as uromodulin undergo a series of folding, intra- and intermolecular 
disulphide bond formation and glycosylation that is initialized in the ER (Hubbard & Ivatt, 
1981; Kornfeld & Kornfeld, 1985; Fewell et al., 2001; Schroder & Kaufman, 2005). Only 
properly processed polypeptides leave the ER for further intracellular trafficking and 
modification in the Golgi apparatus (Ellgaard et al., 1999). A cellular mechanism referred to 
as “quality control” leads to the retention of misfolded or incomplete molecules in the ER 
where they become subject to further modification or degradation (Hurtley & Helenius, 1989; 
Klausner & Sitia, 1990). To a certain degree, abnormal polypeptides are physiological by-
products of protein synthesis which the cell is capable of coping with. If, however, an 
extensive accumulation of mutant, misfolded protein results in ER stress which in turn 
initiates the unfolded protein response (UPR) (Gething et al., 1986; Kozutsumi et al., 1988). 
The UPR tackles an ER-overload in two ways: ER hyperplasia and activation of ER-
associated chaperones and foldases are countermeasures to deal with already assembled 
protein (Schroder & Kaufman, 2005). This mechanism has been well conserved in the cellular 
evolution of yeast, worms, flies and vertebrates (Ishikawa et al., 2011). In addition, increased 
ER associated degradation (ERAD) disburdens the organelle from unfolded protein 
(Friedlander et al., 2000; Travers et al., 2000). To prevent further protein influx to the ER, 
DNA transcription and mRNA translation are reduced to a minimum (Harding et al., 1999; 
Martinez & Chrispeels, 2003; Pakula et al., 2003). If ER stress cannot be alleviated through 
the UPR, the affected cells will become apoptotic (Ma & Hendershot, 2002; Rutkowski & 
Kaufman, 2004). It has been suggested that reactive oxygen species are of relevance as 
triggers for ER stress (Yokouchi et al., 2008). On the other hand, reactive oxygen species are 
a side-product of increased protein oxidation during ER stress and may bring the UPR into 
action (Malhotra & Kaufman, 2007) (Figure 2.9).  
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Figure 2.9: Unfolded protein response scheme. Protein passage through the ER (orange) and main 
mechanisms of the unfolded protein response (blue) to accommodate the ER protein folding capacity to the 
protein influx into the ER. ER: endoplasmic reticulum, ROS: reactive oxygen species (Schroder & Kaufman, 
2005). License for the reuse of this figure was obtained in agreement with Elsevier.  
 
2.5.1 Molecular chaperones  
Although the primary structure of a protein encodes its three-dimensional arrangement and 
suffices for correct protein folding in vitro, conditions in vivo are more complex and require a 
quality control mechanism (refer to 2.5) to assure biosynthesis of intact proteins (Anfinsen, 
1973; Dobson & Karplus, 1999; Lee & Tsai, 2005). Chaperones play an essential part in 
protein quality control: they are proteins of various sizes and structures that catalyse protein 
biosynthesis without integrating into the final protein structure (Ellis, 2006). They do not only 
assist in correct polypeptide folding, oligomerisation, glycosylation or disulphide bond 
formation but also prevent protein aggregation (Fewell et al., 2001; Hartl & Hayer-Hartl, 
2002; Ellgaard & Helenius, 2003; Young et al., 2004). While chaperones are continuously 
expressed in the cell, their synthesis rate rises under cellular stress (Gething & Sambrook, 
1992). This was first discovered in cells exposed to heat and has given some chaperones the 
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name heat shock protein (Hsp). In the meantime, it has been found to apply to a myriad of 
cellular stress conditions leading to an accumulation of immature protein (Ananthan et al., 
1986; Craig & Gross, 1991). ER-associated chaperones and enzymes constitute three major 
groups: heat shock proteins (e.g. Hsp70) and their respective co-chaperones (e.g. Hsp40), 
lectins (e.g. calnexin, calreticulin) and protein disulphide isomerases (PDIs) (Nishikawa et al., 
2005). Typically, ER chaperones recognize and bind regions of nascent proteins that would 
not be exposed in the native state. Hsp70, for instance, binds and releases hydrophobic 
polypeptide regions in an ATP-dependent cycle (Bukau & Horwich, 1998). The ER 
membrane chaperone calnexin and its luminal analogue calreticulin, on the other hand, 
recognize monoglucosylated oligosaccharides of glycoproteins as their substrate (Trombetta 
& Parodi, 2003). While these lectins stabilize the polypeptide, enzymes such as PDIs catalyse 
intramolecular bond formation (Schrag et al., 2003). Proteins that fail to achieve their final 
structure remain bound to chaperones and thus eventually become a target for degradation 
(Hammond & Helenius, 1995).  
2.5.2 Chemical chaperones  
The term “chemical chaperones” was given to a group of exogenous, low molecular weight 
compounds which were found to assist and correct protein folding (Welch & Brown, 1996). 
This was first observed in the treatment of cells expressing mutant cystic fibrosis 
transmembrane conductance regulator protein (CFTR) with substances like glycerol and 
trimethylamine N-oxide (Brown et al., 1996). Hence, an ever increasing number of chemicals, 
including 4-PBA, have been discovered to improve protein homeostasis in ER storage 
diseases (Qi et al., 2004; Ozcan et al., 2006; Basseri et al., 2009; Malo et al., 2012). 
Sodium 4-phenylbutyrate: 
Sodium 4-phenylbutyrate (4-PBA) is the salt of 4-phenylbutyric acid, an aromatic fatty acid 
of low molecular weight (186.18 g/mol) that acts as a non-competitive inhibitor of histone 
deacetylase. In humans 4-PBA functions as a pro-drug, meaning that, after oral 
administration, mitochondrial β-oxidation in liver and kidney cells converts 4-PBA to 4-
phenylacetic acid (4-PAA) which is equally able to inhibit histone deacetylase and to 
penetrate the blood-brain barrier (Spira & Carducci, 2003; Scandinavian Formulas, 2011). 4-
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PAA is conjugated to coenzyme A (CoA) and the resulting compound, 4-phenylacetyl-
conenzyme A (4-PAA-CoA) binds to glutamine. This results in the formation of 4-
phenylacetyl which is excreted with the urine (Yu et al., 2001). In other mammals 4-PAA 
binds glycine rather than glutamine so that the compound excreted is phenylacetylglycine 
(Moldave & Meister, 1957). 4-PBA is licensed in Europe and by the FDA as a treatment for 
urea cycle disorders where its metabolites serve as ammonia scavengers (Brusilow, 1991; 
Iannitti & Palmieri, 2011). 4-PBA has furthermore been found to promote foetal haemoglobin 
production in sickle cell anaemia and β thalassemia (Dover et al.; Dover et al., 1994; Collins 
et al., 1995). Clinical and in vitro trials indicate that 4-PBA could ameliorate spinal muscular 
atrophy and cancer (Carducci et al., 2001; Mercuri et al., 2004). More recent investigations 
attend to the chaperone-like qualities of PBA, beginning with Rubenstein et al. who observed 
that 4-PBA interfered in vitro with the binding of Hsp70 to ΔF508 mutant CFTR protein in 
cystic fibrosis epithelial cells, thus “smuggling” mutant protein past degradation and allowing 
for it to be translocated to the plasma membrane (Rubenstein & Zeitlin, 2000). Since then, 
chaperone-like qualities of 4-PBA were observed in vivo and in vitro for a number of ER 
storage diseases (Chamcheu et al., 2011; Malo et al., 2012; Misawa et al., 2012). Regarding 
the effect of 4-PBA on intracellular trafficking of mutant uromodulin, two separate in vitro 
experiments have delivered concordant results: two sets of HEK293 and TALH cells were 
stably transfected with a vector coding for an in-frame UMOD bp deletion (H177_185del) and 
with another vector carrying a UMOD missense mutation (C148Y). For both types of cell and 
mutation, incubation with 4-PBA increased the amount of wild-type and mutant protein 
excreted from the ER and released into the culture medium. Moreover, it shifted the primarily 
cytosolic accumulation of mutant protein to an increased appearance along the plasma 
membrane. Viability of 4-PBA-treated mutant cells equalled that of untreated wild-type cells. 
In contrast, apoptosis occurred later and to a smaller extent in 4-PBA-incubated cells (Choi et 
al., 2005b). The chaperone-like effect of 4-PBA on MCKD cells expressing wild-type and 
C126R or C217G mutant uromodulin was strikingly similar (Ma et al., 2012). In addition to 
the results explicated above, Ma et al. were able to show that there was not only less of the 
molecular chaperone Hsp70 in C126R and C217G mutant cells but that 4-PBA incubation of 
these cells also boostered Hsp70 expression near wild-type levels. In vivo experiments 
concerning the interaction of 4-PBA and mutant uromodulin have not been published so far.  
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2.6 Oxidative stress in chronic kidney disease  
Chronic renal failure creates a disequilibrium between pro-oxidant metabolites and 
antioxidant systems in a way that reactive oxygen species (ROS) such as superoxide anions 
and peroxides cannot be sufficiently coped with by endogenous antioxidants like glutathione 
or superoxide dismutase (Hasselwander & Young, 1998; Martin-Mateo et al., 1999; Hambali 
et al., 2011). There is evidence that ROS play a role in the signalling pathways of cellular 
apoptosis and renal fibrosis which are common features of chronic kidney disease (Sarkar et 
al., 2011; Nie & Hou, 2012).  
4-Hydroxy-TEMPO: a superoxide dismutase mimetic:  
4-Hydroxy-TEMPO (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl), also referred to as 
tempol, is a heterocyclic nitroxide antioxidant (molecular weight 172.24 g/mol) (Wilcox, 
2010; Sigma-Aldrich, 2011). Tempol can penetrate the plasma membrane and mimics 
superoxide dismutase (SOD) by catalysing the conversion of superoxide anions and other 
ROS to H2O2 and O2 (Krishna et al., 1992; Krishna et al., 1996; Wilcox & Pearlman, 2008). 
The stable organic free radical tempol can be reduced to hydroxylamine by NADPH and 
cytochrome c in liver microsomes as well as by the sulfhydryl residues of proteins (Couet et 
al., 1985; Iannone et al., 1989). In vitro and in vivo comparisons of liver and kidney cells 
showed a shorter half-time reduction for tempol in kidney cells, which was attributed to renal 
mitochondria-richness (Kamataria et al., 2002; Ueda et al., 2003). Furthermore, renal injury 
was found to impair reducing conditions (Ueda et al., 2002; Oteki et al., 2005). Both acute 
and long-term administration of tempol to male spontaneously hypertensive rats (SHR) 
resulted in a blood pressure fall in more than 85% of all rats in the experiments (Okamoto & 
Aoki, 1963; Patel et al., 2006; Wilcox & Pearlman, 2008). Intravenously injected tempol 
induced a rapid response which, besides a blood pressure decline, included a lower heart rate 
and sympathetic tone but was reversed after 15 minutes (Xu et al., 2002, 2004; Patel et al., 
2006). The result of long-term oral and subcutaneous tempol administration was confined to a 
gradual decrease of blood pressure which then remained low for several weeks (Welch et al., 
2005). Systemic tempol administration reduced blood pressure in hypertensive mouse models 
as well (Dikalova et al., 2005). The blood pressure-reducing properties of tempol were also 
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observed in animal models where hypertension had been caused by renal artery clipping 
(Welch et al., 2003; Guron et al., 2006; Christensen et al., 2007), angiotensin II-infusion (Cai 
et al., 2003; Wang et al., 2003), deoxycorticosterone acetate and/or aldosterone salt (Ghosh et 
al., 2004; Hirono et al., 2007), or lead and zinc administration (Vaziri et al., 2001). Renal 
effects of prolonged tempol administration entail an increase in renal blood flow through 
medullary vasodilatation as well as enhanced natriuresis (Feng et al., 2001; Zou et al., 2001). 
Contradictive suggestions have been made as to whether tempol promotes or hinders proximal 
tubular reabsorption (Wu & Johns, 2004; Banday et al., 2005). In contrast, experiments 
performed on perfused TALH segments unanimously indicated an interaction of tempol with 
superoxide, the levels of which rise due to increased luminal flow, tubular transport or stretch. 
Inhibition of superoxide in turn reduced Na
+
 reabsorption in the TALH-segment (Ortiz & 
Garvin, 2002; Garvin & Hong, 2008).  
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3 Materials and methods  
3.1 Research design  
This study was performed on the Umod
A227 
and Umod
C93F
 mutant mouse lines and pursued two
 
objectives.  
First, the development and progression of renal alterations was compared between homozygous 
mutant, heterozygous mutant and wild-type mice of each mouse line. To this end, the occurrence 
of alterations was assessed qualitatively in both mouse lines. IFTA as well as inflammatory cell 
infiltrates, being the most consistent findings in Umod mutant mice, were quantified with 
stereological methods. Whether tubular atrophy affected TALH cells in particular was 
investigated by assessing the renal TALH cell content of these mice. The morphologic analysis 
of kidneys was performed in mice of two age groups (14-month-old and 20-22-month-old mice) 
to obtain information about disease progression and putative correlation of morphologic 
parameters and clinical phenotype. 
The second part of the study investigated the potential of the chemical chaperone 4-PBA and of 
the radical scavenger tempol as causative therapy for UAKD. Therefore, 4-PBA and tempol were 
administered orally to homozygous mutant and wild-type males of both mouse lines over a 
period of two months. A placebo group obtaining no drug served as control group. Evaluations 
of blood and urine parameters as well as morphological kidney analyses were performed to 
evaluate the putative therapeutic effect of drug administration. 
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Table 3.1: Number and age of mice for histological kidney analysis. wt: wild-type mice, het: heterozygous mutant 
mice, hom: homozygous mutant mice. m: male, f: female.  
 
Table 3.2: Number of mice in different types of analyses during the treatment assay. wt: wild-type mice, 
A227T: homozygous Umod
A227T
 mutant mice, C93F: homozygous Umod
C93F
 mutant mice.  
m f m f m f m f m f m f
Qualitative histological kidney 
14 months of age 10 5 9 11 7 4
20-22 months of age 18 13 18 7 20 10 15 19 28 19 4 3
Quantitative evaluation of 
histologic kidney alterations
14 months of age 6 7 7
20-22 months of age 6 6 6 6 6 6
Morphological kidney analysis 
Number of animals examined
Umod
A227T
homhetwthomhetwt
Umod
C93F
wt A227T C93F wt A227T C93F wt A227T C93F
Determination of body weight 
(every 7 days)
19 19 11 13 17 11 14 3 8
Spot urine samples (every 14 
days)
19 19 11 13 17 11 14 3 8
Clinical chemical analysis of 
blood plasma
2 months of age 19 19 11 13 17 11 14 3 8
3 months of age 19 19 11 13 17 11 14 3 8
4 months of age 19 19 11 13 17 11 15 6 13
Clinical chemical analysis of 
urine (at 4 months of age)
19 19 11 13 17 11 15 6 13
Metabolic cage analysis 19 19 11 13 17 11 15 6 13
Necropsy (at 4 months of age)
perfusion fixation of kidneys 9 9 6 5 5 5 1 1 2
kidney preparation for molecular 
analysis
9 10 5 8 12 6 14 5 11
Western blot analysis (urinary 
uromodulin)
19 19 11 13 17 11 15 6 13
Immunohistochemical analysis 
(kidney)
9 9 6 5 5 5 1 1 2
Utrastructural analysis (kidney) 3 4 3 3 4 4 2 2 2
Type of analysis
4-PBA tempol placebo
Number of animals (male) examined in each treatment group
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3.2 Animals 
The two mouse lines, Umod
C93F
 and Umod
A227T
, which were established in the Munich ENU 
mouse mutagenesis project, were analysed in this study. Both mutant mouse lines harbour a 
mutation within the Umod gene leading to an aa exchange. Major characteristics of the 
phenotype of Umod
C93F
 and Umod
A227T
 mutant mice include increased plasma urea levels and 
impaired urine concentrating ability (Kemter et al., 2009; Prueckl, 2011).  
The mutant lines were maintained in the mouse facility at the Chair for Molecular Animal 
Breeding and Biotechnology, Moorversuchsgut, Oberschleißheim under a controlled specific-
pathogen-free (SPF) hygiene standard according to the Federation of European Laboratory 
Animals Science Associations (FELASA) protocols (Nicklas et al. 2002; http://www.felasa.eu/). 
Mouse husbandry was performed under standard environmental conditions (22 ± 2°C, 40-50% 
relative humidity, 12 h light: 12 h dark cycle) and mice were provided with a standard rodent 
diet (V1124-3; Ssniff, Soest, Germany) and water ad libitum. Cages and drinking bottles were 
exchanged weekly. Depending on age and weight, groups of two to four animals per cage were 
kept in polycarbonate cages (Makrolon type II and II long). All animal experiments were 
conducted under the approval of the responsible animal welfare authority (Regierung von 
Oberbayern). 
Both mutant lines Umod
A227T
 and Umod
C93F
 were bred by crossing heterozygous mutant animals 
as well as by mating homozygous mutant males to heterozygous mutant females.  
Offspring were weaned three weeks post-partum and marked by ear punching. A small tissue 
sample was taken for DNA isolation and genotyping.  
3.3 Genotype analysis 
3.3.1 Tissue samples  
Tail tissue samples for DNA isolation were taken from three week old mice and stored at -20°C 
until further usage.  
 ___________________________________________________________ Materials and methods 
36 
 
3.3.2 DNA isolation  
For tissue digestion, 3-5 mm of mouse tails were each transferred into 1.5 ml Eppendorf tubes. 
After the addition of 400 µl cutting buffer master mix (375 μl cutting buffer (2.5 ml 1 M 
Tris/HCl pH 7.5, 5 ml 0.5 M EDTA pH 8.0, 1 ml 5 M NaCl, 250 μl 1 M DTT, 127 μl 
Spermidine, add distilled H2O to make 50 ml), 20 μl 20% SDS, 5 μl proteinase K [20 mg/ml]), 
tubes were incubated at 60°C overnight. On the following day, enzymatically indigestible tissue 
(bones, hair) was removed by centrifugation (5 minutes at 13000 rpm). The supernatant was 
transferred into a new 1.5 ml Eppendorf tube and DNA precipitation was achieved by the 
addition of 400 µl isopropanol and centrifugation at 13000 rpm for two minutes. The DNA pellet 
was washed twice in 70% ethanol. The pellets were air dried at room temperature. Depending on 
the pellet size, DNA was resuspended in 30–300 µl 10 mM Tris/HCl buffer (pH 8.0) and 
incubated at 37°C for 60 minutes. Until further usage the samples were stored at 4°C.  
3.3.3 DNA concentration assessment  
The concentration and purity of genomic DNA were determined by measuring optic density 
(OD) at the wavelengths 260 nm and 280 nm using a Gene Quant Pro spectrophotometer 
(Amersham Biosciences, Freiburg, Germany). 1:20 dilutions of DNA were used for this purpose. 
The final DNA concentration was adjusted to 100ng/μl. 
3.3.4 PCR for mouse genotyping  
PCR was carried out using the Taq polymerase Kit (Qiagen). The standard concentration of 
genomic DNA was 100 ng/μl. PCR conditions were optimized for the product lengths and the 
annealing temperature of the primers used. All PCR reactions were performed in 0.2 ml reaction 
tubes and prepared on ice. The standard composition of the reaction master mix for Taq-
Polymerase with a final volume of 20 μl was as follows:  
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 1x Preparation (μl) 
Aqua bidest.  9.15 
Q-Solution (Qiagen) 4 
10x Coralload PCR Buffer (Qiagen)  2 
MgCl2 50 mM (Qiagen) 1.25 
dNTPs 2 mM  0.5 
Primer 1 (2µM) 1 
Primer 2 (2 µM)  1 
Taq Polymerase 5 U/µl (Qiagen) 0.1 
DNA template  1 
 
The DNA templates were amplified using the Eppendorf PCR Thermocycler Gradient 
(Eppendorf, Hamburg) and the GeneAmp® PCR System 9700 Thermocycler (Applied 
Biosystem, California,USA).  
PCR conditions for genotyping the mouse lines since annealing temperature and extension time 
were as follows:  
PCR conditions for Umod
A227T
: 
 wild-type mutant time  
 
]35x 
Initial denaturation 94°C 94°C 5 min 
Denaturation 94°C 94°C 40 sec 
Annealing 66,5°C 65°C 40 sec 
Extension 72°C 72°C 1 min 
Final Extension 72°C 72°C 10 min 
Cool down 4 °C 4°C 15 min 
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PCR conditions for Umod
C93F
:  
 wild-type mutant time  
 
]35x 
Initial denaturation 94°C 94°C 5 min 
Denaturation 94°C 94°C 40 sec 
Annealing 63.5°C 65°C 40 sec 
Extension 72°C 72°C 50 sec 
Final Extension 72°C 72°C 8 min 
Cool down 4 °C 4°C 15 min 
 
Genotyping in both mutant lines was carried out by allele-specific PCR in two separate PCR 
reactions, one with primers for the amplification of the wild-type (wt) allele, and the other with 
primers for the amplification of the mutant (mut) allele.  
All oligonucleotides were obtained in HPLC-purified form from Thermo Fisher Scientific, Ulm.  
Oligonucleotides for genotyping Umod
A227T
 mice:  
Umod_3_for     5' - TGT GAG CCA GGA CTG GAC TG - 3'   (wt and mut) 
Umod_21_rev    5' - ATT GAG CCA CAT GGG TGC AGC - 3'   (wt) 
Umod_22_rev    5' - ATT GAG CCA CAT GGG TGC AGT - 3'   (mut) 
Oligonucleotides for genotyping Umod
C93F
 mice:  
Umod_26_for    5' - TCA CAA CGT GCT CCT GCC AGA C - 3'  (wt) 
INT1_UMOD_rev  5' - GTC AGA CGA AAA CCA TCC TTA C - 3' (wt) 
INT2_UMOD_for_neu 5' - GGC TCG TTT AAG TGC TCG TT - 3'  (mut) 
Umod_2_rev     5' - TAG CCC ACA CCA TAC TCT GTG C - 3' (mut) 
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3.3.5 Gel electrophoresis  
DNA fragments were separated according to their size via agarose gel electrophoresis. Agarose 
gels were prepared with 1× TAE buffer, 2% and ethidiumbromide (0.5 μg/ml). The DNA 
samples and a molecular weight standard were loaded into the gel slots and an electric current 
was applied. Bands were visualized by UV-light and photographs were taken (BioRad) for 
documentation. The DNA fragments were characterized by comparison with an appropriate 
molecular weight standard.  
3.4 Morphological analysis of age-related renal alterations in Umod mutant mice 
3.4.1 Necropsy and kidney preparation  
Mice of an age of 14 months and of 20 – 22 months were anaesthetized with ketamine-xylazine 
(1.0 ml ketamine 10%, 0.25ml xylazine 2%, 5.0 ml NaCl 0.9%) followed by cervical dislocation. 
The organs were dissected, blotted on tissue paper to remove fluid, and weighed to the nearest 
0.1 mg. The organs kidney, liver, spleen, urinary bladder, stomach, lung, and heart were 
weighed. Carcass weight (excluding head, skin and tail) was weighed to the nearest 0.01 g. Tail 
samples were collected for genotype analysis and stored at -20°C (refer to section 3.3). Left and 
right kidneys were separately immersion-fixed in 4% paraformaldehyde in PBS (37°C, pH 7.4).  
For stereological analyses, kidneys were cut perpendicular to the longitudinal axis of the kidney 
into 5-7 slices of equal thickness which were arranged with equal orientation in a tissue capsule, 
routinely processed and embedded in paraffin (Histomaster, Bavimed, Germany). From the 
paraffin-embedded kidney slices, approximately 4µm thick sections were cut, using a HM 315 
microtome (Microm GmbH, Germany). Sections were mounted on glass slides (Engelbrecht, 
Germany) and dried in a heating cabinet (Wagner & Munz GmbH, Germany) at 37°C for at least 
12 hours. For immunohistochemical analyses and PAS-silver staining, the sections were 
mounted on 3-aminopropyltriethoxy-silane-treated glass slides (Starfrost® microscope slides, 
Engelbrecht, Germany). 
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3.4.2 Qualitative histological analysis by light microscopic investigations 
Haematoxylin and eosin (H&E), Giemsa, Masson’s trichrome (MT), and PAS silver as well as 
uromodulin immunostaining were performed on kidney sections of both mouse lines and age 
groups for qualitative analysis. Blind qualitative evaluation of kidneys from Umod
C93F
 and 
Umod
A227T
 mutants as well as of wild-type mice was performed to assess the occurrence and 
distribution of renal histologic alterations. For each of a total of 220 animals, both the left and 
right kidney was evaluated. After complete evaluation of all animals, mouse line, genotype, 
gender and age were assigned to the specimen. Photographs of structural alterations were taken, 
using a Leica DFC 320 Digital Camera (Leica, Germany) connected to a microscope (Orthoplan, 
Leitz, Germany). For scale bars, an object micrometre (Zeiss, Germany) was photographed at the 
corresponding magnifications.  
3.4.2.1 Haematoxylin and eosin (H&E) staining  
To apply the H&E stain to the paraffin sections, the following solutions were prepared 
beforehand: 
 1% Eosin solution  
10 g Eosin G (Merck, Germany) were dissolved in 1000 ml hot aqua dest. and left to cool 
down. After the addition of 1.5 ml of 100% glacial acetic acid (Nr. 100063, Merck, 
Darmstadt) the solution was filtrated and stored at room temperature.  
 1% HCl ethanol stock solution  
7000 ml of 96% ethanol were mixed with 2500 ml aqua bidest. and 100 ml of 25% HCl 
(neoLab, Germany). 
 0.5% HCl ethanol, ready-to-use  
100 ml of 1% HCl stock solution was mixed with 100 ml of 70% ethanol.  
Following deparaffinization in xylene (Merck, Germany) and rehydration via descending alcohol 
series (2x 100% → 2x 96%, → 1x 70% ethanol), the slides were left in a glass cuvette 
containing Mayer’s haematoxylin (Merck, Germany) for 5 minutes, followed by a 5-minute 
rinsing with tab water. After differentiation in 0.5% HCl ethanol the slides were rinsed with tab 
water for 5 minutes and then dipped into 1% eosin solution 2-7 times. After dehydration in an 
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ascending alcohol series (1x 70% → 2x 96%, → 2x 100% ethanol), the slides were put in xylene 
(Merck, Germany) and mounted under coverslip slides (Menzel GmbH & Co KG, Germany) 
using Roti
®
-Histokitt (Carl Roth, Germany).  
3.4.2.2 Giemsa staining 
To apply Giemsa’s staining to the paraffin sections, the following solutions were prepared 
beforehand:  
 Phosphate buffer 
200 ml of dipotassium hydrogen phosphate (Nr.105104, Merck, Germany) at a concentration 
of 9.12 g/L were mixed with 160 ml of disodium hydrogen phosphate dihydrate (Nr. 106580, 
Merck, Germany) and the pH was adjusted to 6.7.  
 7% Giemsa solution  
200 ml of phosphate buffer (pH 6.7) was added to 14 ml of Giemsa stock solution (Nr. 
109204, Merck, Germany). The solution was set to a pH 6.7.  
 0.5% acetic acid  
5.0 ml of 100% glacial acetic acid (Nr. 100063, Merck, Germany) was added to 1.0 L of 
distilled water.  
The kidney sections were deparaffinised in xylene (Merck, Germany) and rehydrated in a graded 
alcohol series (2x 100% → 2x 96%, → 1x 70% ethanol). The sections were then rinsed with 
aqua dest. for 5 minutes and were immersed in 7% Giemsa solution and kept in a water bath at 
65°C. After 60 minutes, the slides were taken out and dipped into phosphate buffer for 2 
seconds, into 0.5% acetic acid (2x2 seconds) and into aqua dest. for 2 seconds. The slides were 
then run through an ascending alcohol series (1x 70% → 2x 96%, → 2x 100% ethanol) in order 
to dehydrate and were kept in xylene (Merck, Germany) until coverslip slides (Menzel GmbH & 
Co KG, Germany) were mounted using Roti
®
-Histokitt (Carl Roth, Germany). 
3.4.2.3 Masson’s trichrome (MT) staining (modified according to Goldner and Weigert) 
To apply the MT staining to the paraffin sections, the following solutions were prepared 
beforehand: 
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 Weigert's iron haematoxylin 
Solution A 
10 g of Haematoxylin crystalline (Merck, Germany) were dissolved in 1000 ml 96% ethanol. 
Solution A was left to maturation for 1 week.  
Solution B 
11.6 g of Iron (III) chloride (Merck, Germany) was dissolved in 980 ml aqua dest. and 10 ml 
of 25% HCl (neoLab, Germany). Solution B (prepared as a 1:1 mixture) was stored 
separately.  
 Red colour solution 
Solution A 
10g of acid fuchsine (Sigma, Germany) was added to 1000 ml boiling aqua dest. 10 ml 100% 
glacial acetic acid (Applichem, Germany). The mixture was left to cool down in closed glass 
bottle.  
Solution B 
10g of xylidine Ponceau (Waldeck, Germany) was added to 1000 ml boiling aqua dest. 10 ml 
100% glacial acetic acid (Applichem, Germany). The mixture was left to cool down in closed 
glass bottle.  
Azophloxine solution 
1.25 g Azophloxine (Chroma, Germany) was dissolved in 250 ml aqua dest and 0.5 ml 100% 
glacial acetic acid (Applichem, Germany) were added.  
To create the red colour solution, 20 ml of Solution A, 80 ml of solution B and 20 ml of the 
Azophloxine solution were mixed.  
 Phosphotungstic acid-orange G solution 
15 g of tungstophosphoric acid (Merck, Germany) and 10 g of organge G (Merck, Germany) 
were dissolved in 1000 ml aqua dest.. 
 Aniline blue 
10 g aniline blue (Serva Feinbiochemica, Germany) were dissolved in 1000 ml aqua dest. and 
10 ml of 100% glacial acetic acid (Applichem, Germany) were added.  
 0.5% acetic acid 
5 ml of glacial acetic acid 100% (Applichem, Germany) were added to 995 ml aqua dest..  
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Following deparaffinization in xylene (Merck, Germany) and rehydration via descending alcohol 
series (2x 100% → 2x 96%, → 1x 70% ethanol), he slides were left in a glass cuvette containing 
Weigert's iron haematoxylin for 5 minutes, followed by a 5-minute rinsing with tab water. After 
differentiation in 0.5% HCl ethanol the slides were rinsed with warm tab water for 5 minutes. A 
5-minute incubation with red colour solution was followed by 5 minutes of rinsing in 0.5% 
acetic acid, a 3-minute application of phosphotungstic acid-orange G solution and another 
rinsing in 0.5% acetic acid for 5 minutes. Anilin blue was applied to the sections for 5 minutes 
after which they were washed in 0.5% acetic acid for 5 minutes, and dehydrated through an 
ascending alcohol series (1x 70% → 2x 96%, → 2x 100% ethanol). The slides were immersed in 
xylene (Merck, Germany) and mounted under coverslip slides (Menzel GmbH & Co KG, 
Germany) using Roti
®
-Histokitt (Carl Roth, Germany).  
3.4.2.4 PAS-silver staining 
The following solutions were necessary to perform Rambourg’s technique (1967) of periodic 
acid-Schiff Silver staining (modified for paraffin sections):  
 1% periodic acid solution 
10 g periodic acid (Sigma, Germany) was added dissolved in 1000 ml aqua dest. 1.6 g 
sodium acetate (Merck, Germany) was dissolved in 100 ml aqua dest. The separately 
prepared solutions were mixed and stored at 4°C.  
 Sivler methenamine solution  
- 3 g hexamine (= hexamethyletetramine) were dissolved in 100 ml aqua dest. to create 3% 
hexamine (methamine) solution 
- 5 g silver nitrate (AppliChem, Germany) were dissolved in 100 ml aqua dest. to create a 5% 
silver nitrate solution.  
- 2 g disodium tetraborate decahydrate (Borax, Merck, Germany) was dissolved in 100 ml 
warm aqua dest. to create a 2% borax solution  
36 ml 3% hexamine solution and 4 ml 5% silver nitrate solution were stirred until the 
resulting precipitate had redissolved. 4 ml 2% borax solution were then added. The final 
solution was stirred and then filtered. The silver methenamine solution was warmed up 10 
minutes previous to usage.  
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 0.1% gold chloride solution 
0.1 g gold chloride (Merck, Germany) was added to 100 ml aqua dest.. 
 2% sodium thiosulfate solution  
2 g sodium thiosulfate (Merck, Germany) were added to 100 ml aqua dest.. 
 Schiff’s reagent (Carl Roth, Germany) 
The PAS-silver stain was performed as follows. First the kidney sections were deparaffinised in 
xylene (VWR, Germany) and rehydrated in a graded alcohol series (2x 100% → 2x 96%, → 1x 
70% ethanol). The sections were rinsed with aqua dest. for 5 minutes, followed by an immersion 
in 1% periodic acid solution for 15 minutes and another 5-minute washing in aqua dest.. The 
slides were then placed in a standing cuvette and immersed in filtered silver methenamine 
solution at 60°C for 25 minutes. From that point on, the sections analysed every 2-5 minutes 
under the light microscope. As soon as the basal membrane was clearly visible the sections were 
washed with aqua dest. for 5 minutes. By dipping the slides into 0.2% gold chloride solution for 
6 seconds, the staining was differentiated. This was followed by 5 minutes of washing with aqua 
dest., fixation in 2% sodium thiosulfate solution for 1 minute and another 5 minutes of washing 
in aqua dest. For drying, all slides were laid out on a heating plate at 70°C for 10 minutes and 
then reimmersed in aqua dest.. After that, the sections were left in Schiff’s reagent in complete 
darkness at room temperature for at least 45 minutes. After a 5-minute rinsing with aqua dest., 
the reaction intensity was checked on microscopically and Schiff’s reagent was reapplied if 
necessary. Otherwise, the slides were immersed in haematoxylin for 2 minutes and afterwards 
washed with aqua dest. for 5 minutes. Differentiation was achieved by briefly dipping the slides 
into 0.5% HCl alcohol (6-10 times) and was stopped by watering with aqua dest. for 5 minutes. 
The sections were dehydrated in an ascending alcohol series (1x 70% → 2x 96%, → 2x 100% 
ethanol) and finally immersed in xylene (VWR, Germany). Coverslip slides (Menzel GmbH & 
Co KG, Germany) were mounted onto the slides and sealed with Roti
®
-Histokitt (Carl Roth, 
Germany).  
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3.4.2.5 Uromodulin immunostaining of kidney sections  
Immunohistochemical staining using the avidin-biotin-complex (ABC) technique was carried out 
to detect uromodulin. Besides qualitative evaluation of the uromodulin staining pattern, it also 
served as a marker for TAHL cells used for quantitative evaluation (refer to section 3.4.3). 
1x TBS buffer was required for this procedure and diluted from a 10x TBS stock solution that 
consisted of:  
80 g   NaCl 
30 g  Tris 
Ad 10000 ml  aqua bidest. 
Adjust to pH 7.4 with 37% HCl 
Kidney sections were deparaffinised in xylene for 15 minutes, rehydrated in a descending 
alcohol series (2x 100% → 2x 96%, → 1x 70% ethanol) and washed in distilled water. In order 
to retrieve antigens the slides were boiled in 10 mM citrate buffer (pH 6.0) containing 0.05% 
Tween for 46 minutes with the steamer-microwave-method. After a 20-minute cool-down, TBS 
buffer was used to wash the sections for 10 minutes. Endogenous peroxidase activity was 
blocked by incubation 0.3% hydrogen peroxide in TBS at room temperature for 15 minutes, 
followed by a 5 minute-washing in TBS. The Biotin-Blocking Kit (Vector, Peterborough, UK) 
was used to perform a biotin blocking procedure, consisting of two 15 minute-incubations with 
avidin and then biotin at room temperature. Slides were washed in TBS for 10 minutes after each 
incubation. Afterwards, tissue slides were incubated for one hour at room temperature with 2% 
goat serum (diluted in TBS) for blocking. Rabbit-α-THP antibody (#sc-20631, Santa Cruz, 
Germany) was then applied to the sections at a dilution of 1:1000 in TBS. After an overnight 
incubation in the refrigerator, excess primary antibody was removed by 10 minutes of washing in 
TBS after which the sections could were incubated with the secondary antibody: biotinylated 
goat-α-rabbit IgG (Vector, UK) which had been diluted in 2% goat serum in TBS (1:200). 
Incubation duration was one hour, followed by a washing in TBS for 10 minutes. An avidin-
biotin complex (1:100 in TBS, Vector, UK) was then administered to the sections for 30 minutes 
at room temperature. After a final 10 minute-washing with TBS, H2O2-activated chromogen 33’-
diaminobenzidine (DAB, KEM-EN-TEC, Denmark) was pipetted onto the sections and left on 
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them for several minutes, until immunoreactivity was visible. It was taken care to rinse the slides 
with running tab water before the stain became too intense. Mayer’s haematoxylin (Merck, 
Germany) was used as a counterstain that was stopped by running tab water. Tissue dehydration 
was achieved by means of an ascending alcohol series. After clearing in xylene, all sections were 
mounted under coverslip slides (Menzel GmbH & Co KG, Braunschweig) using Roti
®
-Histokitt 
(Carl Roth, Germany).  
3.4.3 Quantitative stereological analysis  
Quantitative stereological investigations of murine kidneys were performed using the unbiased 
model-independent stereological methods as previously described (Gundersen & Jensen, 1987; 
Wanke et al., 1994; Herbach et al., 2005). The kidneys of at least six male mice per age group, 
line and genotype were evaluated. All three parameters were analysed for each kidney. Only 
right kidneys were used.  
3.4.3.1 Quantification of the renal volume fractions  
The volume fractions (Vv) of TALH cells, interstitial fibrosis and tubular atrophy (IFTA) and 
inflammatory cells (IC) in the kidney were determined by the point-counting method (Weibel, 
1979). Point-counting was carried out on paraffin sections by means of an image analysing 
system which consisted of a light microscope (BX41, Olympus, Germany), a colour video 
camera (DP72, Olympus, Germany) and the software new CASTTM (computer assisted 
stereological toolbox, Visiopharm®, Denmark).  
For all three components (TALH cells, IFTA, inflammatory cells) systematic random sampling 
was used to evaluate a pre-defined number of analysis samples per section Counting frames 
containing a point grid were placed upon the selected samples. The mean number of points 
counted per kidney was 10000 ± 300 for TALH and inflammatory cells and 8000 ± 300 for 
IFTA. The volume fractions of TALH, IFTA, and inflammatory cells in the kidney (Vv(TALH/kid) , 
Vv(IFTA/kid) and Vv(IC/kid) respectively) were calculated by dividing the sum of points hitting the 
TALH cells, IFTA and inflammatory cells, respectively (∑P(TALH), ∑P(IFTA) and ∑P(IC)) by the 
sum of points hitting renal tissue (∑P(kid)). 
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3.4.3.2 Quantification of the total volumes  
The renal volume was calculated by dividing its weight by its specific weight (1.05 mg/mm
3
) 
(Wanke, 1996). The total volumes of TALH, IFTA and inflammatory cells in the kidney 
(V(TALH,kid), V(IFTA,kid) and V(IC,kid)) were calculated as the products of the respective volume 
fraction (Vv(TALH/kid) , Vv(IFTA/kid) and Vv(IC/kid)) and V(kid). 
3.5 In vivo testing of two putative causative therapeutics for UAKD 
For testing a potential therapeutic effect of 4-PBA and tempol in UAKD, male homozygous 
Umod
A227T
 mutant mice, male homozygous Umod
C93F
 mutant mice and their respective wild-type 
littermates were used. There were three treatment groups: 4-PBA in drinking water, tempol in 
drinking water and placebo (drinking water with no chemicals added).  
3.5.1 Experimental schedule 
The age of two months (= day 0) marked the beginning of the experiment which lasted for 60±4 
days and was therefore performed on two to four-month-old mice. On day 0, the body weight of 
each mouse was taken and samples of spot urine were collected. 4-PBA and tempol were given 
continuously from day 0 throughout the experiment by the drinking water (refer to section 3.5.2). 
From day 0, body weight was measured weekly and spot urine was collected every other week. 
Sampling of blood plasma was performed at day 0, day 30±4 and at day 60±4 at the end of the 
experiment (refer to section 3.5.3). On day 56±4, the mice were individually transferred to 
metabolic cages (Tecniplast, No. 3600M021, Italy) for the assessment of the 24h-urine excretion 
as well as of drinking water and food intake. A 2-day conditioning period to the metabolic cage 
proceeded the two days of actual data collection. On day 60±4 the animals were anaesthetized 
and, after retro-orbital blood collection, formalin perfusion and necropsy were performed (refer 
to section 3.5.6).  
3.5.2 4-PBA and tempol administration 
The chemical chaperone 4-PBA acid (Scandinavian Formulas, Pennsylvania, USA, water 
solubility: 0.62 g/ml) was dissolved in drinking water and administered at a dosage of 1 g/kg 
body weight. 4-PBA solutions were renewed every third day. As a superoxide dismutase 
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mimetic, 4-hydroxy-tempo (Sigma Aldrich, St. Louis, Missouri, USA, water solubility: 
1.679 g/ml) was given as a 2 mM drinking solution. Due to its sensitivity to light, tempol was 
administered in black drinking bottles (Tecniplast, Italy) and exchanged every other day. 
Corresponding amounts of 4-PBA or tempol powder were weighed to the nearest 0.1 mg. The 
solutions were weighed into drinking bottles and the weight of the full, lid-covered bottles was 
recorded. On the day of solution exchange, the bottles were weighed again to determine the 
water intake per cage. Using this result, the average intake per mouse and day was assessed.  
3.5.3 Blood sampling and analysis 
For blood sampling, mice were anaesthetized (1.0 ml ketamine 10%, 0.25 ml xylazine 2%, 
5.0 ml NaCl 0.9%) by intraperitoneal injection (80-100 µl/10 g body weight) . 
The retro-orbital sinus was punctured with Na-heparin treated glass capillaries (Hirschmann 
Laborgeräte, Germany) and blood was collected in 1 ml lithium-heparin treated tubes (Kabe 
Labortechnik, Germany). By centrifuging the blood twice at 7000 rpm for 10 minutes, a volume 
of approximately 120 μl plasma was obtained, transferred into 1.5 ml tubes and stored at -80°C 
until further usage. The plasma parameters (sodium, potassium, calcium, chloride, phosphate, 
total protein, creatinine, uric acid, urea, cholesterol, TG, AST, ALT, lipase, amylase) were 
measured by Dr. B. Rathkolb, (Chair for Molecular Animal Breeding and Biotechnology, LMU 
München) within the German Mouse Clinic (Prof. Dr. M. Hrabé de Angelis) of the Helmholtz 
Zentrum München. An Olympus AU400 autoanalyzer (Olympus, Germany) was used with the 
respective kits. Plasma creatinine was determined using two different methods, Jaffé’s kinetic 
method (OSR6178, Beckman Coulter, California, USA; creatinine-J) and the enzymatic method 
(OSR61204, Beckman Coulter, California, USA; creatinine-E). 
3.5.4 Metabolic cage experiment 
On day 56±4 of the experiment, homozygous mutant animals and wild-type littermate controls 
were individually transferred to metabolic cages (Tecniplast, No. 3600M021, Italy) for two 
consecutive days for habituation. Crushed food (V1124-3; Ssniff, Soest, Germany) and water 
(containing 4-PBA, tempol, or neither) were provided ad libitum. On day 0 of analysis, the 
metabolic cages were cleaned. Body weight, food weight, and drinking bottle weight were 
 ___________________________________________________________ Materials and methods 
49 
 
measured before the mice were put in the cages. Urine was collected every 24 hours and stored 
at -80°C, and body weight, 24h-water intake, 24h-food intake, 24h-urine volume, and 24h-faeces 
excretion were measured. The mice were provided with fresh water and food on a daily basis. 
Both 4-PBA and tempol solutions were renewed daily while the mice were in the metabolic 
cages. The metabolic cage drinking bottles containing tempol solution were covered in 
aluminium sheet to prevent light penetration To avoid urine evaporation, 1 ml paraffin was 
added in the urine collecting tubes (for urine processing refer to section 3.5.5). On day 2 of the 
metabolic cage analysis (day 60±4 of treatment application), necropsy of mice for tissue 
preparation was performed (refer to section 3.5.6). 
3.5.5 Urine sampling and analysis  
The samples of both spot and 24h-urine of metabolic cage analysis were prepared for storage or 
further analysis in the same way. Urine was transferred into a labelled 1.5-ml- or 2.0-ml-
Eppendorf tube. The samples were centrifuged at 7000 rpm for 10 minutes. The supernatant was 
then pipetted into new 2.0 ml tubes and two 200-µl-aliquots of the 24h-urine were filled into 1.5-
ml-tubes. The urine was kept at -80°C until further usage.  
3.5.5.1 Analysis of clinical chemical parameters in urine  
A 200 µl aliquot of 24h-urine of day 1 and day 2 of metabolic cage analysis were used for 
clinical chemical analysis, performed by Dr. B. Rathkolb, (Chair for Molecular Animal Breeding 
and Biotechnology, LMU München) within the German Mouse Clinic (Prof. Dr. M. Hrabé de 
Angelis) of the Helmholtz Zentrum München. The following clinical chemical parameters of 
urine were determined: sodium, potassium, chlorine, calcium, magnesium, inorganic phosphate, 
creatinine, uric acid, urea, glucose, total protein, and albumin. Daily excretion of solutes was 
normalized to 25 g of body weight (based on the body weight measured on day 0 of analysis) 
and calculated as follows:  
solute excretion24h urine = urine volume24h x [solute]24h urine 
solute excretion24h urine,25g = solute excretion24h / body weightday0 x 25 
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Daily fractional excretion of solutes was calculated using the creatinine clearance of creatinine 
measured by the Jaffe method in the following way:  
creatinine clearance = urine volume24h x [Crea]24h urine / [Crea]plasma 
FEsolute = (urine volume24h x [solute]24h urine) / (creatinine clearance x [solute]blood) 
3.5.5.2 Analysis of urinary osmolality  
Osmolality of 24h-urine was measured with the freezing point method using a digital micro 
osmometer type 5B (Roebling, Germany). As the maximum measurement point of the micro 
osmometer is 2.000 mOsm/kg H2O, urine from polyuric mice was measured undiluted, whereas 
more concentrated urine was diluted in distilled water at a ratio of 1:2 or 1:4 etc. if need be. Each 
sample was measured twice. 
3.5.5.3 Analysis of uromodulin excretion  
Uromodulin excretion was determined by sodiumdodecylsulfat-polyacrylamide gel 
electrophoresis (SDS-PAGE) and Western immunoblot analysis. Therefore, the creatinine 
concentration of 24h-urine was determined (refer to section 3.5.4) and urine samples were 
standardized for equal creatinine concentration. For SDS-PAGE analysis, equal amounts of 
creatinine-standardized urine were boiled for 10 minutes after addition of 
1
/5-th 5xLaemmli 
(327.5 mM Tris-HCl pH 6.8, 5 mM EDTA, 10% SDS, 50% glycerol, 0.01% bromophenol blue) 
and 2-mercaptoethanol at a final concentration of 5%.  
SDS-PAGE:  
SDS-PAGE described by Laemmli in 1970 is a two-step separation of proteins along an electric 
potential. The anionic detergent SDS binds to the protein and the resulting positive charge of the 
protein is proportional to the mass of the molecule. Hence, the fractionation visible is mainly due 
to size. First all samples travel through a macroporous stacking gel of low acrylamide 
concentration so as to focus all proteins to a small area. The second part consists of a fine pored, 
more highly concentrated separating acrylamide gel in which smaller proteins will have travelled 
farther towards the anode after a certain amount of time.  
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The separating gel (10%, 4 gels) consists of:  
8 ml   aqua bidest.  
5 ml   1.5 M Tris-HCl (pH8.8) 
6.66 ml 30% acrylamide/bis solution (29:1) 
200 µl  10% SDS 
10 µl   Temed 
100 µl  10% APS 
 
The stacking gel (5%, 4 gels) consists of:  
7 ml   aqua bidest.  
1.25 ml  10,5M Tris-HCl (pH6.8) 
1.5 ml  30% acrylamide/bis solution (29:1) 
100 µl  10% SDS 
5.5 µl   Temed 
125 µl  10% APS 
 
The 1x SDS-Page running buffer consists of:  
100 ml  10x TBE 
Ad 1000 ml  aqua bidest.  
 
The Laemmli SDS-PAGE method was performed using the Miniprotean III-System (Biorad), 
respectively. The separating gel was poured between to glass plates in a gel caster which were 
then carefully covered with aqua bidest. The separating gel was left to polymerize for at least 60 
minutes. Then, after complete removal of any aqua bidest., the stacking gel was poured on top of 
the separating gel and combs were stuck into it. It also polymerized for at least 60 minutes at 
room temperature. 1x SDS-PAGE running buffer was filled into the prepared Miniprotean 
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system and the combs were removed. The gel pockets were rinsed with buffer in order to remove 
any acrylamide remnants that had not polymerized. A molecular weight size marker was run in 
one lane of each gel. The voltage applied to the Miniprotean III-system was 100 V until the 
separating gel was reached, followed by 140 V.  
Semi-dry-blot:  
With completion of SDS-PAGE, the proteins were transferred from the gel to a protein-binding 
Immobilon PVDF-membrane via electrophoresis. To perform this semi-dry-blot procedure a 
Trans-Blot SD electroblotter (BioRad) was used. A blot-sandwich was prepared on the lower 
anode unit in the following way:  
- 1 thick gel blotting paper (Biorad), soaked in transfer buffer 
- PVDF-membrane (activated with 100% methanol and labelled)  
- Gel 
- 1 thick of gel blotting paper (Biorad), soaked in transfer buffer  
 
The Ponceau S-solution consisted of:  
0.2 g   Ponceau S 
3 ml   Glacial acetic acid  
 
The cathode was then applied with mild pressure. Protein transfer occurred from cathode 
towards anode under 50 V for 45 minutes blotting time. After that, the proteins bound to the 
PVDF-membrane were reversibly stained with Ponceau S-solution for 2-5 minutes and the 
background was discoloured with aqua dest. The membrane was dried and the molecular weight 
size markers were labelled with a biro. Until further usage the membrane was stored at 4°C.  
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Western-immunoblot: 
The PVDF-membrane was put in a 50ml plastic tube and blocked by covering it in TBS-T BSA 
(5%) in a hybridization oven (room temperature) for 60 minutes. This causes saturation of 
potential protein binding sites on the membrane. Afterwards the membrane was washed three 
times in TBS-T (0.1% Tween in TBS) at room temperature (1x 15 minutes, 2x 5 minutes). The 
primary antibody (rabbit-anti-THP, #sc-20631, Santa Cruz) was diluted 1:1,800 in TBS-T-BSA 
(5%) and the membrane was incubated with it overnight at 4°C. After three more TBS-T 
washings of the membrane at room temperature (1x 15 minutes, 2x 5 minutes), the secondary 
antibody [HRP-conjugated goat-anti-rabbit IgG, Cell Signaling, diluted 1:2,000 in TBS-T-BSA 
(5%)] was added for 60 minutes at room temperature. Again, the membrane was washed three 
times in TBS-T at room temperature (1x 15 minutes, 2x 5 minutes). Signals were detected by 
means of an enhanced chemiluminescence detection solution and hyperfilm ECL (GE 
Healthcare). 
3.5.6 Necropsy and tissue preparation 
At the age of 4 months (experimental days 60±4), after the final measurements for the metabolic 
cage experiment (day 2), necropsy of mice was performed. Beforehand, they were anaesthetized 
with ketamine-xylazin solution, weighed and punctured retroorbitally for collecting blood 
samples (refer to section 3.5.3).  
For necropsy, mice were divided in two groups: in the first group of mice, kidneys were fixed via 
orthograde vascular perfusion. For this purpose, after euthanasia, the abdominal and thoracic 
cavity were opened by incision so that the perfusion needle could be injected into the left 
ventricle and, with the start of perfusion, the inferior vena cava was cut cranial to the diaphragm 
to provide outflow of the perfusate. Perfusion started with PBS (pH 7.4, 37°C) until the blood 
was washed out of the circulation. After about 20 seconds, perfusion was continued with 4% 
buffered paraformaldehyde solution and perfusion fixation occurred for 5 minutes. Afterwards, 
the organs were dissected, blotted on tissue paper to remove fluid, and weighed to the nearest 0.1 
mg. Kidney (without capsule), liver, spleen, and heart were weighed. Kidneys were lamellated 
perpendicular to the longitudinal kidney axis into 5-7 slices of equal thickness. Small 1 mm³ 
kidney cortex samples were selected by systematic random sampling and immersion fixed in 
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6.25% glutaraldehyde (Serva, Germany) in PBS (pH 7.4) which was further processed for 
transmission electron microscopic analyses (refer to section 3.5.7.2). The residual kidneys slices 
were postfixed in 4% paraformaldehyde for further 24 hours by immersion and processed for 
paraffin histology.  
For the second group of mice, necropsy was performed as described in section 3.4.1. Both 
kidneys were immediately frozen on dry ice and stored at -80°C for future molecular analyses.  
3.5.7 Histological kidney analysis after treatment application 
3.5.7.1 Light microscopic investigations 
For qualitative analysis of kidney sections by light microscopy, H&E and PAS-silver staining 
were performed (refer to sections 3.4.2.1 and 3.4.2.4.). 
3.5.7.2 Transmission electron microscopic investigations  
Transmission electron microspopic investigations were performed using using a Zeiss EM 10 
electron microscope (Zeiss, Germany). 
In advance, 1 mm³ kidney cortex samples were prepared in the following way. After fixation by 
immersion in 6.25% glutaraldehyde (Serva, Germany) in PBS (pH 7.4) at 8°C for 48 hours, 1 
mm³ kidney samples were postfixed in 1% osmiumtetroxide (OsO4, Merck, Germany), on a 
tumbling shaker, dehydrated and embedded in Epon (Epon is a trademark of the Shell Company 
(USA), but Serva (Germany) distributes the identical chemical substance under the designation 
“glycid ether 100” containing 2% osmium tetroxide (Serva, Germany)). Postfixed samples were 
washed in washing solution for 3 x 2 min at room temperature, dehydrated through a series of 
ascending acetone solutions (Carl Roth, Germany) at 4°C and incubated in a solution containing 
equal amounts of 100% acetone and Epon for 1 h at room temperature, followed by incubation in 
pure glycid ether 100 two times for 30 min at room temperature. Samples were embedded in a 
glycid ether embedding mixture in dried gelatine capsules (Plano, Germany). Polymerization 
took place at 60°C for approximately 48 h.  
Epon blocks were trimmed, using a Reichert-Jung TM60 milling machine (Leica, Germany). 
Semi-thin sections (0.5 μm) were produced with a Reichert-Jung Ultracut E microtome (Leica, 
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Germany), and stained with Toluidine blue O and Safranin O. The regions of interest within the 
semi-thin sections were identified by light microscopy and their positions were marked in a 
drawing. Then, these areas of the Epon blocks were trimmed further, and ultra-thin sections (70-
80 nm) were prepared (Reichert-Jung Ultracut E, Leica, Germany). The sections were mounted 
on coated copper rings, contrasted with 2% uranyl acetate and lead citrate, and examined under 
the electron microscope.  
Materials:  
 Sörensen’s phosphate buffer (Mulisch & Welsch, 2010) 
Solution A                192 ml 
Solution B                808 ml 
 
Solution A 
Potassium dihydrogen phosphate (neoLab, Germany)    9.078 mg 
Aqua dest.                ad 1000 ml 
Solution B 
Sodium phophate dibasic dihydrate (neoLab, Germany)   11.876 mg 
Aqua dest.                ad 1000 ml 
 Washing solution 
D(+) Saccharose (neoLab, Germany)        6.84 g 
Sörensen’s phosphate buffer           ad 100 ml 
 Fixative solution for Epon embedding 
D(+) Saccharose (neoLab, Germany)        0.45 g 
0.1 M HCl (Merck, Germany)          2 ml 
Veronal-acetate buffer            2 ml 
Osmium tetroxide solution 2%          5 ml 
Aqua dest.                1 ml 
 
Veronal-acetate buffer 
5.5-Diethylbarbituric acid Na-salt (Merck, Germany)     1.47 g 
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Sodium acetate (Merck, Germany)          0.97 g 
Aqua dest.                 50 ml 
Adjust pH to 10.3 
Osmium tetroxide solution 2% 
Osmium tetroxide (Chempur, Germany)         1 mg 
Aqua dest.                 50 ml 
 Ascending acetone series (Roth, Germany):  
Acetone 50%: 3 x 2 min, 4°C 
Acetone 70%: 2 x 10 min, 4°C  
Acetone 90%: 2 x 10 min, 4°C 
Acetone 100%: 2 x 20 min, 4°C 
Acetone 100%: 1 x 20 min, room temperature 
 Gycid ether embedding mixture  
Solution A                 70ml 
 Solution B                130 ml 
 
Solution A 
Glycid ether 100 (Serva, Germany)          62 ml 
2-Dodecenyl succinicacid anhydride (Serva, Germany)     100 ml 
Solution B 
Gycid ether 100 (Serva, Germany)          100 ml 
Methylnadic anhydride (Serva, Germany)        89 ml 
 
Staining procedures:  
 Staining protocol for semi-thin sections (Toluidine blue & Safranin O)  
Toluidine blue  
Di-sodiumtetraborate (Merck, Germany)         1 g 
Toluidine blue (Roth, Germany)            0.8 g 
Aqua dest.                  100 ml 
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Dissolve di-sodiumtetraborate in distilled water, add Toluidine blue and stir for 
approximately 2 h. Filter before use. Stain sections for 45-60 sec on a heating plate (Meditel, 
Germany) at 55°C, rinse with aqua dest. and let dry. 
 
Safranin O  
Di-sodiumtetraborate (Merck, Germany)         1 g 
Safranin O (Chroma, Germany)             1 g 
D(+) Saccharose (Merck, Germany)           40 g 
Formaldehyde 37% (Roth, Germany)           2-3 drops 
Aqua dest.                   ad 100ml 
Dissolve di-sodiumtetraborate in aqua dest., add Safranin O and saccharose  and stir for 
approximately 2 h. Add formaldehyde after 24 h. Filter before use. Stain sections for 15 sec 
on a heating plate (Meditel, Germany) at 55°C, rinse with aqua dest. and let dry. Cover the 
sections with coverslips (Menzel, Germany) using Histofluid (Superior, Germany). 
 Contrasting ultra-thin sections with uranyl acetate and lead citrate 
Uranyl acetate  
Uranyl acetate (Merck, Germany)            1 g 
Aqua bidest.                  50 ml 
Swing carefully without stirring. Filter before use. Stain sections for 30 min at room 
temperature. 
 
Lead acetate 
Sodium citrate (Merck, Germany)            6 ml 
Lead nitrate solution (Merck, Germany)           4 ml 
Sodium hydrate solution (Merck, Germany)          8 ml 
Aqua bidest.                  32 ml 
Mix sodium citrate with aqua bidest. and stir gently. Add lead nitrate solution drop by drop 
until the solution becomes milky (precipitation). Use sodium hydrate to clear the solution. 
Filter before use. Stain sections for 10 min at room temperature. 
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3.6 Statistical analysis  
Data were evaluated statistically using the Microsoft Excel 2003 software program. Data are 
presented as means ± standard deviation (SD). Data charts were created with GraphPad Prism 
5.0 (GraphPad Software, California USA). The significance of values was determined using the 
Student’s t-test. The Bonferroni method was applied to control the familywise error rate in 
multiple pair comparisons. p values < (0.05 / number of groups) were considered to be 
significant.  
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4 Results  
4.1 Allelic differentiation of Umod mutant mice  
Genotyping of Umod
A227T
 and Umod
C93F
 mice was conducted by allele-specific PCR-
amplification of the wild-type and the mutant allele, which enabled the distinction between wild-
type, homozygous mutant or heterozygous mutant animals, respectively (refer to section 3.3). 
4.1.1 Genotyping of UmodA227T mutants  
In order to genotype the mice of the Umod
A227T
 line, the wild-type allele was specifically 
amplified using the allele-specific reverse primer Umod_21_rev (5’ attgagccacatgggtgcagc 3’) 
and the forward primer Umod_3_for (5’ tgtgagccaggactggactg 3’), which yielded a 205 bp PCR 
product. Usage of allele-specific reverse primer Umod_22_rev (5’ attgagccacatgggtgcagt 3’) and 
forward primer Umod_3_for (5’ tgtgagccaggactggactg 3’) resulted in the amplification of the 
mutant allele (PCR product length of 205 bp) (Figure 4.1).  
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Figure 4.1: Electrophoresis of allele-specific PCR samples of Umod
A227T
 mutant mice. (A) Mutant allele; (B) 
Wild-type allele; lane M: pUC 8 marker, lanes 2, 3 and 8: wild-type; lanes 1, 4, and 7: heterozygous mutant; lanes 5 
and 6: homozygous mutant; lane 9: negative control (aqua bidest.).  
4.1.2 Genotyping of UmodC93F mutants  
For the Umod
C93F
 mutant mouse line, PCR-amplification of the wild-type allele was performed 
by means of the allele-specific reverse primer INT1_UMOD_rev (5’ gtcagacgaaaaccatccttac 3’) 
and the forward primer Umod_26_forward (5’ tcacaacgtgctcctgccagac 3’) and yielded a 171 bp 
PCR product. The allele-specific forward primer INT2_UMOD_for_neu (5’ ggctcgtttaagtgctcgtt 
3’) and the reverse primer Umod_2_rev (5’ tagcccacaccatactctgtgc 3’) produced the 
corresponding mutant 321 bp DNA segment (Figure 4.2).  
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Figure 4.2: Electrophoresis of allele-specific PCR samples of Umod
C93F
 mutant mice. (A) Mutant allele; (B) 
Wild-type allele; lane M: pUC 8 marker, lanes 1, 2 and 11: wild-type; lanes 3, 4, 7, 8 and 10: heterozygous mutant; 
lanes 5, 6 and 9: homozygous mutant; lane 12: negative control (aqua bidest.).  
 
4.2 Analysis of disease progression  
Compared to wild-type kidneys, renal histology of Umod
A227T
 and Umod
C93F
 mutant mice 
showed alterations in heterozygous mutant and homozygous mutant animals of both lines and 
age groups (14 months and 20-22 months). IFTA as well as inflammatory cell infiltrates were 
consistent pathologic findings in Umod
A227T
 and Umod
C93F
 mutant mice. Therefore, these two 
parameters were quantified by means of an unbiased, model-independent stereological approach 
in wild-type and mutant animals of each mouse line and age group. Morphometric analysis of 
renal TALH cell fractions was performed in order to investigate whether the development of 
kidney malfunction, together with a significant increase in IFTA in Umod
A227T
 and Umod
C93F
 
mutant mice, was caused by TALH cell atrophy.  
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4.2.1 Qualitative analysis of renal histopathology  
Qualitative evaluation of kidneys of Umod
A227T
 and Umod
C93F
 mutant mice at 20-22 months of 
age as well as of Umod
C93F
 mutant mice at 14 months of age revealed an increased occurrence of 
histologic alterations in heterozygous mutant and homozygous mutant mice of both lines and age 
groups when compared to wild-type controls (Table 4.1).  
 
Table 4.1: Qualitative assessment of the occurrence of renal alterations in Umod mutant and wild-type mice. 
m: male, f: female, wt: wild-type mouse, het: heterozygous mutant mice, hom: homozygous mutant mice. Criteria 
for interstitial fibrosis (approximations): >5% to 25% ≙ mild, >25% to 50% ≙ moderate, >50% ≙ severe. Criteria 
for interstitial inflammation (approximations):  >10% to 25% of parenchyma inflamed ≙ mild, >25% to 50% of 
parenchyma inflamed ≙ moderate, >50% of parenchyma inflamed ≙ severe (classifications based on Racusen et al., 
1999).  
m f m f m f m f m f m f m f m f m f
18 13 18 7 20 10 10 5 9 11 7 4 15 19 28 19 4 3
Tubular cysts 0 0 0 0 2 1 0 0 0 0 1 1 0 0 9 4 2 2
Glomerulocystic 
changes
0 0 0 0 0 1 0 0 0 0 1 0 0 0 2 3 1 0
Dilation tubular 4 1 8 2 17 7 1 0 1 2 3 1 3 3 25 17 4 3
Bowman's capsule 2 0 6 1 12 1 0 0 1 0 0 1 2 1 13 7 2 3
Hydronephrosis 0 0 3 2 5 3 0 0 0 0 2 2 0 1 5 6 3 1
Glomerulosclerosis 0 1 3 0 13 7 0 0 0 0 3 2 4 3 21 12 4 3
Interstitial fibrosis mild 8 5 6 4 0 0 2 1 7 8 3 0 6 5 1 2 0 0
moderate 0 0 8 3 8 5 0 0 2 3 2 3 1 0 19 12 0 0
severe 0 0 0 0 12 5 0 0 0 0 2 1 0 0 8 5 4 3
Inflammation mild 4 4 6 2 0 0 2 1 6 5 1 0 7 6 5 5 0 0
moderate 0 0 3 5 14 8 0 0 2 1 5 4 0 2 13 7 1 0
severe 0 0 1 0 6 2 0 0 0 1 1 0 0 0 10 7 3 3
het hom
20-22 months
Umod
C93F
14 months
hom wtwt het hom
Number of animals
Number of animals with renal alterations
Line
Age 20-22 months
Umod
A227T
wt het
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4.2.1.1 Interstitial fibrosis and tubular atrophy (IFTA)  
At 14 months of age, wild-type kidneys showed no pathological alterations while all 
heterozygous and homozygous Umod
C93F
 mutant mice exhibited IFTA. IFTA was predominantly 
apparent in the renal medulla with streaky extensions into the cortex. In some homozygous 
Umod
C93F
 mutant kidneys, the cortex was segmentally retracted due to focal interstitial fibrosis.  
At 20-22 months of age, sparse foci of IFTA appeared in some but not all wild-type kidneys. 
IFTA was further spread and appeared more intensely in age-matched mutants of both mouse 
lines. Although fields of IFTA were still primarily located in the corticomedullary region, 20-22-
month-old mutant mice also exhibited more cortical IFTA than those at 14 months of age. IFTA 
in the renal cortex was sometimes accompanied by segmental retraction thereof (Figure 4.3).  
Figure 4.3: IFTA in Umod 
mutant mice. (A) Mild interstitial 
fibrosis in the kidney of a 
heterozygous UmodA227T mutant 
mouse at 20 months of age. (B) 
Moderate interstitial fibrosis 
ramifying between tubules and 
(C) interstitial fibrosis 
accompanied by inflammatory 
cell infiltrates in the kidneys of 
homozygous Umod
C93F
 mutant 
mice at 14 months of age. (D) 
Interstitial fibrosis surrounding 
atrophic tubules in the kidney of a 
14-month-old homozygous 
Umod
C93F
 mutant mouse. Severe 
interstitial fibrosis in the kidneys 
of heterozygous Umod
C93F
 mutant 
mice at (E) 14 months of age and 
(F) 22 months of age. (A), (B), 
(C), (F): MT staining. (D), (E): 
PAS silver staining.  
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4.2.1.2 Inflammatory cell infiltrates  
Upon light microscopy, more and larger inflammatory cell infiltrates were detected in kidneys of 
14-month-old Umod
C93F
 mutant mice when compared to wild-type controls. The infiltrates found 
consisted mainly of lymphocytes and plasma cells and tended to be localized near the 
corticomedullary border.  
At an age of 20-22 months, the majority of larger inflammatory infiltrates found in the kidneys 
of Umod
A227T
 and Umod
C93F
 mutant mice was localized in the renal medulla and around vessels 
at the corticomedullary junction. Further, multiple smaller foci of inflammation were spread 
within the renal interstitium, also mainly in the corticomedullary region. In contrast, sparse and 
more scattered infiltrates were found in the kidneys of some wild-type mice (Figure 4.4).  
 
Figure 4.4: Pattern of inflammatory cell infiltrates in the kidneys of Umod mutant mice. (A) Larger infiltrates 
as well as disseminated inflammatory cells in the renal interstitium of a 14-month-old heterozygous Umod
C93F
 
mutant mouse. (B) Perivascular inflammation in the kidney of a homozygous Umod
A227T
 mutant mouse at 20 months 
of age. Giemsa staining.  
 
4.2.1.3 TALH cells  
At 14 months of age, immunohistochemistry for uromodulin revealed a homogenous distribution 
of the protein in wild-type TALH epithelial cells with distinct apical membrane reactivity of the 
signal. In contrast, TALH cells of Umod
C93F
 mutant mice showed a strong uromodulin signal in 
coarse clots around the nucleus. Looking at the distribution pattern of the TALH segments of the 
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kidney, section profiles of wild-type mice showed radial streaks of TALH in medulla and cortex. 
TALH segments found in kidneys of Umod
C93F
 mutant mice, on the other hand, were primarily 
located in the medulla with scarce and irregular scatters in the cortex.  
At the age of 20-22 months, the immunohistochemical staining pattern in TALH cells of both 
Umod
A227T
 and Umod
C93F
 mutant mice showed coarse, perinuclear dense aggregates. In contrast, 
a homogenously distributed and apically reinforced uromodulin signal was visible in TALH cells 
of wild-type mice. TALH cells of heterozygous and homozygous Umod
A227T
 mutant as well as of 
heterozygous Umod
C93F
 mutant mice contained both cytosolic and clustered uromodulin. TALH 
cells of homozygous Umod
C93F
 mutant mice contained almost exclusively aggregated 
uromodulin (Figure 4.5). 
 
Figure 4.5: Distribution of uromodulin within TALH cells in the kidneys of Umod mutant and wild-type mice. 
(A) TALH cells in the kidney of a 20-month-old wild-type mouse containing evenly distributed uromodulin with an 
enhanced presence along the luminal cell membrane. (B) TALH cells of a homozygous Umod
A227T
 mutant mouse at 
20 months of age, containing both clustered and homogenous cytosolic uromdodulin. TALH cells of (C) a 14-
month-old heterozygous Umod
C93F
 mutant and (D) a 20-month-old homozygous Umod
C93F
 mutant mouse where 
uromodulin is primarily present in the form of coarse perinuclear aggregates in the TALH cells.   
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4.2.1.4 Sporadic kidney alterations  
Besides larger aggregates of inflammatory cell infiltrates and farther spread IFTA, some kidneys 
of 14-month-old Umod
C93F
 mutant mice exhibited mild to moderate tubular dilation which was 
partially accompanied by epithelial disintegration. Renal cysts were a rare finding. In addition, 
periglomerular fibrosis and mildly to moderately dilated Bowman’s capsules were occasionally 
found in mutant and some wild-type mice of this age group. Mild to moderate dilation of the 
renal pelvis was inconsistently found in both heterozygous and homozygous Umod
C93F
 mutant 
mice at 14 months of age.  
At 20-22 months, some but not all wild-type kidneys occasionally showed mild dilation of 
tubules and Bowman’s capsules. Further sporadic abnormalities included glomerulosclerosis.  
Tubular dilation ranging from mild to high-degree was a frequent finding in 20-22-month-old 
Umod
A227T
 and Umod
C93F
 mutant mice and occurred mostly in the outer medulla. Some 
glomeruli were sclerotic and / or surrounded by a mildly to moderately dilated Bowman’s space. 
The above described abnormalities were found to a higher degree in heterozygous Umod
C93F
 
mutant than in heterozygous Umod
A227T
 mutant mice. Mild to moderate dilation of the renal 
pelvis occurred in homozygous mutant mice of both lines as well as in heterozygous Umod
C93F
 
mutant mice at 20-22 months of age (Figure 4.6).  
Figure 4.6: Tubular and 
glomerular dilative alterations. (A) 
Dilated and (B) cystic Bowman’s 
capsule and (C) tubular dilation/cyst 
in the kidneys of 20-month-old 
heterozygous UmodC93F mutant 
mice. (D) Cystic and dilated tubules, 
surrounded by interstitial fibrosis 
and tubular atrophy in the kidney of 
a 20-month-old homozygous 
UmodA227T mutant mouse. (A), 
(B), (C): H&E staining. (D): MT 
staining.  
 _______________________________________________________________________ Results 
67 
 
4.2.2 Quantitative stereological kidney findings  
20-22-month-old heterozygous and homozygous mutant males of both lines (Umod
A227T
  and 
Umod
C93F
) were compared to age- and gender-matched wild-type controls with regard to volume 
fractions and total volumes of IFTA, inflammatory cell infiltrates and TALH cells (refer to 
section 3.4). In order to assess age-related progressions of pathological alterations, 14-month-old 
male Umod
C93F
 mutant male mice were evaluated for the aforementioned parameters and 
compared to age-and gender-matched wild-type controls as well as to the 20-22-month-old 
Umod
C93F
 mice. For each genotype of each mouse line and age group, the right kidneys of 6-7 
mutant mice and 6-12 wild-type mice were evaluated.  
4.2.2.1 Interstitial fibrosis and tubular atrophy (IFTA)  
PAS-silver staining of paraffin kidney sections was used to quantify the volume fraction and 
total renal volume of IFTA.  
4.2.2.1.1 UmodC93F mutant mice at 14 months of age  
Both heterozygous and homozygous Umod
C93F
 mutant mice at 14-months of age exhibited 
significantly higher fractional volumes of IFTA (Vv(IFTA/kid)) than age-matched wild-type mice. 
Vv(IFTA/kid) was also significantly higher in homozygous than in heterozygous Umod
C93F
 mutant 
mice (Figure 4.7).  
Analogous to volume fractions of IFTA (Vv(IFTA/kid)), total volumes of IFTA (V(IFTA,kid)) were 
significantly increased in both heterozygous and homozygous Umod
C93F
 mutant mice when 
compared to wild-type controls (Figure 4.8).  
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Figure 4.7: Volume fractions of IFTA in kidneys (Vv(IFTA/kid)) of 14-month-old Umod
C93F
 mutant mice. 
Compared to wild-type littermates, mutants showed a significant increase in renal volume fractions of IFTA. Scatter 
dot plot lines represent mean ± SD; n=6-7 per genotype. wt: wild-type mice, het: heterozygous mutant mice, hom: 
homozygous mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.016, **, p<0.01, ***, p<0.001.  
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Figure 4.8: Total volumes of IFTA in kidneys (V(IFTA,kid)) of 14-month-old Umod
C93F
 mutant mice. Compared to 
wild-type littermates, mutant mice showed a significant increase in V(IFTA,kid). Scatter dot plot lines represent mean ± 
SD; n=6-7 per genotype. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous mutant mice. 
Student’s t-test with Bonferroni adjustment: *, p<0.016, **, p<0.01, ***, p<0.001.  
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4.2.2.1.2 UmodC93F and UmodA227T mutant mice at 20-22 months of age  
While volume fractions of IFTA in the kidneys (Vv(IFTA/kid)) of heterozygous Umod
A227T
 mutant 
mice were comparable to the volume fractions measured in age-matched wild-type kidneys, 
Vv(IFTA/kid) of homozygous Umod
A227T
 mutant as well as of heterozygous and homozygous 
Umod
C93F
 mutant mice surpassed the wild-type level to a significant degree. Moreover, 
homozygous Umod
C93F
 mutant Vv(IFTA/kid) values were distinctly higher than those of 
homozygous Umod
A227T
 mutant mice and heterozygous Umod
C93F
 mutant mice (Figure 4.9). 
Assessment of the total renal volumes of IFTA (V(IFTA,kid)) revealed analogous alterations (Figure 
4.10).  
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Figure 4.9: Volume fractions of IFTA in kidneys (Vv(IFTA/kid)) of 20-22-month-old Umod
A227T
 and Umod
C93F
 
mice. Homozygous mutant mice of both lines as well as heterozygous Umod
C93F
 mutant mice exhibited significantly 
higher volume fractions of IFTA than wild-type littermates. Maximum Vv(IFTA/kid) values were measured in 
homozygous Umod
C93F
 mutant kidneys while Vv(IFTA/kid) values of heterozygous Umod
C93F
 mutant mice were similar 
to those of homozygous Umod
A227T
 mutant mice. Scatter dot plot lines represent mean ± SD; number of animals 
analysed: n=12 wild-type mice, n=6 mutant mice per genotype and mouse line. wt: wild-type mice, het: 
heterozygous mutant mice, hom: homozygous mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.01, 
**, p<0.001, ***, p<0.0001. 
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Figure 4.10: Total volumes of IFTA in kidneys (V(IFTA,kid)) in 20-22-month-old Umod
A227T
 and Umod
C93F
 mice. 
Compared to wild-type littermates, heterozygous Umod
C93F
 mutant and homozygous mutant mice of both lines 
showed a significant increase in V(IFTA,kid). Within each mutant mouse line, V(IFTA,kid) levels of homozygous mutant 
mice lay also above those of heterozygous mutant mice. Scatter dot plot lines represent mean ± SD; number of 
animals analysed: n=12 wild-type mice, n=6 mutant mice per genotype and mouse line. wt: wild-type mice, het: 
heterozygous mutant mice, hom: homozygous mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.01, 
**, p<0.001, ***, p<0.0001.  
 
4.2.2.1.3 Vv(IFTA/kid) and V(IFTA,kid) in Umod
C93F
 mutant mice at different ages 
Although the values of both renal volume fractions (Vv(IFTA/kid)) and total volumes (V(IFTA,kid)) of 
IFTA were distinctly increased in Umod
C93F
 mutant mice within each age group (refer to sections 
4.2.2.1.1 and 4.2.2.1.2), neither parameter progressed notably between the age of 14 months and 
20-22 months within the respective genotype groups (Figure 4.11 and Figure 4.12).  
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Figure 4.11: Volume fractions of IFTA in kidneys (Vv(IFTA/kid)) of Umod
C93F
 mice at different ages. Within each 
genotype group, Vv(IFTA/kid) did not change significantly with age. Scatter dot plot lines represent mean ± SD; 
number of animals analysed: n=6-12 wild-type mice, n=6-7 mutants per genotype and mouse line. wt: wild-type 
mice, het: heterozygous mutant mice, hom: homozygous mutant mice. Student’s t-test vs. genotype-matched mice: 
*, p<0.05, **, p<0.01, ***, p<0.001.  
w
t 1
4 
m
o
w
t 2
0-
22
 m
o
he
t 1
4 
m
o
he
t 2
0-
22
 m
o
ho
m
 1
4 
m
o
ho
m
 2
0-
22
 m
o
0
10
20
30
V(IFTA,kid)
 (mm
3
)
 
Figure 4.12: Total renal volumes of IFTA (V(IFTA,kid)) in Umod
C93F
 kidneys at different ages. Within the 
respective genotype groups, V(IFTA,kid) did not change significantly between 14 and 20-22 months. Scatter dot plot 
lines represent mean ± SD; number of animals analysed: n=6-12 wild-type mice, n=6-7 mutants per genotype and 
mouse line. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous mutant mice. Student’s t-test vs. 
genotype-matched mouse: *, p<0.05, **, p<0.01, ***, p<0.001.  
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4.2.2.2 Inflammatory cell infiltrates  
Giemsa-stained kidney sections of Umod
A227T
 and Umod
C93F
 mutant mice were compared to 
those of age-matched wild-type mice (14 and 20-22 months) with regard to the fractional and 
total volumes of inflammatory cell infiltrates.  
4.2.2.2.1 UmodC93F mutant mice at 14 months of age  
Both volume fractions (Vv(IC/kid)) and total renal volume (V(IC,kid)) of inflammatory cell infiltrates 
were significantly higher in Umod
C93F
 mutant mice than in wild-type controls. Vv(IC/kid) measured 
for homozygous Umod
C93F
 mutant mice was also significantly higher than Vv(IC/kid) in 
heterozygous Umod
C93F
 mutant mice (Figure 4.13 and Figure 4.14).  
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Figure 4.13: Volume fractions of inflammatory cell infiltrates in kidneys (Vv(IC/kid)) of 14-month-old Umod
C93F
 
mice. Volume fractions of inflammatory cell infiltrates in the kidneys were significantly higher in both heterozygous 
Umod
C93F
 mutant and homozygous Umod
C93F
 mutant mice versus wild-type littermates. Scatter dot plot lines 
represent mean ± SD; n=6-7 per genotype. wt: wild-type mouse, het: heterozygous mutant mouse, hom: 
homozygous mutant mouse. Student’s t-test with Bonferroni adjustment: *, p<0.016, **, p<0.01, ***, p<0.001.  
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Figure 4.14: Total volumes of inflammatory cell infiltrates in kidneys (V(IC,kid)) of 14-month-old Umod
C93F
 
mice. Compared to wild-type littermates, mutants showed a significant increase in V(IC,kid). Scatter dot plot lines 
represent mean ± SD; n=6-7 per genotype. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous 
mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.016, **, p<0.01, ***, p<0.001.  
 
4.2.2.2.2 UmodC93F and UmodA227T mutant mice at 20-22 months of age  
Regarding volume fractions of inflammatory cell infiltrates (Vv(IC/kid)), heterozygous Umod
A227T
 
mutant mice had similar values as wild-type mice. In contrast, Vv(IC/kid) of homozygous 
Umod
A227T
 mutant mice as well as of heterozygous and homozygous Umod
C93F
 mutant mice 
were significantly higher compared to wild-type controls (Figure 4.15).  
Total volumes of inflammatory cell infiltrates (V(IC,kid)) were lowest in wild-type and 
heterozygous Umod
A227T
 mutant kidneys. V(IC,kid) in homozygous Umod
A227T
 mutant mice was 
higher than V(IC,kid) of both wild-type and heterozygous Umod
A227T
 mutant kidneys. V(IC,kid) in 
heterozygous and homozygous Umod
C93F
 mutant mice surpassed wild-type levels significantly 
(Figure 4.16).  
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Figure 4.15: Volume fractions of inflammatory cell infiltrates in kidneys (Vv(IC/kid)) of 20-22-month-old Umod
A227T and 
UmodC93F mice. Homozygous mutant mice of both lines as well as heterozygous UmodC93F mutant mice exhibited significantly 
higher volume fractions than wild-type controls. Scatter dot plot lines represent mean ± SD; number of animals analysed: n=12 
wild-type mice, n=6 mutants per genotype and mouse line. wt: wild-type mice, het: heterozygous mutant mice, hom: 
homozygous mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.01, **, p<0.001, ***, p<0.0001. 
w
t
A
22
7T
 h
et
A
22
7T
 h
om
C
93
F 
he
t
C
93
F 
ho
m
0
2
4
6
8
***
***
***
**
V(IC,kid)
 (mm
3
)
 
Figure 4.16: Total volumes of inflammatory cell infiltrates in kidneys (V(IC,kid)) of 20-22-month-old Umod
A227T and 
UmodC93F mice. Homozygous mutant mice of both lines as well as heterozygous UmodC93F mutant mice exhibited significantly 
higher total volume of inflammatory cell infiltrates than wild-type controls. Scatter dot plot lines represent mean ± SD; number 
of animals analysed: n=12 wild-type mice, n=6 mutant mice per genotype and mouse line. wt: wild-type mice, het: heterozygous 
mutant mice, hom: homozygous mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.01, **, p<0.001, ***, 
p<0.0001. 
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4.2.2.2.3 Inflammatory cell infiltrates in UmodC93F mutant mice at different ages  
Although there was a tendency towards an age-dependent increase in Vv(IC/kid) within each 
genotype-group, only 20-22-month-old heterozygous Umod
C93F
 mutant mice exhibited a 
significantly higher Vv(IC/kid) compared to genotype-matched mice at the age of 14 months. 
However, heterozygous Umod
C93F
 mutant mice at the age of 20-22 months constituted the group 
with the largest variation of Vv(IC/kid) values (Figure 4.17).  
In comparison, total volumes of inflammatory cell infiltrates in the kidneys (V(IC,kid)) of 20-22-
month-old wild-type and heterozygous Umod
C93F
 mutant mice were significantly higher than in 
the kidneys of genotype-matched 14-month-old mice. Older homozygous Umod
C93F
 mutant mice 
only showed a tendency towards an increase in (V(IC,kid)) when compared to 14-month-old 
homozygous mutant mice Again, heterozygous Umod
C93F
 mutant mice at an age of 14 months 
exhibited the largest variation of V(IC,kid) values (Figure 4.18).  
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Figure 4.17: Volume fractions of inflammatory cell infiltrates in kidneys (Vv(IC/kid)) of Umod
C93F
 mice at 
different ages. Within each genotype group, Vv(IC/kid) did not change significantly with age, with the exception of 
heterozygous Umod
C93F
 mutants. Scatter dot plot lines represent mean ± SD; number of animals analysed: n=6-12 
wild-type mice, n=6-7 mutants per genotype and mouse line. wt: wild-type mice, het: heterozygous mutant mice, 
hom: homozygous mutant mice. Student’s t-test vs. genotype-matched mice at 14 months: *, p<0.05, **, p<0.01, 
***, p<0.001.  
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Figure 4.18: Total volumes of inflammatory cell infiltrates in kidneys (V(IC,kid)) of Umod
C93F
 mice at different 
ages. In wild-type and heterozygous mutant mice a marked increase of V(IC,kid) was detected with age. Scatter dot 
plot lines represent mean ± SD; number of animals analysed: n=6-12 wild-type mice, n=6-7 mutant mice per 
genotype and mouse line. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous mutant mice. 
Student’s t-test vs. genotype-matched mice at 14 months: *, p<0.05, **, p<0.01, ***, p<0.001. 
 
4.2.2.3 TALH cells  
TALH cells were defined as those cells that were positive for anti-uromodulin 
immunohistochemical staining. In cases where only one cell of a tubule profile showed positivity 
for uromodulin, the remaining cells of the tubule profile were defined as TALH cells as well.  
4.2.2.3.1 UmodC93F mutant mice at 14 months of age  
TALH cell volume fractions (Vv(TALH/kid)) did not differ significantly between Umod
C93F
 mutant 
mice and wild-type controls. However, heterozygous Umod
C93F
 mutant mice showed a 
significantly higher mean Vv(TALH/kid) than homozygous Umod
C93F
 mutant mice (p = 0.0057) 
(Figure 4.24). Total TALH cell volumes (V(TALH,kid)) revealed no significant difference between 
mutants and wild-type controls. Notably, V(TALH,kid) values tended to drop in homozygous mutant 
Umod
C93F
 mice and the lowest V(TALH,kid) was measured in this group (Figure 4.20). 
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Figure 4.19: Volume fractions of TALH cells in kidneys (Vv(TALH/kid)) of 14-month-old Umod
C93F
 mice. 
Compared to wild-type littermates, mutants showed no significant decrease in Vv(TALH/kid). Homozygous mutant 
mice exhibited a significantly lower Vv(TALH/kid) than heterozygous mutant mice. Scatter dot plot lines represent 
mean ± SD; n=6-7 per genotype. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous mutant 
mice. Student’s t-test with Bonferroni adjustment: *, p<0.016, **, p<0.01, ***, p<0.001.  
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Figure 4.20: Total volumes of TALH cells in kidneys (V(TALH,kid)) of 14-month-old Umod
C93F
 mice. Compared to 
wild-type littermates, mutants showed no significant decrease in V(TALH,kid). There was a trend towards lower total 
TALH cell volumes in homozygous Umod
C93F
 mutant mice. Scatter dot plot lines represent mean ± SD; n=6-7 per 
genotype. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous mutant mice. Student’s t-test with 
Bonferroni adjustment: *, p<0.016, **, p<0.01, ***, p<0.001. 
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4.2.2.3.2 UmodC93F and UmodA227T mutant mice at 20-22 months of age 
At 20-22 months of age, neither heterozygous Umod
A227T
 mutant nor heterozygous Umod
C93F
 
mutant mice differed from age-matched wild-type controls with regard to TALH cell volume 
fractions. The kidneys of both homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 
mutant mice in this age group contained significantly lower fractional volumes of TALH cells 
when compared to wild-type controls (Figure 4.21).  
Similarly, total volumes of TALH cells of heterozygous mutant mice of both lines were not 
significantly below those of wild-type controls. Homozygous Umod
A227T
 and Umod
C93F
 mutant 
kidneys, on the other hand, contained significantly lower total volumes of TALH cells when 
compared to wild-type controls (Figure 4.22).  
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Figure 4.21: Volume fractions of TALH cells in the kidneys (Vv(TALH/kid)) of 20-22-month-old Umod
A227T
 and 
Umod
C93F
 mice. Compared to wild-type controls, homozygous mutant mice of both lines had significantly reduced 
renal Vv(TALH/kid). Scatter dot plot lines represent mean ± SD; number of animals analysed: n=12 wild-type mice, n=6 
mutant mice per genotype and mouse line. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous 
mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.01, **, p<0.001, ***, p<0.0001. 
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Figure 4.22: Total volumes of TALH cells (V(TALH,kid)) in 20-22-month-old Umod
A227T
 and Umod
C93F
 mice. 
Compared to wild-type controls, heterozygous mutant mice of both lines exhibited similar V(TALH,kid). In contrast, the 
V(TALH,kid) of homozygous Umod
A227T
 and Umod
C93F
 mutant mice was significantly lower compared to age-matched 
wild-type controls. Scatter dot plot lines represent mean ± SD; number of animals analysed: n=12 wild-type mice, 
n=6 mutant mice per genotype and mouse line. wt: wild-type mice, het: heterozygous mutant mice, hom: 
homozygous mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.01, **, p<0.001, ***, p<0.0001. 
 
4.2.2.3.3 Vv(TALH/kid) and V(TALH,kid) in Umod
C93F
 mutant mice at different ages  
Neither wild-type nor heterozygous or homozygous Umod
C93F
 mutant mice exhibited a 
significant change in fractional renal TALH cell volumes between the ages of 14 and 20-22 
months. There was, however, a tendency towards an age-related rise of Vv(TALH/kid) values in 
wild-type and heterozygous mutant mice. In contrast, Vv(TALH/kid) slightly dropped with age in 
homozygous Umod
C93F
 mutant mice (20-22 months of age compared to 14-month-old mice, 
p=0.066) (Figure 4.23).  
Regarding total renal TALH cell volumes (V(TALH,kid)), there was a significant increase with age 
in both wild-type and heterozygous Umod
C93F
 mutant mice. In contrast, the mean V(TALH,kid) 
dropped in aged (20-22-month-old) homozygous mutant mice of this line but the decline 
remained insignificant (p=0.1329) (Figure 4.24). 
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Figure 4.23: Volume fractions of TALH cells in kidneys (Vv(TALH/kid)) of Umod
C93F
 mice at different ages. Only 
homozygous mutant mice showed a tendency to a decreasing Vv(TALH/kid) value with age (p=0.066). Scatter dot plot 
lines represent mean ± SD; number of animals analysed: n=6-12 wild-type, n=6-7 mutants per genotype and mouse 
line. wt: wild-type mice, het: heterozygous mutant mice, hom: homozygous mutant mice. Student’s t-test vs. 
genotype-matched mice at 14 months: *, p<0.05, **, p<0.01, ***, p<0.001. 
w
t 1
4 
m
o
w
t 2
0-
22
 m
o
he
t 1
4 
m
o
he
t 2
0-
22
 m
o
ho
m
 1
4 
m
o
ho
m
 2
0-
22
 m
o
0
10
20
30
40
50
** *
V(TALH,kid)
 (mm
3
)
 
Figure 4.24: Total volumes of TALH cells in kidneys (V(TALH,kid)) of Umod
C93F
 mice at different ages. 
Homozygous Umod
C93F
 mutant mice leaned towards lower V(TALH,kid) values at a higher age. The opposite was 
detected in heterozygous mutant mice and wild-type controls. Scatter dot plot lines represent mean ± SD; number of 
animals analysed: n=6-12 wild-type, n=6-7 mutants per genotype and mouse line. wt: wild-type mice, het: 
heterozygous mutant mice, hom: homozygous mutant mice. Student’s t-test vs. genotype-matched mice at 14 
months: *, p<0.05, **, p<0.01, ***, p<0.001. 
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4.3 In vivo testing of two putative causative therapeutics for UAKD  
After the mating of heterozygous mutant animals in each mouse line, genotyping of the litters 
was performed in order to select a total of 47 wild-type, 42 homozygous Umod
A227T
 mutant and 
36 homozygous Umod
C93F
 mutant male mice for the therapy experiment. Each treatment group 
consisted of homozygous mutant mice from both mouse lines and of wild-type controls. 19 wild-
type, 19 homozygous Umod
A227T
 mutant and 11 homozygous Umod
C93F
 mutant mice were given 
4-PBA. The tempol treatment group consisted of 13 wild-type, 17 homozygous Umod
A227T
 
mutant and 11 homozygous Umod
C93F
 mutant mice. 15 wild-type, 6 homozygous Umod
A227T
 
mutant and 14 homozygous Umod
C93F
 mutant mice received drinking water only and thus 
constituted the placebo group. Having been divided into three treatment groups (4-PBA, tempol 
and placebo), all mice were compared with regard to body weight, clinical chemistry of blood 
plasma and urine, kidney function, urinary uromodulin excretion and renal histology (refer to 
section 3.5). 
4.3.1 Body weight 
During the 8 weeks of drug administration (4-PBA, tempol and placebo), the body weight of all 
mice was measured every 7 days. In all treatment groups and at all points of measurements, the 
lowest body weights were detected in homozygous Umod
C93F
 mutant mice, while the highest 
body weights were measured in wild-type mice. Of a total of 35 mice in the placebo treatment 
group, 10 animals were only tested at the age of 4 months and are therefore not included in the 
data presentation below (Figure 4.25).  
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Figure 4.25: Body weights of homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice 
compared to wild-type controls between day 0 and day 56 of (A) 4-PBA, (B) tempol and (C) placebo 
treatment. In both the 4-PBA and the tempol treatment group the body weights of homozygous Umod
A227T
 and 
Umod
C93F
 mutant mice remained significantly below those of wild-type controls. Data are represented as mean ± 
SD; number of animals analysed: n=9-19 wild-type, n=1-19 homozygous Umod
A227T
 mutant mice, 3-11 homozygous 
Umod
C93F
 mutant mice per treatment group. wt: wild-type mouse, A227T: homozygous Umod
A227T
 mutant mice, 
C93F: homozygous Umod
C93F
 mutant mice. Student’s t-test with Bonferroni adjustment: *, p<0.016, **, p<0.01, 
***, p<0.001, ****, p<0.0001. ° Umod
A227T
 body weight represents 1 animal only.  
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4.3.2 Clinical chemical analysis  
ER storage of mutant uromodulin results in disturbed ER homeostasis and subsequently in renal 
dysfunction leading to elevated plasma urea levels, which is the major phenotypic characteristic 
of Umod
A227T
 and Umod
C93F
 mutant mice. At the ages of 2, 3 and 4 months, plasma urea levels 
and other clinical chemical parameters were compared between the different genotypes within 
each treatment group (homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant male 
mice as well as wild-type male mice). Blood plasma parameters of genotype-matched mice 
receiving different treatments (4-PBA, tempol or placebo) were compared as well. The principal 
purpose of this analysis was to answer the question whether 4-PBA or tempol application may 
decrease plasma urea values of homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 
mutant mice to a level similar to the values in wild-type mice (Tables 4.2, 4.3 and 4.4).  
Regardless of treatment, the plasma urea levels of all mice increased with age. At all points of 
the analysis and within each treatment group, the plasma urea levels of homozygous Umod
C93F
 
mutant mice and those of homozygous Umod
A227T
 mutant mice were significantly above wild-
type mice levels.  
At the age of 3 months, wild-type mice of the 4-PBA treatment group exhibited a significantly 
higher plasma urea concentration than those of the placebo group. Although plasma urea 
concentrations of both wild-type and homozygous Umod
A227T
 mutant mice in the 4-PBA 
treatment group were significantly higher than in genotype-matched mice of the tempol 
treatment group, this had already been the case at the start of treatment application (at 2 months 
of age). Similarly, plasma urea concentrations of 3-month-old homozygous Umod
C93F
 mutant 
mice tended to be highest in the 4-PBA and lowest in the tempol treatment group but differences 
were insignificant.  
At 4 months of age, plasma urea concentrations were highest in mice receiving 4-PBA when 
compared to genotype-matched mice of other treatment groups (Figure 4.26).  
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Figure 4.26: Plasma urea levels of homozygous Umod
A227T
 and Umod
C93F
 mutant mice as well as of wild-type 
controls of the different treatment groups at the ages of (A) 2 months, (B) 3 months and (C) 4 months. All 
genotypes and treatment groups exhibited an increase in plasma urea concentration over time. Plasma urea levels 
tended to be highest for each genotype in the 4-PBA treatment group. At the age of 4 months, mutant mice in all 
groups exhibited significantly higher plasma urea levels than wild-type controls. Data represents mean ± SD. n=13-19 
wild-type mice, n=3-19 homozygous Umod
A227T
 mutant mice, n=8-13 homozygous Umod
C93F
 mutant mice; wt: wild-
type animal; Umod
A227T
: homozygous Umod
A227T
 mutant animal; Umod
C93F
: homozygous Umod
C93F
 mutant animal. 
Student’s t-test with Bonferroni adjustment: p: *, <0.016; **, <0.01; ***, <0.001; ****, <0.0001. §p<0.05 vs. 
matching genotype in 4-PBA treatment group; #p<0.01 vs. matching genotype in 4-PBA treatment group.  
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Plasma uric acid concentrations did not differ between mice of different genotypes in any of the 
treatment groups.  
Plasma cholesterol levels in Umod mutant mice tended to be decreased in all treatment groups at 
the ages of 2 and 3 months. At 4 months of age, both homozygous Umod
A227T
 mutant and 
homozygous Umod
C93F
 mutant mice reached cholesterol levels which were similar to those of 
wild-type controls within both the 4-PBA and the tempol treatment group. Plasma cholesterol 
values of wild-type and homozygous Umod
A227T
 mutant mice were highest in the tempol 
treatment group when compared to genotype-matched mice in the 4-PBA and placebo treatment 
groups (Figure 4.27).  
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Figure 4.27: Plasma cholesterol levels of homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant 
mice as well as of wild-type controls of the different treatment groups at the ages of (A) 2 months, (B) 3 
months and (C) 4 months. At the age of 2 and 3 months, homozygous mutant mice of both lines exhibited lower 
plasma cholesterol levels than wild-type controls. At 4 months of age, plasma cholesterol levels of mutant mice in 
the 4-PBA and the tempol treatment group showed no significant difference from those of wild-type mice. Mutants 
in the placebo group never exhibited significantly lower plasma cholesterol concentrations when compared to wild-
type mice. Data represent mean ± SD. n=13-19 wild-type mice, n=3-19 homozygous Umod
A227T
 mutant mice, n=8-
13 homozygous Umod
C93F
 mutant mice. wt: wild-type animal; Umod
A227T
: homozygous Umod
A227T
 mutant animal; 
Umod
C93F
: homozygous Umod
C93F
 mutant animal. Student’s t-test with Bonferroni adjustment: p:*, <0.01; **, 
<0.001; ***, <0.0001. §p<0.016 vs. matching genotype in 4-PBA treatment group; #p<0.01 vs. matching genotype 
in 4-PBA treatment group; $p<0.001 vs. matching genotype in 4-PBA treatment group, Ψp<0.01 vs. matching 
genotype in placebo group.  
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In all treatment groups, the plasma triglyceride concentrations of homozygous Umod
A227T
 mutant 
and homozygous Umod
C93F
 mutant mice were significantly beneath those of wild-type controls 
by the age of 3 months and remained low in 4-month-old mutant animals, regardless of the 
treatment received (Figure 4.28).  
A 2 Months
4-
PB
A
Te
m
po
l
Pl
ac
eb
o
0
100
200
300
WT
A227T
C93F
***
tr
ig
ly
c
e
ri
d
e
s 
(m
g
/d
l)
 
B 3 Months
4-
PB
A
Te
m
po
l
Pl
ac
eb
o
0
100
200
300
WT
A227T
C93F
***
***
***
***
 *
tr
ig
ly
c
e
ri
d
e
s 
(m
g
/d
l)
C 4 Months
4-
PB
A
Te
m
po
l
Pl
ac
eb
o
0
100
200
300
WT
A227T
C93F
***  **
**
 **
tr
ig
ly
c
e
ri
d
e
s 
(m
g
/d
l)
 
Figure 4.28: Plasma triglyceride levels of homozygous Umod
A227T
 and Umod
C93F
 mutant mice as well as of 
wild-type controls of the different treatment groups at the ages of (A) 2 months, (B) 3 months and (C) 4 
months. In all treatment groups plasma triglyceride levels in homozygous mutant mice of both lines were 
significantly lower when compared to wild-type controls. Data represents mean ± SD. n=13-19 wild-type mice, n=3-
19 homozygous Umod
A227T
 mutant mice, n=8-13 homozygous Umod
C93F
 mutant mice; wt: wild-type animal; 
Umod
A227T
: homozygous Umod
A227T
 mutant animal; Umod
C93F
: homozygous Umod
C93F
 mutant animal. Student’s t-
test with Bonferroni adjustment: *, p<0.016; **, p<0.01; ***, p<0.001; ****p <0.0001.  
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Both Jaffe- and enzymatically measured plasma creatinine levels tended to be increased in 
homozygous Umod
A227T
 and Umod
C93F
 mutant mice at all times of measurement. After two 
months of treatment, 4-PBA-treated homozygous mutant mice of both lines showed significantly 
increased creatinine levels when compared to wild-type controls. Animals which had been given 
tempol or placebo showed no genotypic difference. After two months of treatment, creatinine 
levels did not differ significantly between genotype-matched mice of different treatment groups.  
By the age of 4 months, plasma lipase activity was elevated in homozygous Umod
C93F
 mutant 
mice in the 4-PBA and placebo treatment group when compared to wild-type controls. The 
comparison of plasma lipase levels of genotype-matched mice receiving different treatments 
revealed no significant difference at this age.  
In the tempol treatment group, 4-month-old homozygous mutant mice of both lines exhibited 
significantly higher plasma levels of α-amylase than wild-type controls. The same was detected 
for homozygous Umod
C93F
 mutant mice in the placebo treatment group and for homozygous 
Umod
A227T
 mutant mice in the 4-PBA treatment group. Compared to the other treatment groups, 
α-amylase concentrations of wild-type and homozygous UmodC93F mutant mice were lowest in 
the 4-PBA treatment group.  
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Table 4.2: Plasma clinical chemistry of homozygous UmodA227T and UmodC93F mutant mice and wild-type controls at the 
age of 2 months. Data presentation as means ± SD; SD: standard deviation. Student's t-test with Bonferroni adjustment: *, 
p<0.016; **, p<0.01; ***, p<0.001; ****p <0.0001. n: number of the animals analysed. A227T: homozygous UmodA227T mutant 
mice, C93F: homozygous UmodC93F mice wt: wild-type mice. *) 10 of the 35 mice in the placebo group were tested at the age of 
4 months only.  
wt (n=19) A227T (n=19) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Na (mmol/l) 149 ± 3 149 ± 3 149 ± 5
K (mmol/l) 4.0 ± 0.4 4.2 ± 0.3 4.1 ± 0.2
Ca (mmol/l) 2.4 ± 0.1 2.4 ± 0.1 2.4 ± 0.1
Cl (mmol/l) 110 ± 2 110 ± 2 110 ± 4
Pi (mmol/l) 2.6 ± 0.3 2.6 ± 0.4 2.4 ± 0.3
Total protein (g/dl) 5.0 ± 0.3 4.8 ± 0.2 4.9 ± 0.2 *
Creatinine-J (mg/dl) 0.32 ± 0.05 0.33 ± 0.04 0.34 ± 0.02
Creatinine-E (mg/dl) 0.10 ± 0.02 0.11 ± 0.02 0.10 ± 0.02
Urea (mg/dl) 58 ± 6 84 ± 11 96 ± 17 **** ****
Uric acid (mg/dl) 1.1 ± 0.5 1.0 ± 0.5 0.9 ± 0.5
Cholesterol (mg/dl) 134 ± 10 126 ± 8 126 ± 8
Triglycerides (mg/dl) 118 ± 40 111 ± 45 97 ± 23
ALT (U/l) 27 ± 11 27 ± 7 36 ± 10 **
AST (U/l) 43 ± 5 41 ± 5 48 ± 7 **
Lipase (U/l) 53 ± 11 51 ± 11 55 ± 5
Amylase (U/l) 515 ± 32 520 ± 55 532 ± 46
wt (n=13) A227T (n=17) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Na (mmol/l) 147 ± 3 148 ± 4 147 ± 4
K (mmol/l) 4.0 ± 0.3 4.1 ± 0.3 3.8 ± 0.4
Ca (mmol/l) 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1
Cl (mmol/l) 110 ± 2 111 ± 2 110 ± 2
Pi (mmol/l) 2.5 ± 0.4 2.5 ± 0.4 2.2 ± 0.2 *
Total protein (g/dl) 4.9 ± 0.2 4.8 ± 0.2 4.9 ± 0.3
Creatinine-J (mg/dl) 0.32 ± 0.03 0.31 ± 0.02 0.31 ± 0.02
Creatinine-E (mg/dl) 0.10 ± 0.02 0.10 ± 0.02 0.09 ± 0.01
Urea (mg/dl) 53 ± 6 76 ± 9 96 ± 8 **** **** ****
Uric acid (mg/dl) 1.1 ± 0.7 0.8 ± 0.4 0.7 ± 0.2
Cholesterol (mg/dl) 133 ± 10 128 ± 9 122 ± 7 **
Triglycerides (mg/dl) 120 ± 24 87 ± 23 99 ± 38 ***
ALT (U/l) 33 ± 10 35 ± 29 39 ± 23
AST (U/l) 39 ± 6 39 ± 6 43 ± 7
Lipase (U/l) 50 ± 9 56 ± 16 50 ± 5
Amylase (U/l) 521 ± 50 524 ± 50 503 ± 30
wt (n=14) A227T (n=3) C93F (n=8) 
C93F vs A227T C93F vs wt A227T vs wt wt A227T C93F wt A227T C93F wt A227T C93F
Na (mmol/l) 148 ± 5 148 ± 2 148 ± 5
K (mmol/l) 3.9 ± 0.3 4.5 ± 0.5 3.9 ± 0.4
Ca (mmol/l) 2.3 ± 0.0 2.3 ± 0.0 2.3 ± 0.1
Cl (mmol/l) 110 ± 2 108 ± 2 110 ± 3
Pi (mmol/l) 2.6 ± 0.5 2.5 ± 0.3 2.3 ± 0.3
Total protein (g/dl) 4.9 ± 0.3 4.7 ± 0.1 4.9 ± 0.3
Creatinine-J (mg/dl) 0.29 ± 0.02 0.33 ± 0.01 0.33 ± 0.05 **
Creatinine-E (mg/dl) 0.09 ± 0.02 0.11 ± 0.03 0.10 ± 0.02
Urea (mg/dl) 58 ± 9 84 ± 26 98 ± 14 **** **
Uric acid (mg/dl) 0.8 ± 0.6 1.2 ± 1.2 0.8 ± 0.3
Cholesterol (mg/dl) 129 ± 13 115 ± 17 122 ± 8
Triglycerides (mg/dl) 111 ± 55 104 ± 8 89 ± 38
ALT (U/l) 29 ± 9 57 ± 51 33 ± 10 **
AST (U/l) 40 ± 3 44 ± 9 44 ± 4 *
Lipase (U/l) 53 ± 10 57 ± 4 54 ± 12
Amylase (U/l) 499 ± 31 518 ± 31 533 ± 76
t-test
4-PBA
t-test
Tempol
t-test
Placebo
*) Treatment comparison
4-PBA vs Placebo Tempol vs Placebo Tempol vs 4-PBA
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Table 4.3: Plasma clinical chemistry of homozygous UmodA227T and UmodC93F mutant mice and wild-type controls at the 
age of 3 months. Data presentation as means ± SD; SD: standard deviation. Student's t-test with Bonferroni adjustment: *, 
p<0.016; **, p<0.01; ***, p<0.001; ****p <0.0001 n: number of the animals analysed. A227T: homozygous UmodA227T mutant 
mice, C93F: homozygous UmodC93F mutant mice. wt: wild-type mice. ALT: alanine aminotransferase; AST: aspartate 
aminotransferase. *) 10 of the 35 mice in the placebo group were tested at the age of 4 months only.   
wt (n=19) A227T (n=19) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Na (mmol/l) 153 ± 4 152 ± 3 150 ± 4
K (mmol/l) 4.3 ± 0.5 4.2 ± 0.3 3.9 ± 0.3
Ca (mmol/l) 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1
Cl (mmol/l) 112 ± 4 113 ± 3 111 ± 2
Pi (mmol/l) 2.2 ± 0.2 2.3 ± 0.3 2.2 ± 0.3
Total protein (g/dl) 5.3 ± 0.3 5.2 ± 0.3 5.0 ± 0.2 *
Creatinine-J (mg/dl) 0.31 ± 0.05 0.34 ± 0.03 0.35 ± 0.06 *
Creatinine-E (mg/dl) 0.10 ± 0.02 0.11 ± 0.02 0.11 ± 0.01 **
Urea (mg/dl) 65 ± 5 103 ± 10 122 ± 19 *** **** ****
Uric acid (mg/dl) 1.5 ± 1.2 1.1 ± 0.6 1.0 ± 0.6
Cholesterol (mg/dl) 139 ± 11 126 ± 10 117 ± 8 **** ***
Triglycerides (mg/dl) 188 ± 62 117 ± 37 99 ± 51 *** ***
ALT (U/l) 35 ± 11 31 ± 7 32 ± 8
AST (U/l) 48 ± 15 45 ± 6 50 ± 15
Lipase (U/l) 49 ± 7 53 ± 7 54 ± 15
Amylase (U/l) 515 ± 39 511 ± 47 512 ± 48
wt (n=13) A227T (n=17) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Na (mmol/l) 152 ± 3 153 ± 3 151 ± 3
K (mmol/l) 4.1 ± 0.3 4.2 ± 0.3 4.0 ± 0.3
Ca (mmol/l) 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1
Cl (mmol/l) 110 ± 3 113 ± 2 111 ± 3 **
Pi (mmol/l) 2.1 ± 0.3 2.3 ± 0.3 1.9 ± 0.4
Total protein (g/dl) 5.2 ± 0.20 5.0 ± 0.3 5.1 ± 0.3
Creatinine-J (mg/dl) 0.30 ± 0.03 0.32 ± 0.02 0.31 ± 0.02
Creatinine-E (mg/dl) 0.09 ± 0.02 0.11 ± 0.02 0.10 ± 0.02
Urea (mg/dl) 58 ± 5 90 ± 12 113 ± 11 **** **** ****
Uric acid (mg/dl) 1.5 ± 1.2 1.3 ± 0.7 1.8 ± 1.1
Cholesterol (mg/dl) 141 ± 12 130 ± 12 133 ± 11
Triglycerides (mg/dl) 180 ± 53 105 ± 47 98 ± 39 *** ***
ALT (U/l) 35 ± 14 35 ± 37 35 ± 19
AST (U/l) 40 ± 6 47 ± 35 43 ± 8
Lipase (U/l) 50 ± 5 51 ± 10 54 ± 6
Amylase (U/l) 521 ± 34 511 ± 51 515 ± 44
wt (n=14) A227T (n=3) C93F (n=8) 
C93F vs A227T C93F vs wt A227T vs wt wt A227T C93F wt A227T C93F wt A227T C93F
Na (mmol/l) 151 ± 3 149 ± 2 152 ± 1 *
K (mmol/l) 4.1 ± 0.3 4.1 ± 0.1 4.0 ± 0.3
Ca (mmol/l) 2.2 ± 0.1 2.3 ± 0.0 2.3 ± 0.1 **
Cl (mmol/l) 110 ± 2 112 ± 1 111 ± 2
Pi (mmol/l) 2.0 ± 0.3 2.1 ± 0.3 1.9 ± 0.4
Total protein (g/dl) 5.1 ± 0.2 5.0 ± 0.1 5.1 ± 0.2
Creatinine-J (mg/dl) 0.29 ± 0.02 0.29 ± 0.02 0.33 ± 0.06 * *
Creatinine-E (mg/dl) 0.09 ± 0.01 0.10 ± 0.01 0.10 ± 0.02
Urea (mg/dl) 59 ± 5 102 ± 19 121 ± 13 **** **** * ** **
Uric acid (mg/dl) 1.4 ± 1.0 0.4 ± 0.1 1.0 ± 0.7
Cholesterol (mg/dl) 134 ± 9 125 ± 3 131 ± 6 *** ***
Triglycerides (mg/dl) 176 ± 57 91 ± 36 104 ± 57 *
ALT (U/l) 33 ± 12 25 ± 7 38 ± 13
AST (U/l) 40 ± 5 40 ± 5 40 ± 2
Lipase (U/l) 52 ± 15 51 ± 14 49 ± 11
Amylase (U/l) 514 ± 32 486 ± 35 514 ± 32
Treatment comparison
4-PBA vs Placebo Tempol vs Placebo Tempol vs 4-PBA
t-test
4-PBA
Tempol
Placebo
*)
t-test
t-test
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Table 4.4: Plasma clinical chemistry of homozygous UmodA227T and UmodC93F mutant mice and wild-type controls at the 
age of 4 months. Data presentation as means ± SD; SD: standard deviation. Student's t-test with Bonferroni adjustment: *, 
p<0.016; **, p<0.01; ***, p<0.001; ****p <0.0001. n: number of the animals analysed. A227T: homozygous UmodA227T mutant 
mice, C93F: homozygous UmodC93F mutant mice wt: wild-type mice. ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; *) 10 of the 35 mice in the placebo group were tested at the age of 4 months only. Due to a weight loss of >15 
%, one homozygous UmodC93F mutant mouse of the placebo group was excluded from the metabolic cage experiment  
wt (n=19) A227T (n=19) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Na (mmol/l) 154 ± 4 156 ± 2 156 ± 1.9
K (mmol/l) 3.9 ± 0.2 4.2 ± 0.3 4.0 ± 0.3 **
Ca (mmol/l) 2.2 ± 0.1 2.3 ± 0.1 2.4 ± 0.1 *** ****
Cl (mmol/l) 114 ± 3 115 ± 2 116 ± 1 ** **
Pi (mmol/l) 2.1 ± 0.3 1.9 ± 0.4 1.9 ± 0.3
Total protein (g/dl) 5.1 ± 0.3 5.2 ± 0.2 5.3 ± 0.2
Creatinine-J (mg/dl) 0.31 ± 0.03 0.34 ± 0.05 0.36 ± 0.05 **
Creatinine-E (mg/dl) 0.09 ± 0.02 0.11 ± 0.02 0.11 ± 0.01 ** ***
Urea (mg/dl) 66 ± 8 123 ± 13 156 ± 18 **** **** ****
Uric acid (mg/dl) 0.9 ± 0.7 1.3 ± 0.6 0.9 ± 0.4
Cholesterol (mg/dl) 124 ± 16 128 ± 9 134 ± 10
Triglycerides (mg/dl) 146 ± 52 110 ± 45 81 ± 20 ***
ALT (U/l) 39 ± 24 43 ± 45 31 ± 5
AST (U/l) 69 ± 49 72 ± 55 58 ± 8
Lipase (U/l) 44 ± 8 50 ± 8 56 ± 5 ***
Amylase (U/l) 516 ± 73 577 ± 67 572 ± 26 *
wt (n=13) A227T (n=17) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Na (mmol/l) 157 ± 2 157 ± 3 157 ± 3
K (mmol/l) 4.3 ± 1.1 4.1 ± 0.3 4.8 ± 1.6
Ca (mmol/l) 2.3 ± 0.1 2.3 ± 0.0 2.4 ± 0.1
Cl (mmol/l) 116 ± 2 115 ± 2 115 ± 2
Pi (mmol/l) 2.3 ± 0.6 2.5 ± 0.5 2.5 ± 0.8
Total protein (g/dl) 5.1 ± 0.2 5.2 ± 0.2 5.4 ± 0.2 ** **
Creatinine-J (mg/dl) 0.31 ± 0.06 0.33 ± 0.04 0.36 ± 0.05
Creatinine-E (mg/dl) 0.10 ± 0.02 0.11 ± 0.01 0.12 ± 0.02
Urea (mg/dl) 60 ± 8 119 ± 23 140 ± 18 * **** ****
Uric acid (mg/dl) 1.6 ± 1.3 1.2 ± 0.8 1.6 ± 1.1
Cholesterol (mg/dl) 140 ± 6 142 ± 8 141 ± 11
Triglycerides (mg/dl) 124 ± 38 75 ± 36 78 ± 24 ** **
ALT (U/l) 35 ± 17 34 ± 13 34 ± 10
AST (U/l) 59 ± 20 64 ± 21 113 ± 152
Lipase (U/l) 47 ± 13 48 ± 10 53 ± 5
Amylase (U/l) 559 ± 30 592 ± 33 610 ± 47 ** **
wt (n=15) A227T (n=6) C93F (n=13) 
C93F vs A227T C93F vs wt A227T vs wt wt A227T C93F wt A227T C93F wt A227T C93F
Na (mmol/l) 147 ± 3 131  ± 7 156 ± 4 * **
K (mmol/l) 4.1 ± 0.3 4.4 ± 0.4 4.2 ± 0.6
Ca (mmol/l) 2.3 ± 0.07 2.3 ± 0.2 2.4 ± 0.1 ** **
Cl (mmol/l) 115 ± 1.9 112 ± 4 114 ± 4 * *
Pi (mmol/l) 2.4 ± 0.4 2.6 ± 0.7 2.3 ± 0.6 ** ***
Total protein (g/dl) 5.1 ± 0.2 5.0 ± 0.4 5.2 ± 0.2
Creatinine-J (mg/dl) 1.25 ± 0.05 1.17 ±  0.05 0.35 ± 0.04
Creatinine-E (mg/dl) 0.10 ± 0.02 0.11 ± 0.01 0.11 ± 0.02
Urea (mg/dl) 58 ± 7 107 ± 14 139 ± 15 **** ****
Uric acid (mg/dl) 1.9 ± 0.5 1.9 ± 0.3 1.0 ± 0.6
Cholesterol (mg/dl) 130 ± 16 114 ± 6 146 ± 10 ** ** ** ** ***
Triglycerides (mg/dl) 142 ± 77 79 ± 24 70 ± 21 **
ALT (U/l) 31 ± 14 26 ± 9 28 ± 6
AST (U/l) 56 ± 15 49 ± 5 66 ± 30
Lipase (U/l) 46 ± 8 54 ± 6 56 ± 6 ***
Amylase (U/l) 578 ± 39 526 ± 50 642 ± 52 ** ** ***
t-test
t-test
4-PBA
Tempol
Placebo
*)
t-test
Treatment comparison
4-PBA vs Placebo Tempol vs Placebo Tempol vs 4-PBA
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4.3.3 Metabolic cage analysis  
After two months of treatment, metabolic cage analysis of the 4-month-old mice was carried out 
and data was collected every 24 hours over the course of two days. Corresponding to their 
respective treatment group, the application of 4-PBA, tempol or pure drinking water was 
continued (Table 4.5).  
In all treatment groups homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice 
weighted significantly less than wild-type controls both at the start and throughout the metabolic 
cage experiment. Percent body weight change did not differ significantly between genotypes. 
Food intake per gram body weight did not vary between the three genotypes.  
In both the 4-PBA and the tempol treatment group, the water intake per gram body weight 
tended to be highest in homozygous Umod
C93F
 mutant mice and lowest in wild-type controls. 
This trend reached a degree of significance only in the 4-PBA treatment group where 
homozygous Umod
C93F
 mutant mice showed a significantly higher water intake per gram body 
weight than wild-type controls (p<0.01) on day 1.  
Compared to wild-type controls, homozygous Umod
A227T
 mutant as well as homozygous 
Umod
C93F
 mutant mice excreted a significantly higher volume of urine per gram body weight in 
both the 4-PBA and the tempol treatment group (day 1 and 2). Urine volumes per gram body 
weight did not vary significantly between the different genotypes receiving placebo treatment 
(Figure 4.29 A). 
On both days of the metabolic cage experiment, urine osmolality was significantly decreased in 
homozygous mutant mice of both lines in the 4-PBA and tempol treatment group. Urine 
osmolality was lowest in homozygous Umod
C93F
 mutant mice in both the 4-PBA and the tempol 
treatment group. In the placebo treatment group, the urine osmolality of wild-type and 
homozygous Umod
A227T
 mutant mice showed no significant difference. Homozygous Umod
C93F
 
mutant mice showed a significantly reduced urine osmolality in this treatment group as well 
(Figure 4.29 B).  
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Figure 4.29: Urine volume and urine osmolality of 24h-urine of 4-month-old Umod
A227T
 and Umod
C93F
 mice. 
(A) In all treatment groups, homozygous Umod
C93F
 mutant mice excreted the highest volume of urine per gram body 
weight. (B) In the 4-PBA and tempol treatment group, urine osmolality was decreased significantly in homozygous 
mutant mice of both lines when compared to wild-type controls. In the placebo treatment group, urine osmolality 
was significantly reduced only in homozygous Umod
C93F
 mutant mice. wt: wild-type mice, A227T: homozygous 
Umod
A227T
 mutant mice, C93F: homozygous Umod
C93F
 mutant mice. D1: day 1 on the metabolic cage analysis. D2: 
day 2 of the metabolic cage analysis. Student’s t-test with Bonferroni adjustment: *, p<0.016; **, p<0.01; ***, 
p<0.001; ****p <0.0001. 
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Table 4.5: 24h-metabolic cage data of 4 month-old homozygous UmodA227T and UmodC93F mutant mice and wild-type controls. Data presentation as means ± SD; SD: standard deviation. 
Student's t-test, p<0.016, p<0.01, p<0.001 and p<0.0001. n: number of the animals analysed. A227T: homozygous UmodA227T mutant mice. C93F: homozygous UmodC93F mutant mice; wt: wild-type 
male mice.  
t-test t-test t-test t-test t-test t-test
Day (A227T vs wt) (C93F vs wt) (A227T vs wt) (C93F vs wt) (A227T vs wt) (C93F vs wt)
0 28.6 ± 2.5  25.0 ± 2.4 **** 20.9 ± 1.5 **** 29.4 ± 2.0 25.3 ± 1.7 ****  23.8 ± 0.9 **** 29.3 ± 1.7 25.8 ± 1.4 ***  23.8 ± 1.9 ****
1  28.9 ± 2.1  25.4 ± 1.2 **** 21.3 ± 1.3 **** 29.3 ± 1.8  25.3 ± 1.5 ****  23.7 ± 1.3 ****  29.2 ± 1.7  25.9 ± 1.8 ***  23.6 ± 1.9 ****
2 29.4 ± 2.1 25.9 ± 1.1 ****  21.9 ± 0.9 ****  28.9 ± 3.0  25.4 ± 1.5 ***  24.1 ± 1.3 *** 29.6 ± 1.5  26.3 ± 1.7 ***  23.9 ± 1.9 ****
1  1.3 ± 2.8  1.6 ± 2.4  1.9 ± 2.4 - 0.2 ± 2.1  1.2 ± 2.3 - 0.5 ± 2.4 -0.5 ± 2.4  0.3 ± 2.7 - 0.8 ± 1.7
2  1.7 ± 2.0  2.0 ± 1.6  2.8 ± 3.1  -1.3 ± 9.0  0.6 ± 3.3  1.4 ± 2.1  1.5 ± 2.5  1.3 ± 1.7  1.4 ± 1.7
1 4.4  ± 0.5 4.1 ± 0.6 3.5 ± 0.5 *** 4.8 ± 0.5  4.2 ± 0.4 ***  3.6 ± 0.3 ****  4.4 ± 1.0  3.8 ± 0.7  3.3 ± 0.5 **
2  4.5 ± 0.6 4.2 ± 0.4  3.7 ± 0.3 *** 4.9 ± 0.5 4.1 ± 0.6 *** 3.7 ± 0.2 **** 4.5 ± 0.7  4.0 ± 0.6  3.6 ± 0.6 ***
1 0.16 ± 0.02 0.17 ± 0.03  0.17 ± 0.03  0.17 ± 0.02 0.17 ± 0.03  0.15 ± 0.01  0.15 ± 0.03  0.15 ± 0.02  0.14 ± 0.02
2 0.16 ± 0.03 0.17 ± 0.02  0.18 ± 0.02  0.17 ± 0.02  0.17 ± 0.03 0.16 ± 0.01 0.16 ± 0.02  0.15 ± 0.03  0.15 ± 0.02
1 5.8 ± 2.2  6.7 ± 3.4 6.4 ± 1.6  8.7 ± 2.2  7.4 ± 1.7 8.6 ± 2.1 7.3 ± 5.7  4.8 ± 1.5 5.9 ± 1.8
2  6.6 ± 3.6  6.2 ± 1.6 6.1 ± 1.6  9.6 ± 3.0  8.1 ± 2.3 9.6 ± 2.9  10.4 ± 10.1  5.0 ± 1.0  7.3 ± 1.5
1 0.21 ± 0.09 0.27 ± 0.13  0.31 ± 0.08 **  0.30 ± 0.08  0.30 ± 0.07  0.36 ± 0.09  0.25 ± 0.19  0.18 ± 0.05 0.25 ± 0.07
2  0.24 ± 0.14  0.25 ± 0.07 0.29 ± 0.08 0.33 ± 0.11 0.32 ± 0.08 0.40 ± 0.13  0.35 ± 0.34  0.19 ± 0.03 0.31 ± 0.05
1  1.6 ± 0.7 2.3 ± 1.1  2.2 ± 0.6 1.3 ± 0.5  1.6 ± 0.4  2.1 ± 0.4 ***  2.0 ± 1.4  1.6 ± 0.7  2.4 ± 0.7
2  2.0 ± 0.9  2.4 ± 0.5 2.4 ± 0.9  1.4 ± 0.6  1.7 ± 0.5  2.5 ± 0.7 ***  2.6 ± 2.0  1.7 ± 0.7  2.8 ± 0.7
1  0.06 ± 0.03  0.09 ± 0.04 **  0.11 ± 0.03 ****  0.04 ± 0.02  0.06 ± 0.1 ** 0.09 ± 0.02 **** 0.07 ± 0.05  0.06 ± 0.03  0.10 ± 0.03
2 0.07 ± 0.03 0.10 ± 0.02 ** 0.12 ± 0.05 **   0.05 ± 0.02  0.07 ± 0.02 *  0.10 ± 0.03 ****  0.09 ± 0.07  0.06 ± 0.02  0.12 ± 0.03
1 3132 ± 713 2372 ± 496 *** 2073 ± 322 *** 3898 ± 831 2832 ± 453 *** 1766 ± 222 **** 2984 ± 928 2856 ± 458 1746 ± 428 ***
2 2979 ± 681 2345 ± 390 ** 2073 ± 437 *** 3702 ± 557 2914 ± 485 *** 1747 ± 345 **** 2956 ± 1319 2921 ± 494 1667 ± 327 **
1  1.9 ± 0.4 1.7 ± 0.4 1.4 ± 0.3 ***  2.1 ± 0.3  1.8 ± 0.2 **  1.7 ± 0.2 *** 1.8 ± 0.4  1.3 ± 0.2 **  1.3 ± 0.3 ***
2  1.9 ± 0.4  1.7 ± 0.3  1.4 ± 0.3 *** 2.1  ± 0.4  1.7 ± 0.3 **  1.6 ± 0.2 ***  2.0 ± 0.3  1.4 ± 0.3 ***  1.4 ± 0.3 ****
1 0.07 ± 0.02  0.07 ± 0.02  0.07 ± 0.01 0.07 ± 0.02  0.07 ± 0.01 0.07 ± 0.01  0.06 ± 0.01 0.05 ± 0.01  0.05 ± 0.01
2  0.07 ± 0.01  0.07 ± 0.02 0.07 ± 0.01  0.07 ± 0.02  0.07 ± 0.01  0.07 ± 0.01  0.07 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 *
C93F          
(n = 13)
wt                 
(n =15)
Placebo
Faeces excretion (g)
Faeces excretion (g/g 
body weight)
PBA
Body weight (g)
Body weight change 
(%)
Food intake (g/day)
Food intake (g/g 
body weight)
Water intake (g)
A227T       
(n = 19)
wt                
(n = 19)
C93F             
(n = 11)
wt                 
(n = 13)
A227T         
(n = 17)
C93F          
(n = 11)
A227T          
(n = 6)
Tempol
Urine osmolality 
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Water intake (g/g 
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Urine volume (ml)
Urine volume (ml/g 
body weight)
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4.3.4 Urine analysis  
Western blot analysis was used to examine 24h-urine samples from the metabolic cage analysis 
for their respective uromodulin content. In addition, the 24h-urine collected in the metabolic 
cage experiment underwent clinical chemical analysis.  
4.3.4.1 Western blot analysis of 24h-urine  
Western blot analysis of uromodulin content in 24h-urine revealed that homozygous Umod
C93F
 
mutant mice secreted a distinctly lower amount of the protein than both wild-type controls and 
homozygous Umod
A227T
 mutant mice, regardless of the treatment received. The urinary 
uromodulin content of homozygous Umod
A227T
 mutant mice also remained lower than that of 
wild-type controls after treatment application. Uromodulin appeared slightly reduced in the urine 
of 4-PBA-treated homozygous Umod
A227T
 mutant mice when compared to genotype-matched 
placebo-treated animals (Figure 4.30).  
Figure 4.30: Western blot analysis 
of urinary uromodulin content in 
homozygous Umod
C93F
 mutant and 
homozygous Umod
A227T
 mutant 
mice compared to wild-type 
controls.  Homozygous Umod
C93F
 
mutant mice treated with (A) 4-PBA 
and (B) tempol excreted similarly 
low amounts of uromodulin as 
homozygous Umod
C93F
 mutant mice 
of the placebo treatment group. (C) 
Compared to homozygous Umod
C93F
 
mutant mice, a distinctly higher 
urinary uromodulin content was 
detected in homozygous Umod
A227T
 
mutant mice of both the 4-PBA and 
placebo treatment group but did not 
reach wild-type levels. M: MBI 
unstained protein marker; wt: wild-
type.  
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4.3.4.2 Clinical chemistry of 24h-urine  
24h-urine was collected on day 1 and 2 of the metabolic cage analysis for clinical chemical 
analysis. Urine parameters were standardized to 25 grams of body weight and compared between 
homozygous mutant mice of both lines and wild-type controls as well as between genotype-
matched mice of the three treatment groups (Tables 4.6 and 4.7).  
Placebo treatment group:  
Compared to wild-type mice in this treatment group, urinary calcium excretion tended to be 
higher in homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice but this 
difference reached a degree of significance on day 1 only.  
On both days, uric acid excretion tended to be highest in wild-type mice and lowest in 
homozygous Umod
A227T
 mutant mice but differences did not reach a degree of significance.  
On both day 1 and 2, the total urinary protein excretion was significantly lower in mutants of 
both mouse lines than in wild-type controls, with homozygous Umod
C93F
 mutant mice excreting 
the least amount of protein.  
On day 2, urinary albumin excretion of homozygous Umod
A227T
 mutant mice was significantly 
reduced versus wild-type controls and homozygous Umod
C93F
 mutant mice. On both days, the 
urinary albumin concentrations were lowest in homozygous Umod
A227T
 mutant and highest in 
wild-type mice.  
4-PBA treatment group:  
Urinary sodium excretion in this treatment group tended to be lowest in wild-type and highest in 
homozygous Umod
C93F
 mutant mice on both days of the metabolic cage analysis. On day 1 the 
difference in sodium excretion was significant between homozygous Umod
C93F
 mutant mice and 
wild-type controls. Compared to genotype-matched mice of the other treatment groups, 4-PBA-
treated homozygous Umod
C93F
 mutant and homozygous Umod
A227T
 mutant mice exhibited the 
highest urinary sodium excretions.  
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On both days of analysis, urinary potassium excretion was significantly increased in Umod
C93F
 
mutant mice when compared to wild-type controls. While potassium excretion was lowest in 
homozygous Umod
A227T
 mutant mice on day 1, the least amount of potassium was excreted by 
wild-type mice on day 2.  
On both days of the metabolic cage analysis, homozygous mutant mice of both mouse lines 
showed a significantly increased urinary calcium excretion when compared to wild-type 
controls. Homozygous Umod
C93F
 mutant mice excreted the highest amount of calcium on day 1 
and 2. On both days homozygous Umod
C93F
 mutant mice receiving 4-PBA also exhibited 
significantly increased urinary calcium concentrations when compared to genotype-matched 
mice in the placebo treatment group. 
Urinary urea excretions were significantly elevated in homozygous Umod
A227T
 mutant and 
homozygous Umod
C93F
 mutant mice on day 1. On day 2, the same tendency was detected but 
urinary urea excretions did not differ significantly between the different genotypes. Urinary urea 
excretion of 4-PBA-treated homozygous Umod mutant mice of both lines tended to be higher 
when compared to genotype-matched mice in the tempol and placebo treatment groups.  
Phosphate concentrations in the urine of homozygous Umod
C93F
 mutant mice of both lines were 
significantly lower than those of wild-type controls on both days of analysis. 
Urinary excretion of enzymatically measured creatinine was significantly increased in 
homozygous Umod
C93F
 mutant mice of both lines on day 2. On both days of analysis, creatinine 
measured by the enzymatic and the Jaffe method tended to be increased in Umod mutant mice of 
both lines.  
Tempol treatment group:  
Urinary sodium excretion did not differ between genotypes within the tempol treatment group. 
However, urinary sodium excretion of homozygous Umod mutant and wild-type mice receiving 
tempol was significantly lower than those of 4-PBA-treated genotype-matched mice.  
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Urinary potassium excretion was lowest in wild-type mice on day 1 and 2. Compared to wild-
type controls, potassium excretion was significantly increased in homozygous Umod
A227T
 mutant 
mice on day 1 and in homozygous Umod
C93F
 mutant mice on day 2 of analysis.  
Homozygous mutant mice of both lines showed a significantly higher urinary calcium excretion 
on both days of the metabolic cage analysis when compared to wild-type controls. Compared to 
wild-type and homozygous Umod
C93F
 mutant mice in the 4-PBA treatment group, urinary 
calcium excretion of genotype-matched mice was significantly reduced in the tempol treatment 
group.  
Total protein was decreased in the urine of both homozygous Umod
A227T
 mutant and 
homozygous Umod
C93F
 mutant mice versus wild-type controls. The difference between 
homozygous Umod
C93F
 mutant and wild-type mice was significant on both days of analysis.  
Compared to wild-type controls, urinary magnesium excretion on day 2 was significantly 
increased in homozygous Umod
C93F
 mutant mice and significantly reduced in homozygous 
Umod
A227T
 mutant mice.  
Homozygous Umod
C93F
 mutant mice showed an increased urinary glucose excretion when 
compared to wild-type mice on day 2 of analysis. 
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Table 4.6: Clinical chemistry of 24h-urine from 4 month-old homozygous UmodA227T mutant and homozygous UmodC93F mutant 
mice and wild-type controls, day 1. Urine parameters are normalized to 25 g body weight and presented as means ± SD; SD: standard 
deviation. Student's t-test with Bonferroni adjustment: *, p<0.016; **, p<0.01; ***, p<0.001; ****p <0.0001. n: number of the animals 
analysed. A227T: homozygous UmodA227T mutant mice. C93F: homozygous UmodC93F: mutant mice; wt: wild-type mice. 
wt (n=19) A227T (n=19) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Urine volume (ml) 1.6 ± 0.7 2.3 ± 1.1 2.2 ± 0.6
Urine osmolality 
(mOsm/kg)
3132 ± 713 2372 ± 496 2073 ± 322 *** ***
Na (µmol/day) 325 ± 91 340 ± 112 426 ± 115 *
K (µmol/day) 497 ± 130 387 ± 194 702 ± 169 *** ***
Ca (µmol/day) 3.1 ± 1.1 9.8 ± 5.5 10.3 ± 4.4 **** ****
Cl (µmol/day) 462 ± 112 515 ± 118 517 ± 127
Creatinine-J (µmol/day) 5.7 ± 1.7  7.5 ± 1.8 7.3 ± 2.4 **
Urea (mmol/day) 2.5 ± 0.6 3.1 ± 0.7 3.2 ± 0.5 ** **
Uric acid (nmol/day) 205 ± 157 133 ± 101 140 ± 45
Total protein (µg/day) 14750 ± 3801 12401 ± 3375 6993 ± 2637 *** ****
Glucose (µmol/day) 4.5 ± 5.8 4.0 ± 1.8 4.0 ± 2.0
Microalbumin (µg/day) 19.2 ± 4.8 19.1 ± 6.5 20.5 ± 5.5 
Mg (µmol/day) 36 ± 13 45 ± 18 49 ± 25
Pi (µmol/day) 127 ± 58 86 ± 51 53 ± 62 **
Creatinine-E (µmol/day) 3.0 ± 0.7 3.7 ± 1.0 3.7 ± 0.9
wt (n=13) A227T (n=17) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Urine volume (ml) 1.3 ± 0.5 1.6 ± 0.4 2.1 ± 0.4 ** ***
Urine osmolality 
(mOsm/kg)
3898 ± 831 2832 ± 453 1766 ± 222 *** ***
Na (µmol/day) 264 ± 66 301 ± 69 260 ± 56
K (µmol/day) 445 ± 146 561 ± 103 530 ± 101 *
Ca (µmol/day) 2.1 ± 0.6 8.0 ± 2.6 6.2 ± 1.6 **** ****
Cl (µmol/day) 470 ± 112 491 ± 96 412 ± 85
Creatinine-J (µmol/day) 5.1 ± 1.9 6.6 ± 1.5 6.3 ± 1.6
Urea (mmol/day) 2.4 ± 0.7 2.7 ± 0.4 2.4 ± 0.4
Uric acid (nmol/day) 117 ± 76 90 ± 41 91 ± 32
Total protein (µg/day) 13935 ± 4393 11424 ± 3080 8117 ± 2340 ** ***
Glucose (µmol/day) 2.6 ± 0.7 3.4 ± 1.4 4.8 ± 3.6
Microalbumin (µg/day) 19.0 ± 6.7 16.7 ± 3.6 15.4 ± 4.3
Mg (µmol/day) 25 ± 12 45 ± 13 40 ± 14
Pi (µmol/day) 137 ± 58 131 ± 54 122 ± 65
Creatinine-E (µmol/day) 2.3 ± 0.5 2.9 ± 0.5 3.1 ± 0.4
wt (n=15) A227T (n=6) C93F (n=13) 
C93F vs A227T C93F vs wt A227T vs wt
Urine volume (ml) 2.0 ± 1.4 1.6 ± 0.7 2.4 ± 0.7
Urine osmolality 
(mOsm/kg)
2984 ± 928 2856 ± 458 1746 ± 428 *** *** wt A227T C93F wt A227T C93F wt A227T C93F
Na (µmol/day) 279 ± 99 279 ± 78 291.5 ± 53.1 ** ** ***
K (µmol/day) 517 ± 202 485 ± 167 594 ± 139 **
Ca (µmol/day) 3.5 ± 2.6 6.7 ± 1.9 6.4 ± 1.9 ** * ** ** **
Cl (µmol/day) 466 ± 139 431 ± 116 450 ± 77
Creatinine-J (µmol/day) 5.7 ± 1.7 5.8 ± 1.3 6.1 ± 1.2
Urea (mmol/day) 2.6 ± 0.7 2.6 ± 0.7 2.7 ± 0.5 ***
Uric acid (nmol/day) 298 ± 250 96 ± 34 134 ± 54 **
Total protein (µg/day) 16522 ± 5358 10257 ± 3101 9257 ± 2964 *** *
Glucose (µmol/day) 3.2 ± 1.0 2.5 ± 0.6 3.3 ± 1.7
Microalbumin (µg/day) 18.5 ± 6.1 13.2 ± 2.8 18.2 ± 3.7 **
Mg (µmol/day) 34 ± 12 49 ± 37 43 ± 13
Pi (µmol/day) 124 ± 37 113 ± 45 96 ± 42 *
Creatinine-E (µmol/day) 3.0 ± 1.0 3.0 ± 0.6 3.5 ± 0.8 ** ** **
t-test
Treatment comparison
PBA vs Placebo Tempol vs Placebo Tempol vs PBA
Tempol
PBA
Placebo
t-test
t-test
 _______________________________________________________________________ Results 
100 
 
 
Table 4.7: Clinical chemistry of 24h-urine from 4 month-old homozygous UmodA227T mutant and homozygous UmodC93F mutant 
mice and wild-type controls, day 2. Urine parameters are normalized to 25 g body weight and presented as means ± SD; SD: standard 
deviation. Student's t-test with Bonferroni adjustment: *, p<0.016; **, p<0.01; ***, p<0.001; ****p <0.0001. n: number of the animals 
analysed. A227T: homozygous UmodA227T mutant mice. C93F: homozygous UmodC93F: mutant mice; wt: wild-type mice. 
wt (n=19) A227T (n=19) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Urine volume (ml) 2.0 ± 0.9 2.4 ± 0.4 2.4 ± 0.9
Urine osmolality (mOsm/kg) 2979 ± 681 2345 ± 390 2073 ± 437 *** **
Na (µmol/day) 368 ± 88 420 ± 90 456 ± 103
K (µmol/day) 592 ± 137 692 ± 141 758 ± 178 **
Ca (µmol/day) 3.8 ± 1.9 10.0 ± 3.6 11.3 ± 4.2 **** ****
Cl (µmol/day) 513 ± 119 538 ± 561 546 ± 105
Creatinine-J (µmol/day) 6.2 ±2.1 7.2 ± 1.9 7.8 ± 1.9
Urea (mmol/day) 2.8 ± 0.6 3.1 ± 0.6 3.3 ± 0.5
Uric acid (nmol/day) 197 ± 113 146 ± 56 177 ± 111
Total protein (µg/day) 17134 ± 4228 12626 ± 2375 7412 ± 2526 **** **** ***
Glucose (µmol/day) 3.5 ± 1.3 3.8 ± 2.1 3.7 ± 3.3
Microalbumin (µg/day) 19.2 ± 4.3 17.8 ± 4.1 20.9 ± 5.5
Mg (µmol/day) 41 ± 24 40 ± 21 52 ± 19
Pi (µmol/day) 103 ± 62 62 ± 46 22 ± 34 ***
Creatinine-E (µmol/day) 3.1 ± 0.5 3.6 ± 0.8 3.8 ± 0.5 ***
wt (n=13) A227T (n=17) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Urine volume (ml) 1.4 ± 0.6 1.7 ± 0.5 2.5 ± 0.7 *** **** *
Urine osmolality (mOsm/kg) 3702 ± 557 2914 ± 485 1747 ± 345 **** **** ***
Na (µmol/day) 271 ± 85 299 ± 68 305 ± 54
K (µmol/day) 462 ± 156 563 ± 128 649 ± 138 **
Ca (µmol/day) 2.3 ± 0.9 7.9 ± 2.6 8.1 ± 2.7 **** ****
Cl (µmol/day) 478 ± 139 494 ± 102 499 ± 97
Creatinine-J (µmol/day) 5.4 ± 2.0 6.6 ± 2.0 7.3 ± 2.0
Urea (mmol/day) 2.4 ± 0.8 2.7 ± 0.6 2.9 ± 0.4
Uric acid (nmol/day) 133 ± 54 94 ± 38 102 ± 47
Total protein (µg/day) 14008 ± 4754 11916 ± 2863 9558 ± 2365 *
Glucose (µmol/day) 2.8 ± 0.9 3.6 ± 2.7 4.3 ± 1.4 **
Microalbumin (µg/day) 18.6 ± 5.8 16.0 ± 3.6 16.7 ± 3.9
Mg (µmol/day) 26 ± 15 16.0 ± 3.6 48 ± 17 ** **
Pi (µmol/day) 136 ± 60 113 ± 62 115 ± 58
Creatinine-E (µmol/day) 2.5 ± 0.7 2.9 ± 0.5 3.1 ± 0.4
wt (n=15) A227T (n=6) C93F (n=13) t-test
C93F vs A227T C93F vs wt A227T vs wt
Urine volume (ml) 2.6 ± 2.0 1.7 ± 0.7 2.8 ± 0.8 **
Urine osmolality (mOsm/kg) 2956 ± 1319 2921 ± 494 1667 ± 327 **** ** wt A227T C93F wt A227T C93F wt A227T C93F
Na (µmol/day) 345 ± 199 302 ± 58 318 ± 50 ** *** ** *** ***
K (µmol/day) 626 ± 306 529 ± 156 662 ± 84 **
Ca (µmol/day) 5.8 ± 6.6 8.1 ± 1.7 7.8 ± 2.3 *
Cl (µmol/day) 569 ± 242 472 ± 92 492 ± 58
Creatinine-J (µmol/day) 7.2 ± 4.6 6.2 ± 0.9 6.6 ± 0.7
Urea (mmol/day) 3.0 ± 1.2 2.7 ± 0.6 3.0 ± 0.4
Uric acid (nmol/day) 279 ± 244 97 ± 35 142 ± 60 **
Total protein (µg/day) 19144 ± 5051 11241 ± 3278 9938 ± 2553 **** ** *
Glucose (µmol/day) 3.7 ± 1.8 2.4 ± 0.5 3.4 ± 1.6
Microalbumin (µg/day) 22.4 ± 7.4 13.4 ± 3.1 17.7 ± 2.6 ** *
Mg (µmol/day) 46 ± 17 42 ± 16 47 ± 15 **
Pi (µmol/day) 148 ± 48 100 ± 66 110 ± 60 *** ** ***
Creatinine-E (µmol/day) 3.3 ± 1.1 3.1 ± 0.5 3.7 ± 0.6 ** ** ** **
Treatment comparison
PBA vs Placebo Tempol vs Placebo Tempol vs PBA
PBA
Tempol
Placebo
*)
t-test
t-test
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4.3.4.3 Fractional excretion of urinary solutes 
The fractional excretions (FE) of sodium (FENa), potassium (FEK), urea (FEurea), uric acid  
(FE(uric acid)), chloride (FECl), calcium (FECa), potassium (FeK) and phosphate (FEPi) were 
evaluated in 24h-urine of day 2 of the metabolic cage analysis and compared between genotypes 
and treatment groups (Table 4.8).  
In all three treatment groups, FEurea was highest in wild-type and lowest in homozygous 
Umod
C93F
 mutant mice. The difference between mutant mice of both lines and wild-type controls 
was significant in all treatment groups. FEurea did not differ between genotype-matched mice of 
different treatment groups (Figure 4.31 A).  
In both the 4-PBA and the placebo treatment group FE(uric acid) was significantly decreased in 
homozygous Umod
A227T
 mutant mice when compared to wild-type controls. Genotypic 
differences remained insignificant otherwise but wild-type mice tended to show the highest 
FE(uric acid) in each treatment group (Figure 4.31 B).  
There was no genotypic difference of FENa in any of the treatment groups. However, FENa was 
significantly increased in homozygous Umod
C93F
 mutant mice of the 4-PBA treatment group 
when compared to genotype-matched placebo-treated animals. FENa of homozygous Umod
A227T
 
mutant and homozygous Umod
C93F
 mutant mice in the 4-PBA treatment group was also 
significantly higher than that of the corresponding genotypes in the tempol treatment group 
(Figure 4.31 C).  
In each treatment group, FECa was significantly increased in homozygous mutant mice of both 
lines when compared to wild-type mice. A comparison of genotype-matched mice receiving 
different treatments revealed no difference (Figure 4.31 D).  
While the lowest FEK was detected in wild-type mice in each treatment group, it was increased 
to a degree of significance only in homozygous Umod
C93F
 mutant mice of the placebo treatment 
group.  
FEPi was significantly reduced in homozygous Umod
C93F
 mutant mice of the 4-PBA and the 
placebo treatment group. The same was detected for homozygous Umod
A227T
 mutant mice in the 
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placebo treatment group. 4-PBA-treated homozygous Umod
C93F
 mutant mice also showed a 
lower FEPi than genotype-matched mice in the tempol and placebo treatment groups.  
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Figure 4.31: Fractional excretion (FE) of (A) urea, (B) uric acid, (C) sodium, and (D) calcium in the urine of 
homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice as well as of wild-type controls of 
different treatment groups. While FEurea and FE(Uric acid) were significantly increased in wild-type mice of all 
treatment groups, genotypic differences in FENa remained insignificant. The fractional excretion of calcium was 
significantly increased in homozygous mutant animals of both mouse lines. Data represents mean ± SD. n=13-19 
wild-type mice, n=3-19 homozygous Umod
A227T
 mutant mice, n=8-13 homozygous Umod
C93F
 mutant; wt: wild-type 
mice; Umod
A227T
: homozygous Umod
A227T
 mutant mice; Umod
C93F
: homozygous Umod UmodC93F mutant mice. 
Student’s t-test with Bonferroni adjustment: *, p<0.016; **, p<0.01; ***, p<0.001; ****, p<0.0001. §p<0.016 vs. 
matching genotype in placebo treatment group; ψp<0.01 vs. matching genotype in 4-PBA treatment group.  
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Table 4.8: Fractional excretion of urine parameters of 24h-urine from 4-month-old A227T and C93F 
homozygotes and wild-type controls, day 2. Fractional excretions are presented as means ± SD; SD: standard 
deviation. Student's t-test with Bonferroni adjustment: *, p<0.016; **, p<0.01; ***, p<0.001; ****, p<0.0001. n: 
number of the animals analysed. A227T: homozygous Umod
A227T
 mutant mice. C93F: homozygous Umod
C93F
 
mutant male mice; wt: wild-type male mice.  *) Due to a weight loss of >15 %, one mouse of the placebo group was 
excluded from the metabolic cage experiment. 
wt (n=19) A227T (n=19) C93F (n=11) 
Fractional excretion C93F vs A227T C93F vs wt A227T vs wt
Na (%) 1.1 ± 0.2 1.2 ± 0.4 1.2 ± 0.3
K (%) 69.3 ± 14.2 74.3 ± 24.1 78.4 ± 18.0
Urea (%) 119.2 ± 25.3 67.5 ± 18.4 53.1 ± 10.5 **** ****
Uric acid (%) 2.8 ± 2.5 1.1 ± 1.3 1.8 ± 2.1 *
Cl (%) 2.1 ± 0.4 2.1 ± 0.5 1.9 ± 0.4
Ca (%) 0.8 ± 0.4 1.9 ± 0.7 2.0 ± 0.8 **** ****
Pi (%) 23.8 ± 16.5 16.2 ± 15.9 4.7 ± 6.9 **
wt (n=13) A227T (n=17) C93F (n=11) 
C93F vs A227T C93F vs wt A227T vs wt
Na (%) 1.0 ± 0.3 0.9 ± 0.2 0.9 ± 0.2
K (%) 58.3 ± 15.1 61.2 ± 10.3 63.7 ± 18.9
Urea (%) 129.6 ± 18.1 63.3 ± 13.4 55.7 ± 11.2 **** ****
Uric acid (%) 1.2 ± 0.9 0.9 ± 0.7 0.6 ± 0.4
Cl (%) 2.3 ± 0.7 2.0 ± 0.5 1.9 ± 0.4
Ca (%) 0.5 ± 0.2 1.5 ± 0.5 1.5 ± 0.5 **** ****
Pi (%) 35.3 ± 17.5 23.6 ± 17.2 23.7 ± 17.5
wt (n=15) A227T (n=6) C93F (n=13) 
C93F vs A227T C93F vs wt A227T vs wt
Na (%) 0.9 ± 0.3 1.0 ± 0.2 1.0 ± 0.2
K (%) 57.9 ± 11.6 66.2 ± 20.7 74.9 ± 15.7 **
Urea (%) 127.0  ± 25.6 70.6 ± 22.2 61.3 ± 10.8 **** ***
Uric acid (%) 1.7 ± 1.0 0.7 ± 0.4 1.4 ± 0.9 *
Cl (%) 2.2 ± 0.6 2.2 ± 0.4 2.0 ± 0.4
Ca (%) 0.5 ± 0.1 1.8 ± 0.4 1.5 ± 0.5 **** ****
Pi (%) 33.9 ± 8.2 18.8 ± 10.4 22.1 ± 10.2 ** **
t-test
Tempol
PBA
Placebo
*)
t-test
t-test
wt A227T C93F wt A227T C93F wt A227T C93F
Na (%) * ** **
K (%)
Urea (%)
Uric acid (%)
Cl (%)
Ca (%)
Pi (%) *** **
Treatment comparison
PBA vs Placebo Tempol vs Placebo Tempol vs PBA
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4.3.5 Histopathology  
4.3.5.1 Light microscopic analysis  
Uromodulin accumulation in perinuclear clusters was demonstrated by immunohistochemical 
analysis in TALH cells of homozygous Umod
C93F
 mutant and homozygous Umod
A227T
 mutant 
mice after both 4-PBA and tempol treatment. In contrast, TALH cells of wild-type controls 
exhibited a diffuse cytosolic distribution pattern of uromodulin with an apically reinforced 
signal. Renal histology of mutants from both lines and treatment groups showed no further 
alterations compared to wild-type controls (Figure 4.32).  
 
Figure 4.32: TALH cells of wild-type, homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice 
of the 4-PBA and of the tempol treatment group: Representative TALH profiles of the indicated genotype and 
treatment group. Immunohistochemical staining for uromodulin. 
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4.3.5.2 TEM analysis  
Irrespective of their treatment, TALH cell nuclei of both homozygous Umod
A227T
 mutant and 
homozygous Umod
C93F
 mutant mice were surrounded by membranous piles that were 
interspersed with granular bodies (Figure 4.33). 
 
Figure 4.33: TALH cells of wild-type, homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice 
of the 4-PBA and the tempol treatment group. Ultrastructural analysis of TALH cells of mice of the 4-PBA and 
tempol treatment group revealed distinct perinuclear, lamellated membrane stacks (red circles) in TALH cells of 
homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice. wt: wild-type mice, A227T: homozygous 
Umod
A227T
 mutant mouse, C93F: homozygous Umod
C93F
 mutant mouse. 4-PBA, tempol: treatment groups.   
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5 Discussion  
5.1 Uromodulin-associated kidney disease  
Uromodulin-associated kidney disease (UAKD) is a human renal disease of autosomal dominant 
inheritance that is caused by mutations in the UMOD gene. Frequent symptoms include 
hyperuricaemia and gout as well as defective urine concentrating ability. UAKD patients develop 
renal lesions leading to end-stage renal disease (ESRD) between the third and seventh decade of 
life (Kumar, 2007; Rampoldi et al., 2011). The clinical phenotype of UAKD shows 
heterogeneity regarding the onset as well as the severity of chronic kidney disease, even within 
affected families. Likewise, corticomedullary and glomerular cysts are inconsistently found in 
kidneys of UAKD patients (Rampoldi et al., 2003; Bleyer et al., 2011). UAKD patients are 
hitherto treated symptomatically for hyperuricaemia and gout with allopurinol but causative 
therapies for the disease remain to be found.  
Mutant uromodulin is misfolded and precipitates in the endoplasmic reticulum (ER) of TALH 
cells. Thus, intracellular trafficking and full maturation of both wild-type and mutant uromodulin 
is impaired. A gain of toxic function of mutant uromodulin in TALH cells is hypothesized. 
However, the exact pathophysiologic mechanisms of UAKD are incompletely understood and 
are subject to continued in vitro and in vivo research (Dahan et al., 2003; Rampoldi et al., 2003).  
The objective of this study was twofold. For one, the aim was to quantify histologic alterations in 
the kidneys of mice harbouring a mutation in the murine Umod gene and to compare the severity 
thereof with regard to different genotypes and ages. Secondly, the chemical chaperone 4-PBA as 
well as the superoxide dismutase mimetic tempol were tested as causative therapies at the onset 
of UAKD. Both parts of the study were conducted on mice of the Umod
A227T
 and the Umod
C93F 
mouse lines.  
5.2 Umod mutant mouse lines as a murine model for UAKD  
Two ENU-induced missense point mutations of autosomal dominant inheritance were identified 
in the Umod gene of the mouse lines Umod
A227T
 and Umod
C93F
. Mutant mice of both lines mirror 
the clinical phenotype of human UAKD regarding impaired urinary concentrating ability, 
azotaemia and reduced fractional excretion of uric acid. Furthermore, the ER storage of 
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uromodulin detected in TALH cells of Umod mutant mice resembles the findings in kidney 
biopsies of UAKD patients. Both the Umod
A227T
 and the Umod
C93F
 mutation cause an increase in 
plasma urea levels in juvenile and young adult mice, with homozygous mutant mice of both lines 
exhibiting the maximal plasma urea concentrations at the age of 20-22 months. However, the 
two lines differ with regard to onset and severity of plasma urea elevation which was detected 
earlier in Umod
C93F
 mutant than in Umod
A227T
 mutant mice. Also, the clinical phenotype depends 
on the allelic status of animals and is expressed more severely by homozygous mutant than by 
heterozygous mutant mice in each line. Thus, the phenotype of homozygous Umod
A227T
 mutant 
mice compares to that of heterozygous Umod
C93F
 mutant mice (Kemter et al., 2009; Prueckl, 
2011; Kemter, 2012). Similarly, UAKD phenotypes described for humans depend on the location 
of the UMOD mutation and on the allelic status of patients (Rezende-Lima et al., 2004; Williams 
et al., 2009)  
At the age of 6 months, mutant mice of both lines showed no alterations of renal histology, 
except for perinuclear uromodulin accumulations in TALH cells. Upon ultra-structural 
evaluation, hyperplastic membranous bundles were detected in TALH cells of these animals. 
This suggests ER stress and disturbed ER homeostasis as a probable cause of TALH cell 
dysfunction. In addition to these abnormalities, aged Umod mutant mice exhibited renal IFTA as 
well as interstitial infiltrates of lymphocytes and plasma cells. Therefore, quantitative stereology 
was used to investigate whether renal pathology of Umod
A227T
 and Umod
C93F
 mutant mice was 
correlated to their age- and genotype-dependent clinical phenotype.  
5.3 Tubulointerstitial lesions in Umod mutant mice  
In chronic kidney disease, irreversible tissue scarring is commonly marked by tubular atrophy as 
well as by interstitial fibrosis. Consequently, both parameters have been summarized as the term 
IFTA and, in this study, were evaluated as such (Bröcker et al., 2010; Farris & Colvin, 2012).  
At 20-22 months of age, renal IFTA was distinctly increased in homozygous Umod
C93F
 mutant 
and homozygous Umod
A227T
 mutant mice when compared to both heterozygous mutant and wild-
type mice of the corresponding mouse line. While the presence of IFTA was comparably low in 
wild-type and heterozygous Umod
A227T
 mutant mice, homozygous Umod
A227T
 mutant mice 
showed IFTA levels similar to those measured in the kidneys of heterozygous Umod
C93F
 mutant 
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mice. Inflammatory cell infiltration of wild-type and heterozygous Umod
A227T
 mutant kidneys 
was similarly low at 20-22 months as well. In comparison, the presence of lymphocytes and 
plasma cells was distinctly increased in the renal interstitium of both homozygous Umod
A227T
 
mutant and of heterozygous and homozygous Umod
C93F
 mutant mice. Clearly, the occurrence of 
both IFTA and inflammatory cell infiltration relates to both the location of the murine Umod 
mutation and to the genotype of the animal. This finding is in accordance with previous studies 
comparing the clinical phenotypes of these two lines (Prueckl, 2011).  
As in this study, chronic inflammatory cell infiltrates such as lymphocytes and plasma cells 
frequently accompany renal interstitial fibrosis. Whether fibrosis triggers inflammation or vice 
versa is subject to continued discussion, though (Bröcker et al., 2010). To gather further insight 
into the pathomechanism of UAKD, renal volumes of IFTA and inflammatory cell infiltrates 
were quantified in the kidneys of 14-month-old Umod
C93F
 mutant mice. Umod
A227T
 mutant mice 
were not analysed at this age since the occurrence of IFTA and inflammatory cell infiltrates in 
heterozygous Umod
A227T
 mutant mice at 20-22 months of age was still comparable to that 
measured in wild-type controls. Compared to wild-type controls, 14-month-old heterozygous and 
homozygous Umod
C93F
 mutant mice showed significantly increased IFTA and inflammatory cell 
infiltration. Homozygous Umod
C93F
 mutant mice showed no significant difference in either 
parameter between 14 and 20-22 months of age. In contrast, the kidneys of 14-month-old 
heterozygous Umod
C93F
 mutant mice were significantly less infiltrated by lymphocytes and 
plasma cells than those of 20-22-month-old animals. IFTA was present to a similar degree at 14 
and 20-22 months of age in heterozygous Umod
C93F
 mutant mice. These findings indicate that 
the occurrence of IFTA is an earlier event and is followed by inflammatory cell infiltration in the 
kidneys of UAKD affected mutant mice. As described by Prückl in 2011, the clinical phenotype 
of Umod
C93F
 mutant mice manifests itself later in heterozygous than in homozygous mutant 
animals. This could explain why inflammation in the kidneys of homozygous Umod
C93F
 mutant 
mice did not progress between 14 and 20-22 months of age.  
Bohle et al. were among the first to point out a close correlation between the degree of interstitial 
fibrosis and the loss of renal urine concentrating ability in chronic kidney disease, regardless of 
the primary pathologic event (Schainuck et al., 1970; Bohle et al., 1977; Bohle et al., 1987). 
Therefore, the IFTA measurements described above (refer to 4.1.1.2) agree with the deterioration 
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of urine concentration ability with UAKD progression described for mutant mice of both lines 
(Kemter et al., 2009; Prueckl, 2011; Kemter, 2012). From the increased amount of IFTA and 
inflammatory cell infiltrates in Umod mutant murine kidneys, a parallel to biopsy findings of 
human UAKD patients can be drawn, where both interstitial fibrosis and infiltrates of 
lymphocytes indicate chronic tubulointerstitial nephropathy (Nasr et al., 2008; Smith et al., 
2011). IFTA and interstitial inflammation were also detected in the kidneys of Tg
UmodC147W
 mice. 
However, Bernascone et al. (2010) described an upregulation of markers for macrophages and 
granulocytes which pointed to a more acute process of inflammation (Ackermann, 2009). 
Beyond the necrosis of TALH cells, the authors listed the release of uromdodulin into the renal 
interstitium as possible proinflammatory trigger (Bernascone et al., 2010). Moreover, the 
elevated uromodulin serum levels detected in UAKD patients with interstitial uromodulin 
deposits were associated with an increase in serum concentrations of pro-inflammatory cytokines 
and growth factors (Jennings et al., 2007; Prajczer et al., 2010). Despite the absence of 
interstitial uromodulin in Umod mutant mice, a comparable pathomechanism in the process of 
renal inflammation cannot be excluded.  
5.4 Renal TALH cell volumes and tubular atrophy  
At the age of 20-22 months, both heterozygous and homozygous Umod
A227T
 mutant and 
homozygous and heterozygous Umod
C93F
 mutant mice exhibited irregular aggregates of 
uromodulin in the cytoplasm of TALH cells. This observation was analogous to previously 
described alterations in immunohistochemically stained kidney sections of 3-6 month-old 
homozygous Umod
A227T
 mutant and heterozygous Umod
C93F
 mutant mice (Kemter et al., 2009; 
Prueckl, 2011). However, the immunohistochemical staining pattern of uromodulin in TALH 
cells of aged mutant mice appeared more heterogeneous than in younger mutants, as there were 
some intensely stained TALH cells and also TALH cells with irregular weak or absent 
uromodulin signal in the same TALH section profile. Signs of intracellular uromodulin 
accumulation have also been detected in the kidneys of 3- and 6-month-old Tg
UmodC147W
 mice as 
well as in humans harbouring a UMOD mutation (Dahan et al., 2003; Rampoldi et al., 2003; 
Nasr et al., 2008; Bernascone et al., 2010). Both in vivo and in vitro immunofluorescence 
findings favour the ER as the location of uromodulin retention (Vylet'al et al., 2006; Bernascone 
et al., 2010). Whether the above described tubular atrophy affected predominantly TALH-
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segments was investigated by the stereological analysis of the renal TALH volumes in Umod 
mutant mice in comparison to age-matched wild-type controls. Further, genotype-matched mice 
of the Umod 
UmodC93F
 line were compared with regard to age-dependent alterations of renal 
TALH cell contents.  
At the age 20-22 months, both the fractional and total volume of TALH cells was significantly 
reduced in homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice when 
compared to wild-type controls. The comparison of 14-month-old wild-type mice to age-
matched homozygous Umod
C93F
 mutant mice showed the same tendency. However, differences 
were still insignificant at that age. This suggests that, with age, a permanent, ever-increasing ER 
stress due to uromodulin accumulation in the TALH cells cannot be compensated for by the 
unfolded protein response alone, leaving cell death as the final pathway (Shore et al., 2011; 
Moore & Hollien, 2012). Decreased renal TALH cell contents are not only reciprocated by an 
increase in IFTA but also reflect the situation in UAKD patients where cells undergo ER stress 
and eventually become atrophic (Rampoldi et al., 2003; Bleyer & Hart, 2007). A consequent 
release of uromodulin into the renal interstitium has been described in UAKD patients (Resnick 
et al., 1978; Zager et al., 1978; Chambers et al., 1986) but was not detected in either of the two 
Umod mutant mouse lines (refer to 5.3). Nonetheless, a reduction in TALH cells did not 
necessarily seem to be strongly linked to the occurrence of IFTA since the latter was also 
detected in 20-22-month-old Umod mutant mice exhibiting renal TALH cell volumes at wild-
type level. This may suggest either that a signal for uromodulin can still be detected in early 
apoptotic cells, or that nephron segments other than the TALH are affected by tubular atrophy as 
well. It has been proposed that the gain-of-toxic effect of mutant uromodulin is compensated for 
by other nephron segments, which may ultimately lead to ER stress and apoptosis in the 
epithelium of proximal tubules or the collecting duct (Gersch et al.; Scolari et al., 2004). 
5.5 Age-related lesions in Umod mutant mice  
Between the ages of 14 and 20-22 months, neither the loss of TALH volume nor the increase of 
IFTA progressed to a degree of significance in heterozygous or homozygous Umod
C93F
 mutant 
mice. Regarding inflammatory cell infiltrates, both their fractional and total volumes increased in 
aged heterozygous Umod
C93F
 mutant mice compared to middle-aged 14-month-old heterozygous 
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mutant mice. However, as explained beforehand, standard deviation is high in this group so a 
general trend is hardly assessable. The mild increase in inflammatory cell infiltrates in 20-22-
month-old wild-type mice leads to the assumption that, with age, some of the nephritic processes 
detected occur independently to UAKD. Considering the results of this study together with the 
fact that Umod mutant mice showed no light microscopic histopathological alterations at 3-6 
months of age (Kemter et al., 2009), it seems likely that UAKD-associated alterations in mutant 
kidneys set in at some point between 6 and 14 months and that the progression of histopathology 
largely takes place in this space of time.  
5.6 Sporadic renal histopathology in Umod mutant mice  
In contrast to IFTA and inflammatory infiltrates, dilated or cystic tubules and Bowman capsules 
represented sporadic findings. Therefore, they were described solely qualitatively. Their 
occasional presence in mutants of both mouse lines, especially in the 20-22-month age group, 
parallels pathologic features described for humans suffering from UAKD. Upon ultrasound 
examination, dilated tubules and cysts were inconsistently detected in these patients, particularly 
at the corticomedullary junction and, similar to the findings in Umod mutant mice, as a 
comparatively late phenomenon (Scolari et al., 1998; Dahan et al., 2001; Dahan et al., 2003; 
Nasr et al., 2008). Focal glomerulosclerosis was also described in humans expressing mutant 
uromodulin (Williams et al., 2009; Smith et al., 2011). Intraluminal cast formation was detected 
in the Umod mutant mice of this study as well as in Tg
UmodC147W
 mice and constitutes another 
similarity to UAKD. Bernascone et al. suggested that mutant uromodulin is released into the 
lumen from cellular debris or that some of it skirts ER quality control and is secreted 
(Bernascone et al., 2010; Schaeffer et al., 2012). This may serve as an explanation for the 
absence of interstitial uromodulin deposits in Umod
A227T
 and Umod
C93F
 mutants. 
5.7 UAKD therapy approach  
So far, a causative therapy for human UAKD does not exist. Allopurinol and uricosuric drugs are 
in use to reduce hyperuricaemia or to increase the urinary excretion of uric acid, respectively 
(Pacher et al., 2006; Schaffer et al., 2010). However, the origin of UAKD presumably lies in ER 
retention of misfolded uromodulin and subsequent ER stress in TALH cells (Dahan et al., 2003; 
Rampoldi et al., 2011). Neither allopurinol nor uricosurics tackle the maturation retardation and 
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the resulting renal dysfunction on cellular and, eventually, on organ level. Thus, the 
administration of allopurinol ameliorates gout as a symptom of hyperuricaemia while the 
underlying kidney disease continues to progress (Bleyer & Hart, 2003). To date, renal 
transplantation presents the only effective cure for UAKD (Labriola et al., 2007; Rampoldi et al., 
2011). In vitro studies proved that the chemical chaperone 4-PBA was beneficial in promoting 
the maturation of mutant uromodulin in transfected human embryonic kidney 293 cells, in 
immortalized TALH cells and in Madin-Darby canine kidney cells. It increased the translocation 
of mutant uromodulin from the ER to the cell membrane, thereby improving cell viability. 
Allopurinol, on the other hand, was found to have no such effect (Choi et al., 2005b; Ma et al., 
2012). Based on these studies, we hypothesized that 4-PBA might act in a similar way upon 
TALH cells of Umod mutant mice in vivo and that, consequently, the renal plasma and urine 
parameters of Umod mutant mice might assimilate to those of wild-type littermates.  
Reactive oxygen species are increasingly formed during chronic kidney disease (Hasselwander 
& Young, 1998; Martin-Mateo et al., 1999; Banday et al., 2005). Regarding the TALH-segment 
in particular, the free radical superoxide is hypothesized to reduce the bioavailability of nitroxide 
which is an important regulator of sodium chloride absorption in the TALH. In vitro perfusion of 
this nephron segment with tempol enhanced the release of nitroxide (Ortiz & Garvin, 2002). 
Therefore, the administration of the radical scavenger tempol to a second treatment group was 
expected to counteract an increase in reactive oxygen species in dysfunctional TALH cells of 
Umod mutant mice and to ameliorate their clinical and histopathological phenotype. 
Since male and female mice differ significantly in some blood and urine parameters, for instance 
in urine osmolality (Kemter et al., 2009), and to exclude hormonal influences of ovarian cycle of 
female mice the treatment assay was conducted on male mice. 
5.8 Treatment of Umod mutant mice with 4-PBA and tempol 
Starting at 2 months of age, sodium 4-PBA was continuously administered via drinking solution 
to homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant male mice at a dosage of 1 
g per kg of body weight. A second treatment group was orally given 2mM tempol in drinking 
solution ad libitum. Plasma and urine parameters as well as body weights were compared 
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between mutant and wild-type mice in each group. Animals receiving regular drinking water 
without drug supplements served as a placebo treatment group.  
Contrary to the initial hypothesis, plasma urea levels of homozygous Umod mutant mice of both 
lines and treatment assays rose above those of wild-type controls. A hypertonic medullary 
interstitium is essential for the urine concentrating ability of the kidney. It results mainly from 
the tubular reabsorption of sodium and urea (Yang & Bankir, 2005). Since renal urea transport 
occurs in the thin descending limb and the collecting duct (Yang & Bankir, 2005; Fenton & 
Knepper, 2007), these results suggest that TALH cell dysfunction may be compensated by 
increased urea reabsorption in other nephron segments to keep up the medullary 
hyperosmolality. This effect did not seem to be ameliorated by 4-PBA or tempol. 4-PBA-treated 
mutant and wild-type mice tended to exhibit the highest plasma urea levels and the lowest 
fractional excretion of urea when compared to genotype-matched mice in the other treatment 
groups. This implies a potential adverse effect of 4-PBA on the function of various renal cell 
types to reabsorb urea and ions in order to maintain an efficient countercurrent mechanism. 
Hyperuricaemia due to reduced fractional excretion of uric acid is a major symptom of UAKD 
(Hart et al., 2002). Possibly an impaired sodium reabsorption in TALH cells is compensated for 
by the proximal tubule where sodium reabsorption triggers the reabsorption of urate (Scolari et 
al., 2004). In neither treatment group, plasma concentrations of uric acid differed between Umod 
mutant mice and wild-type controls. Different from humans, mice express uricase as a functional 
active enzyme which is a catalyst in the conversion of uric acid to allantoin (Choi et al., 2005a) 
and which might explain the unaltered plasma levels of uric acid in Umod mutant mice.  
UAKD patients frequently exhibit low urine osmolality and sometimes polyuria, which gives rise 
to the assumption that defective uromodulin trafficking may interfere with the functionality of 
TALH-located ion transporters such as the NKCC2 co-transporter (Rampoldi et al., 2003). 
Together with other ion transporters, NKCC2 regulates the exchange and reabsorption of 
sodium, potassium, and chloride and, consequently, is essential for the creation and maintenance 
of a hypertonic interstitium of the renal medulla and thus for the urine concentration capability of 
the kidney. It also plays an important role in the paracellular reabsorption of magnesium and 
calcium (Figure 5.1) (Greger, 1985; Gamba, 2005). Thus, ion transport of TALH cells build up 
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an electric gradient between luminal side and blood side, which in turn enables the passive 
paracellular transport of divalent cations by this electric gradient. 
 
 
Figure 5.1: Scheme of the hypothesized impairment of ion exchange in TALH cells expressing mutant 
uromodulin. The reduced reabsorption of sodium, magnesium and divalent cations leads to an increased urinary 
excretion thereof.  
Calcium excretion in the 24h-urine of 4-PBA- and tempol-treated homozygous Umod
A227T
 and 
Umod
C93F
 mutant mice was significantly elevated versus wild-type levels. Overall, calcium 
excretion was highest in animals of the 4-PBA treatment group when compared to genotype-
matched mice receiving tempol or pure drinking water. Again, these results point to an adverse 
effect of 4-PBA on TALH cells and on their salt transport in particular. While deficiencies in 
sodium reabsorption in the TALH cells might be enhanced, they might also be compensated for 
to a substantial extent in other nephron segments. Calcium reabsorption on the other hand, is 
largely dependent on TALH functionality (Silbernagl & Lang, 2005; Gamba & Friedman, 2009) 
and therefore TALH dysfunction has a greater effect on FECa than on FENa.  
The resulting loss of urine concentrating ability has previously been described for mutant mice 
of both lines (Kemter et al., 2009; Prueckl, 2011). An increased urine volume as well as reduced 
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urine osmolalities persisted in homozygous Umod mutant mice of both lines under the treatment 
with 4-PBA and tempol and rendered no evidence for an effect of either drug on urine 
concentrating ability.  
Regardless of treatment group, the total protein excretion in the 24h-urine of homozygous 
Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice lay distinctly below wild-type levels. 
In all treatment groups, homozygous Umod
C93F
 mutant mice showed the lowest concentration of 
total urinary protein, which is in line with results from the western blot analysis where minimal 
urinary uromodulin excretion was detected in homozygous Umod
C93F
 mutant mice. In 
comparison, more urinary uromodulin was excreted by homozygous Umod
A227T
 mutant mice of 
all treatment groups but did not reach wild-type levels. Mutations in the human UMOD gene 
result in comparably reduced urinary uromodulin excretion (Wei et al., 2012). In contrast to in 
vitro results, the administration of 4-PBA did not seem to improve the intracellular trafficking of 
uromodulin in Umod mutant mice.  
Reduced body weight as well as a disturbed lipid metabolism have been described for both 
mouse lines in former studies and were interpreted as secondary alterations to renal malfunction 
(Kemter et al., 2009; Prueckl, 2011). Compared to wild-type controls, neither 4-PBA nor tempol 
affected the decrease in plasma triglyceride levels in homozygous mutant mice of both lines. In 
analogy, the body weight of 4-PBA and tempol-treated homozygous Umod
C93F
 mutant and 
homozygous Umod
A227T
 mutant mice remained significantly below that of age-matched wild-
type mice throughout the experiment.  
From a young age, uromodulin retention and ER hyperplasia were detected in Umod mutant 
mice. Immunohistochemical and ultrastructural analysis showed similar alterations to those 
observed in renal biopsies of UAKD patients and present the hallmark of ER storage of mutant 
uromodulin (Nasr et al., 2008; Kemter et al., 2009). Contrary to the initial hypothesis, clusters of 
uromodulin as well as hyperplastic bundles of ER remained apparent in the kidneys of 
homozygous Umod
A227T
 mutant and homozygous Umod
C93F
 mutant mice after both 4-PBA and 
tempol treatment.  
Unexpectedly and contrary to the published in vitro effects, both 4-PBA and tempol failed to 
bring the clinical and histological phenotypes of homozygous Umod mutant mice closer to those 
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of wild-type controls. Alterations such as reduced uromodulin excretion and increased urinary 
calcium excretion even appeared to be accentuated after 4-PBA treatment. To gain further 
insight behind the outcome of our treatment assay, a closer look at possible metabolic pathways 
of 4-PBA and tempol in vivo might be of help.  
5.9 Metabolic pathways and efficacy of 4-PBA as a chemical chaperone  
In the mammalian organism, the liver is the main location where 4-PBA is broken down into 
other compounds (Yu et al., 2001). Phenylacetylglutamine, phenylbutyrylglutamine, 
phenylacetate and phenylbutyryl are four major metabolites of 4-PBA which are excreted in 
human urine (Comte et al., 2002). However, they only constitute less than 50% of the amount of 
ingested PBA (Kasumov et al., 2004). 4-PBA-metabolism in non-primates differs in that 
phenylacetyl-CoA is conjugated to glycine rather than glutamine. Yet, new PBA-metabolites 
were discovered in both rats and humans by Kasimov et al. (2004). From their results, the 
authors suggest that further, potentially toxic, metabolites remain to be searched for. Fractions of 
phenylacetate and phenylbutyryl glucuronides in the livers of ad libitum-fed rats were elevated 
compared to urine from humans who had fasted prior to 4-PBA administration. Thus, the intake 
of food may enhance the formation of compounds that do not act as chemical chaperones in the 
organism (Kasumov et al., 2004). This assumption might be of relevance since all mice in this 
study were fed ad libitum and 4-PBA ingestion with the drinking water occurred throughout the 
whole day. This may have decreased the efficacy of 4-PBA as a chemical chaperone. In addition, 
it was found that, at a dosage of 0.4 - 0.6 g per kg and day, the sodium of Na 4-PBA increases 
extracellular fluid volume in cancer patients. Kasumov et al. point to the risk this constitutes to 
people with impaired heart and kidney function. Considering that 4-PBA was administered as a 
highly soluble sodium salt at a dosage of 1g per kg and day and that renal ion transport is already 
disturbed in Umod mutant mice, the form of application may have factored into the outcome of 
the 4-PBA treatment assay. Na 4-PBA is rapidly absorbed in the intestine and may have been 
converted to ineffective metabolites before entering the systemic circulation (McGuire et al., 
2010). Beyond the positive effect on uromodulin maturation in vitro, an amelioration of various 
other ER stress-induced conditions including diabetic nephropathy and adipogenesis has been 
reported for 4-PBA. Two of the studies were performed on mice and one on rats and in all three 
of them 4-PBA was administered at a dosage of 1g per kg of body weight (Basseri et al., 2009; 
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Luo et al., 2010; Qi et al., 2011). However, the expression of unfolded-protein-response-related 
proteins in TALH cells may differ from the affected cell types used in the abovementioned 
studies. Thus, 4-PBA might not exert a regulating effect on TALH-specific unfolded protein 
response proteins (Dihazi et al., 2005; Comes et al., 2007).  
5.10 Metabolizaton of tempol  
Investigations of tempol pharmacokinetics in rats revealed that, at a fixed dose, tempol was 
reduced more quickly in the kidney than in the liver, due to a higher mitochondrial density in 
kidney cells (Kamataria et al., 2002). These observations were made after intravenous injection 
of a bolus, however, and were sought to be prevented by continuously providing tempol as a 
drinking solution in this study. At the same time, it is important to note that renal reduction of 
tempol occurs primarily in the mitochondria and that this reaction is impaired by renal damage 
(Kamataria et al., 2002; Ueda et al., 2002; Oteki et al., 2005). Yet, tempol administration has 
proved to ameliorate renal disorders in murine models such as insulin receptor knockout mice 
(Li et al., 2012) and conditions caused by hypoxia in mice with reduced renal mass (Lai et al., 
2012). Again, it is noteworthy that other mouse strains were used in these studies and that tempol 
is likely to be oxidized in other, or additional, cells types than TALH cells.  
The results discussed above indicate that, beyond the proper function of ion transport in TALH 
cells, mitochondrial metabolism might be affected by ER stress in uromodulin storage disease. 
Also, oxidative stress may not be a driving factor in the progression of UAKD and potential 
amelioration of oxidative stress by tempol might have been outweighed by other 
pathomechanisms.  
5.11 Conclusion and outlook  
Histopathological evaluation of the ENU mutant mouse lines Umod
A227T 
and Umod
C93F
 has now 
shown that Umod mutant mice exhibit distinct renal alterations compared to wild-type controls. 
Moreover, quantitative stereological kidney findings show that the degree of lesions correlates 
with the kind of mutation and thus with the degree of maturation retardation of mutant 
uromodulin as well as with the allelic status of the animal. It can further be concluded that renal 
morphological alterations progress largely between 6 and 14 months of age, rather than later on. 
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The findings described herein, together with previous phenotypic characterizations, validate the 
Umod
A227T
 and Umod
C93F
 mouse lines as useful animal models for UAKD.  
The evaluation of causative treatment approaches for UAKD will remain subject to further 
investigations, ideally involving toxic dose low establishments and minimal interference of the 
metabolization of the drug with its efficacy in the kidney.  
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6 Summary  
Pathomorphologic analysis and therapeutic in-vivo assay on two murine models of 
uromodulin-associated kidney disease 
Uromodulin-associated kidney disease (UAKD) is a human renal disorder caused by mutations 
in the UMOD gene. UMOD encodes uromodulin, which is the most abundantly present protein 
in mammalian urine. Uromodulin, a GPI-anchored glycoprotein, is expressed in the cells of the 
thick ascending limb of the loop of Henle (TALH) and early parts of the distal convoluted 
tubule, exclusive of macula densa cells. To date, the complete functional scope of uromodulin 
remains to be clarified. Mutant, immature uromodulin aggregates in the endoplasmic reticulum 
of cells of the thick ascending limb of Henle. UAKD patients develop chronic kidney disease 
and end-stage renal failure between the third and seventh decade in their lives. Increasing ER 
stress leading to TALH cell dysfunction is regarded as the underlying pathomechanism. Despite 
their common genetic origin, clinical phenotypes vary with regard to onset, severity and renal 
morphologic alterations, depending on the localization of the mutation in the UMOD gene and 
the allelic status of the affected individual. Symptomatic heterogeneity occurs even within 
affected families. Most patients develop hyperuricaemia and gout, along with deficient urine 
concentrating ability. To date, UAKD cannot be cured. Therapy is limited to symptom 
amelioration by allopurinol or uricosuric drugs. Besides in vitro studies, in vivo research on 
UAKD has hitherto been performed on murine models. The mutant mouse lines, Umod
A227T
 and 
Umod
C93F
, were developed in the Munich ENU mouse mutagenesis project and both harbour an 
autosomal dominant missense mutation in the murine Umod gene. Mutant mice of both lines 
exhibit elevated plasma urea levels, defective urinary concentrating ability and an increased 
excretion of bivalent cations, with Umod
C93F
 mutant mice expressing a stronger phenotype.  
The first aim of this study was to qualify and quantify histomorphological alterations in the 
kidneys of Umod
A227T
 and Umod
C93F
 mutant mice of different allelic status and age in order to 
relate the findings to the onset, expression and progression of their clinical phenotype.  
Secondly, the efficacy of two differently acting drugs as a causative treatment for UAKD was 
tested on homozygous mutant mice of the two mouse lines. Oral administration of the chemical 
chaperone 4-phenylbutyric acid and the antioxidant tempol to two different treatment groups was 
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aimed at evaluating their effect on Umod mutant mice. To this end, the clinical and 
histopathological phenotype of treated mutant mice was compared to treated wild-type controls 
as well as to animals of a placebo treatment group.  
Interstitial fibrosis and tubular atrophy (IFTA) as well as inflammatory infiltrates were consistent 
findings in mutant mice and their quantification revealed a similar increase of both parameters in 
homozygous Umod
A227T
 mutant and in heterozygous Umod
C93F
 mutant mice at 20-22 months of 
age. IFTA had developed to the greatest extent in 20-22-month-old homozygous Umod
C93F
 
mutant mice. Between the ages of 14 and 20-22 months, progressive inflammatory cell 
infiltration was detected in heterozygous Umod
C93F
 mutant mice. Homozygous mutant mice of 
both lines showed a tendency towards a loss of TALH cells at 20-22 months of age. Renal cysts 
and glomerulosclerosis were sporadically detected in Umod mutant mice of both lines. 
Elevated plasma urea levels, impaired urine concentrating ability and increased urinary calcium 
excretion remained eminent in homozygous Umod mutant mice of both lines after two months of 
treatment with both 4-PBA and tempol. ER retention of uromodulin and, consequently, reduced 
urinary uromodulin excretion equally persisted after the application of either drug. Compared to 
untreated and tempol-treated mice, 4-PBA treatment appeared to stress clinical alterations in 
homozygous Umod mutant mice.  
Quantification of renal histologic alterations of Umod mutant mice revealed that the expression 
and progression of alterations was dependent on age, line, and genotype. Comparable 
observations had been mad for the clinical phenotype of Umod mutant mice. Moreover, the 
results indicated that, in the pathogenesis of tubulointerstitial nephropathy in Umod mutant mice, 
interstitial fibrosis and tubular atrophy preceded inflammation. The results of 4-PBA treatment 
suggest a minimally toxic effect on TALH cells, since plasma urea levels and the fractional 
excretion of sodium and calcium were most elevated in mice of this treatment group. Urinary 
uromodulin excretion appeared further diminished by 4-PBA treatment in homozygous mutant 
mice. Tempol treatment showed that, if there was a reduction of oxidative stress in the kidneys 
of Umod mutant mice, it was overshadowed by other pathological processes. Due to numerous 
clinical and histopathological analogies to the human disease, Umod
A227T
 and Umod
C93F
 mutant 
mice present a suitable murine model for further in vivo UAKD therapy assays.  
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7 Zusammenfassung  
Pathomorphologische Untersuchung und in vivo Therapieversuch an zwei Mausmodellen 
für die Uromodulin-assoziierte Nierenerkrankung 
 
Die Uromodulin-assoziierte Nierenerkrankung ist eine Nierenerkrankung des Menschen, die 
durch Mutationen des UMOD Gens verursacht wird. UMOD kodiert für Uromodulin, das auch 
unter dem Namen Tamm-Horsfall-Protein bekannt ist, und das am häufigsten vorgefundene 
Protein im Harn von Säugetieren darstellt. Bei Uromodulin handelt es sich um ein GPI-
gebundenes Glykoprotein, das von den Zellen des dicken aufsteigenden Schenkels der Henle 
Schleife (TALH) sowie in frühen Abschnitten des distalen gewundenen Tubulus, ausgenommen 
Macula densa Zellen, exprimiert wird. Die gesamte Bandbreite der Funktion von Uromodulin 
bleibt bisher ungeklärt. Mutiertes, unreifes Uromodulin reichert sich im endoplasmatischen 
Retikulum (ER) von Zellen des TALH an. Zwischen der dritten und siebten Lebensdekade 
entwickeln UAKD Patienten chronische Niereninsuffizienz und terminales Nierenversagen. Man 
nimmt an, dass ansteigender endoplasmatischer Retikulum (ER)-Stress in den Zellen des TALH 
eine Fehlfunktion derselben nach sich zieht und somit den der UAKD zu Grunde liegenden 
Pathomechanismus darstellt. Trotz ihres gemeinsamen genetischen Ursprungs unterscheiden sich 
die klinischen Phänotypen der UAKD hinsichtlich Krankheitsbeginn und –schweregrad sowie in 
Bezug auf die Morphologie und Ausprägung der Nierenveränderungen, abhängig von der 
Lokalisation der Mutation im UMOD Gen und vom Allelstatus der betroffenen Person. Dabei 
treten selbst intrafamiliär heterogene Symptome auf. Bei den meisten Menschen kommt es zu 
Hyperurikämie und Gicht, sowie zu einer beeinträchtigten Harnkonzentrierungsfähigkeit. Bisher 
kann UAKD nicht geheilt werden. Therapien beschränken sich auf die Linderung von 
Symptomen durch Allopurinol und Urikosurika. Neben in vitro Studien wurde UAKD in vivo 
bisher an Mausmodellen untersucht. Die beiden Umod mutanten Linien, Umod
A227T
 und 
Umod
C93F
 entstanden aus dem Münchener ENU Maus Mutagenese Projekt und tragen jeweils 
eine autosomal dominante Missense-Mutation im murinen Umod Gen. Mutante Mäuse beider 
Linien haben erhöhte Plasmaharnstoffwerte, eine eingeschränkte Harnkonzentrierungsfähigkeit 
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und scheiden vermehrt bivalente Kationen aus, wobei Umod
C93F 
mutante Mäuse einen stärkeren 
Phänotyp zeigen.  
Der erste Teil dieser Arbeit verfolgte das Ziel der qualitativen und quantitativen Bestimmung 
von histomorphologischen Nierenveränderungen bei Umod
A227T
 und Umod
C93F
 mutanten Mäusen 
von unterschiedlichem Allelstatus und Alter, um diese in Relation zu Beginn, Ausprägung und 
Progression ihres klinischen Phänotyps zu setzen.  
Des Weiteren wurden zwei unterschiedlich agierende Medikamente hinsichtlich ihrer 
Wirksamkeit als Kausaltherapie für UAKD an homozygot mutanten Mäusen beider Linien 
getestet. Orale Abgabe des chemischen Chaperones 4-Phenylbutyrat und des Antioxidans 
Tempol an zwei verschiedene Behandlungsgruppen diente der Ermittlung ihrer Wirkung auf 
Umod mutante Mäuse. Hierzu wurden behandelte mutante Mäuse hinsichtlich ihres klinischen 
und histopathologischen Phänotyps mit gleich behandelten Wildtypkontrollen sowie mit Tieren 
aus einer Placebo-Gruppe verglichen. 
Interstitielle Fibrose und tubuläre Atrophie (IFTA) sowie Entzündungszellinfiltrate stellten 
konstante pathologische Befunde in mutanten Mäusen beider Linien dar und ihre Quantifizierung 
zeigte einen ähnlichen Anstieg beider Parameter in den Nieren homozygot Umod
A227T
 mutanter 
und heterozygot Umod
C93F
 mutanter Mäuse im Alter von 20-22 Monaten. Homozygot Umod
C93F
 
mutante Mäuse zeigten die stärkste Ausprägung von IFTA. In den Nieren von heterozygot 
Umod
C93F
 mutanten Mäusen wurde eine Progression der Entzündungszellinfiltration zwischen 
den Altersstufen von 14 und 20-22 Monaten festgestellt. Im Alter von 20-22 Monaten zeigen 
homozygot mutante Mäuse beider Linien eine Tendenz zu TALH-Zellverlust. Zysten und 
Glomerulosklerose wurden sporadisch in den Nieren mutanter Mäuse aus beiden Linien 
identifiziert.  
Erhöhte Plasmaharnstoffwerte, verringerte Harnkonzentrierungsfähigkeit und vermehrte 
Kalziumausscheidung mit dem Urin blieben sowohl nach der Behandlung mit 4-PBA als auch 
mit Tempol bestehen. Gleichermaßen persistierten ER-Retention von Uromodulin und die 
dadurch bedingte verringerte Uromodulin-Ausscheidung im Harn nach Gabe beider 
Medikamente. Im Vergleich zu Tempol-behandelten und unbehandelten Tieren, erschienen die 
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klinischen Veränderungen in homozygot Umod mutanten Mäusen durch die 4-PBA-Behandlung 
verstärkt zu werden.  
Die Quantifizierung histopathologischer  Nierenveränderungen Umod mutanter Mäuse zeigte, 
dass deren Ausprägung und Progression vom Alter, der Mauslinie und dem Genotyp abhingen. 
Vergleichbare Beobachtungen wurden bereits für den klinischen Phänotyp gemacht. Darüber 
hinaus ging aus den Ergebnissen hervor, dass bei Pathogenese der tubulointerstitiellen 
Nephropathie von Umod mutanten Mäusen interstitielle Fibrose und tubuläre Atrophie der 
Infiltration durch Entzündungszellen vorangingen. Die Ergebnisse der Behandlung von Mäusen 
mit 4-PBA weisen auf einen minimal toxischen Effekt auf TALH-Zellen hin, da die 
Plasmaharstoffwerte und die fraktionelle Ausscheidung von Natrium und Kalzium sowohl bei 
Mäusen in dieser Behandlungsgruppe am höchsten lagen. Zudem schien die Ausscheidung von 
Uromodulin im Harn homozygot mutanter Tiere in dieser Behandlungsgruppe zusätzlich 
verringert. Sollte Tempol den oxidativen Stress in den Nieren von Umod mutanten Mäusen 
verringert haben, so wurde dieser Effekt von anderen pathologischen Prozessen überschattet. 
Aufgrund zahlreicher klinischer und histopathologischer Übereinstimmungen zur Erkrankung 
beim Menschen stellen Umod
A227T
 und Umod
C93F
 mutante Mäuse ein geeignetes Modell für 
weitere in vivo Therapieversuche für UAKD dar.  
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